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2001 2000 Change
in %
Sales € million 30,275 30,971 – 2.2
Operating result € million 1,611 3,287 – 51.0
Income before income taxes € million 1,115 2,990 – 62.7
Net income € million 965 1,816 – 46.9 
Gross cash flow € million 2,923 4,164 – 29.8
Stockholders’ equity € million 16,922 16,140 + 4.8
Total assets € million 37,039 36,451 + 1.6
Capital expenditures € million 2,617 2,647 – 1.1
Employees at year end 116,900 122,100 – 4.3
Personnel expenses € million 7,849 7,735 + 1.5
Research and development expenses € million 2,559 2,393 + 6.9
2001 2000 Change
in %
Total dividend payment € million 657 1,022 – 35.7
Dividend per share € 0.90 1.40 – 35.7
Bayer AG
Bayer Group
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Operating 
Result Before
Exceptional
Items
Health Care 2001 2000 Change
External sales € million 9,833 10,028 – 1.9 %
Operating result before exceptionals € million 771 1,476 – 47.8 %
Operating result € million 392 1,337 – 70.7 %
Capital expenditures € million 682 745 – 8.5 %
€ million
– 47.8%
1,476
771
2001 2000
Agriculture 2001 2000 Change
External sales € million 3,696 3,455 + 7.0 %
Operating result before exceptionals € million 625 558 + 12.0 %
Operating result € million 625 584 + 7.0 %
Capital expenditures € million 264 283 – 6.7 %
€ million
+ 12.0 %
625 558
2001 2000
Polymers 2001 2000 Change
External sales € million 10,788 10,892 – 1.0 %
Operating result before exceptionals € million 434 1,078 – 59.7 %
Operating result € million 284 988 – 71.3 %
Capital expenditures € million 1,084 1,011 + 7.2 %
€ million
– 59.7 %
434
1,078
2001 2000
Chemicals 2001 2000 Change
External sales € million 3,749 3,410 + 9.9 %
Operating result before exceptionals € million 271 370 – 26.8 %
Operating result € million 203 394 – 48.5 %
Capital expenditures € million 483 424 + 13.9 %
€ million
– 26.8 %
271
370
2001 2000
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Chairman’s Letter
Dr. Manfred Schneider
Chairman of the Board of
Management of Bayer AG
An improved
portfolio...
Bayer today is changing faster than ever before. I’m referring above all to our
decision to extensively reorganize the company and its management structure.
We will create a new Bayer – an efficient enterprise consisting of strategically
linked but independently operating companies with a management culture based,
as before, on performance and value creation.
The objectives are to pool our core competencies even more closely within the
four business areas, to streamline the portfolio and to focus our business structures
in line with changing market requirements and competitive conditions.
With these aims in view we plan to create legally separate HealthCare,
CropScience, Polymers and Chemicals companies, supported by equally independent
service companies, and to endow them with all the expertise and the resources they
need to be leaders in their respective markets.
An important milestone is the acquisition of Aventis CropScience. Subject to
antitrust approvals, this would put our crop science activities – and our global crop
protection business in particular – in a top position worldwide.
In the polymers industry we are already among the leaders, with a
comprehensive range of products, technologies and customer-oriented materials
solutions. The new structure is intended to strengthen this role.
In chemicals we seek strategic partnerships to enhance our positions in key
markets. Here, too, the reorganization will improve our agility.
Undoubtedly, the greatest challenge is to realign our healthcare business.
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We are convinced of the new healthcare company’s ability to position itself
successfully in the market. We have turned the diagnostics business around and now
plan to bring innovative products to market. For our consumer care business with its
first-rate brands, we see good opportunities to strengthen our activities through
selective acquisitions. In biological products, the planned merger with Aventis
Behring under our management control would give us a leading market position and
considerable potential for improving profitability. Our animal health business is one
of the industry’s strongest and most profitable, partly because of its links to our
research expertise in pharmaceuticals and crop science.
The pharmaceuticals business is crucial to the performance of Bayer HealthCare.
Here we need to restore sales and margins to levels that stand comparison with our
competitors and capitalize fully on the value creation potential of this business. We
will therefore step up our restructuring program to improve efficiency and reduce
costs, and adapt our structures to temporarily diminished growth expectations.
We believe that in all the activities we are now realigning under the Bayer Group
umbrella, we possess sufficient resources to hold our own against the competition
and create the kind of value our stockholders expect.
A key factor here will be strategic management, which means actively managing
the Group’s portfolio, deploying our resources selectively and transparently, and
achieving ambitious sales and profitability goals. These – along with guiding and
developing the Group’s executive team – will be the main roles of the management
holding company we plan to establish.
Reorganizing the enterprise is an exceptionally weighty and complex task. But
we will take care not to neglect our daily operations, especially because there is still
no sign of a material shift in the current economic situation.
2001 was a disappointing year. We did not reach our goals – due to the
economic situation, the problems in biologicals and not least because of the major
setback for our pharmaceuticals business that resulted from the withdrawal of our
cholesterol-lowering drug.
We will therefore work for a sustained improvement in our structures and
processes. Our actions in this regard include ten major cost-structure projects
structure
...in a new
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designed to generate annual savings of some €1.8 billion by 2005 and enhance our
efficiency for the long term. We expect these projects to contribute more than €500
million to our operating result this year.
What’s more, we have all but solved the problems for our biological products,
and anticipate significant earnings growth in the current year. It will also be
tremendously important to rapidly integrate the crop science activities we plan to
acquire, and we will redouble our efforts to overcome the cyclical problems in
polymers and chemicals.
We intend to continue streamlining and focusing our portfolio by divesting
activities we now consider to be non-core.
All in all, we remain confident despite the modest economic outlook for the
coming year. Our goal is to substantially improve earnings.
As for myself, I will relinquish my active duties at Bayer’s helm after 26 years
with the company, 10 of them as Management Board Chairman. I thank you for the
trust you have placed in me and the Board of Management under my charge – even
in the difficult situation we faced last year. At the same time, I would like to thank
each and every Bayer employee for his or her commitment to the company.
I would ask that you provide the same level of support to my successor, 
Werner Wenning, and his management team. I firmly believe we will succeed in
getting Bayer back on track.
Sincerely, 
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The course is 
set for the future
Bayer stock had a bad year in 2001, particularly as a
result of the Lipobay®/Baycol® withdrawal. Yet the
corporate reorganization program we have intro-
duced, together with further portfolio streamlining
measures, not only creates an excellent basis for value
growth and a successful future for our company, but
should also increase the share price over the medium
term.
Difficult year for our stockholders 
2001 was a difficult year not just for our company, but also for our stockholders. The
voluntary withdrawal in August of Lipobay®/Baycol®, the leading growth driver of our
pharmaceuticals business, impacted heavily on the price of Bayer stock. Exerting further
pressure on our share price were the marked deterioration in the global economy, which
affected our industrial business in particular, and production problems for our biological
products. The terrorist attacks of September 11 also depressed the stock markets for a
time. Although our stock picked up again toward the end of the year, the closing price of
€35.80 per share was 36 percent below the previous year. The German share index
DAX 30 lost 20 percent in the same period, while the Dow Jones EURO STOXX 50 index
declined by 19 percent. Bayer AG’s market capitalization dropped by €15 billion to
€26.1 billion.
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Bayer Share Price
Dividend
Tax credit
Earnings per share
Cash flow per share
Equity per share
Year-end price*
High for the year*
Low for the year*
Shares issued as of year end
Shares to be issued upon 
the exercise of warrants
Share turnover on German stock exchanges
Share turnover on German stock exchanges
Market capitalization at year end
Total dividend payment
Price/earnings ratio
Price/cash flow ratio
Dividend yield
€
€
€
€
€
€
€
€
million
million
million
€ billion
€ billion
€ million
%
0.90
0.00
1.32
4.00
23.17
35.80
57.80
24.05
730.34
0.0
865
35.6
26.1
657
27.1
9.0
2.5
1.40
0.45
2.49
5.70
22.10
55.87
55.89
38.55
730.34
0.0
648
29.4
40.8
1,022
22.4
9.8
3.3
BAY E R STO C K DATA 2001 2000**
Dec. 31, 2001Jan. 1, 2001
60
80
100
Index (Jan. 2, 2001=100)
EURO STOXX 50 DAX 30 Bayer share price
*) Xetra closing prices 
**) 2000 figures restated
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Entire net income of the parent company to be distributed
The adverse financial effect of the Lipobay®/Baycol® withdrawal and the production
problems for biological products, coupled with a considerably lower earnings
contribution from our industrial business, led to a decline of 47 percent in Group net
income, to €965 million. However, to achieve an appropriate dividend yield for our
stockholders, the Board of Management and the Supervisory Board are proposing to
distribute the entire net income of €657 million of the parent company Bayer AG,
amounting to a dividend of €0.90 per share for the 2001 fiscal year. This also reflects
the confidence of Bayer’s management that the reorganization measures being
introduced will lead to increased earnings again in the medium term.
In view of recent changes to German tax law, the dividend payment can no longer be
accompanied by a corporate income tax credit. To make up for this, only half of
stockholders’ dividend income is now taxable.
Number of stockholders grows by about 25 percent
The result of the latest stock ownership survey as at June 1, 2001, which covered nearly
96 percent of the company’s capital stock, further demonstrates the popularity of 
Bayer stock in Germany and around the world. Compared with 1999, the number of
stockholders in Germany has gone up by 70,000 to 437,000 and the number of non-
domestic stockholders by 23,000 to 59,000. 
67 percent of the capital covered by the survey is in the hands of institutional
investors. Private individuals hold 24 percent. Of these people, 12 percent are Bayer
employees, who between them own 2.1 percent of the stock. Allianz AG, which owns
5.7 percent of Bayer stock, remains the biggest single stockholder and the only one with
a holding in excess of 5 percent. The other shares are held by industry and commerce,
foundations, church institutions or welfare organizations, for example.
Dividends Paid,  1991 -2001
Dividend per share (€)
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Total dividend payment
(€ million)
200
400
600
800
1,000
1,200
0.66
428
0.56
370
0.56
377
0.66
461
0.77
541
0.87
629
0.97
710
1.02
747
1.30
949
1.40
1,022
657
0.90
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2001 1999
Stockholders % Stockholders %
Individuals 466,586 94.1 375,550 93.3 
Banks/insurance companies 2,091 0.4 2,276 0.6 
Investment funds 3,065 0.6 3,357 0.8 
Industry and commerce 8,294 1.7 6,823 1.7 
Other 15,911 3.2 14,538 3.6 
495,947 100 402,544 100 
Some 39 percent of the stock is held outside Germany. This not only underscores
the company’s international alignment, it also reflects the importance of Bayer stock on
the international financial markets. British and U.S. investors continue to be the largest
non-domestic shareholder groups.
Listing in New York
Since January 24, 2002, Bayer AG’s shares have been listed on the New York Stock
Exchange, the world’s largest securities market, under the symbol “BAY”. This listing
creates a number of new advantages and opportunities for Bayer. For example, it gives
us direct access to the U.S. capital market. In addition, Bayer shares can now be used
as a currency to finance possible acquisitions in the future. The listing also makes it
easier for U.S. stockholders to purchase Bayer shares, which is consistent with our goal
of increasing the number of shareowners in that country. What’s more, the Wall Street
listing gives Bayer the opportunity to initiate stock ownership programs for employees at
our U.S. subsidiaries. 
New corporate structure introduced
We aim to transform the Bayer Group into a management holding company with four
legally independent operating units for HealthCare, CropScience, Polymers and
Chemicals, as well as three service companies. The umbrella of a Bayer holding
company provides optimum conditions for the strategic partnerships we seek, especially
in Health Care and Chemicals. This organizational structure creates an ideal foundation
for the rapid and successful integration of the Aventis CropScience agrochemicals
business. In Polymers, the holding structure will allow an even closer alignment of our
business with the needs of the market and our customers. The tasks of the holding
company’s management board will include determining overall strategy, setting
performance targets, finance and capital allocation, and developing management
personnel.
Number of Stockholders
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We expect this biggest reorganization project in Bayer’s history to lead to more
operational flexibility, greater transparency and a sharper focus on market opportunities
and customer needs.
Portfolio management accelerated
The change process at Bayer goes beyond the creation of a holding structure. For
example, we have greatly stepped up portfolio management, our central instrument for
sustained value creation in the enterprise. We have spent more than €13 billion over the
past four years alone to strengthen core activities. Examples include the acquisitions of
Chiron Diagnostics, the Lyondell polyols business, and the FLINT® line of fungicides from
Syngenta. In the Chemicals business area, we selectively expanded our specialty
chemicals business by acquiring Sybron, CSM and the paper chemicals business of
Cytec. In addition, we have created a leading-edge pharmaceutical research platform
through targeted investments in genomics projects. The acquisition of Aventis
CropScience, which still requires the approval of the antitrust authorities, is intended to
strengthen our crop protection business over the long term and make us a leading
company in this sector.
We plan to further accelerate our value-oriented alignment of the Group portfolio
toward highly profitable businesses, and we will more rapidly divest parts of the
company that are unable to meet our performance goals or are no longer core
businesses. The most recent examples are the announced divestitures of Haarmann &
Reimer, Rhein Chemie Rheinau and our interest in PolymerLatex. We will capitalize more
aggressively on acquisition opportunities while ensuring such actions make economic
sense.
Cost structure projects and stricter capital discipline
As a further value enhancement measure, we will fully implement the efficiency-
improvement and cost-containment projects already initiated. Cost structure projects in
Percentages of Bayer Stock Held by
Respondents to the Survey
Banks and insur-
ance companies
55%
Industry and commerce 3%
Other 6%
Investment 
funds 12%
Individuals 24%
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Health Care, Polymers and Chemicals will aim to achieve approximately €1.8 billion a
year in efficiency improvements by 2005. We also expect to achieve several hundred
million euros in synergies through the integration of Aventis CropScience. Improvements
in working capital management already led to a 25 percent increase in net cash flow
last year, and we plan to reduce working capital by a further €1 billion to €1.5 billion.
By reducing capital spending to the level of depreciation, we aim to achieve further
cost savings without limiting growth opportunities for investment-intensive businesses
such as Polymers. 
A new way of thinking
The commitment and motivation of Bayer’s employees are key factors in the success of
our company, and the focus on performance will become increasingly significant in the
future. In the new structures, we will aim to meet our goal of steady growth in corporate
value by expanding success-related and performance-based remuneration systems.
Excellent foundation for sustained value growth
Our Health Care business already occupies leadership positions in its Consumer Care,
Diagnostics, Biological Products and Animal Health business groups, and our
pharmaceutical research activities are among the best in the industry. The acquisition of
Aventis CropScience, which is subject to the approval of the antitrust authorities, would
allow us to create one of the world’s largest crop protection companies. Our Polymers
business is already a market leader in many areas and is well situated to expand these
positions. We will continue to focus our Chemicals activities on the high-earning fine
chemicals and specialties businesses.
The planned holding structure, the continued intensification of our portfolio
management, the efficiency-improvement and cost-containment initiatives and the new
corporate culture in the new Bayer Group create the foundation for sustained growth in
the value of our company. The course is set for a successful future.
U.K. 9.7 11.2 24.9 26.5
U.S.A. 8.2 8.8 21.1 20.8
Switzerland, Liechtenstein 7.6 7.2 19.5 17.0
Luxembourg 4.0 3.9 10.3 9.2
Belgium 2.3 2.2 5.9 5.2
Netherlands 1.6 2.8 4.1 6.6
Other countries 5.5 6.2 14.2 14.7
38.9 42.3 100 100
Non-Domestic 2001 1999 2001 1999
Shareholdings
% of total stock in survey % of non-domestic ownership
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Bayer’s plastic Baytron® P – a trans-
parent, conductive polymer – is used 
as an intermediate layer in innovative
organic light-emitting diodes. 
It extends their service life, increases
their luminosity and reduces their
power requirement.
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In 2001 we faced major challenges. The weak
economic environment had a negative effect on the
performance of our Polymers and Chemicals business
areas. Cautious optimism in the spring regarding a
gradual economic recovery proved to be
unwarranted. The Health Care business area was hit
with the market withdrawal of our Lipobay®/Baycol®
blockbuster and production problems for our
genetically engineered Factor VIII product Kogenate®.
Sales and earnings hampered 
by setbacks in pharmaceuticals and 
by continuing economic weakness
Gratifying improvement in 
operating cash flow
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Despite these problems, sales from continuing operations rose by 1 percent to 
€28.9 billion, with the Lipobay®/Baycol® withdrawal alone depressing projected sales
by €0.7 billion. Three percentage points of the €0.3 billion growth in sales were due to
portfolio changes and 1 point to price increases. 
The operating result before exceptional items decreased by 42 percent to 
€1.9 billion. This significant decline was due partly to the unfavorable economic
situation and partly to the adverse factors in our Health Care business area, which
diminished earnings by €0.6 billion. If this one-time effect is disregarded, the operating
result declined by 23 percent to €2.5 billion.
Of the €0.6 billion in exceptional items, the Health Care business area accounted
for €0.4 billion – due almost exclusively to the Lipobay®/Baycol® market withdrawal –
while spending for restructuring and site consolidation accounted for €0.2 billion. The
operating result after exceptionals thus fell by 59 percent to €1.2 billion.
The discontinuing operations are the Haarmann & Reimer and Fibers business
groups, which we plan to divest, and EC Erdölchemie, our interest in which was already
sold in 2001.
Group sales including discontinuing operations dipped by 2 percent to 
€30.3 billion, and the operating result dropped by 51 percent to €1.6 billion.
The Bayer Group has introduced extensive programs designed to improve earnings.
We expect that these programs will boost operating profit by €0.5 billion in 2002 and
lead to annual savings of €1.8 billion by 2005.
The Group-wide project to reduce working capital has already borne fruit, resulting in
a 25 percent improvement in net cash flow.
Reported – 2%
Continuing operations + 1%
Volumes – 3%
Prices + 1%
Exchange rates 0%
Portfolio changes + 3%
Sales from Continuing
Operations
1999 20012000
Foreign sales
Domestic sales
7,265
16,307
8,136
20,479
8,116
20,822
€ million
Change in Sales
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Operating Result From Continuing Operations 
Before Exceptionals
2,703
3,209
1,855
€ million
200120001999
Economic Environment
Overall economic situation
In 2001 the global economy was heavily affected by weakness in North America, with the
United States in recession since the spring. This further hampered the business climate in
Japan, which has been muted for a number of years. The downturn spread faster than
expected to Southeast Asia, and then to Canada, Mexico and ultimately Western Europe.
Although early indicators in the summer of 2001 had pointed to an economic upswing,
the terrorist attacks in the United States shook investor and consumer confidence to such
an extent that the expected recovery did not materialize.
The economic situation in Germany deteriorated considerably in the second half of
2001, with manufacturing and construction the most affected sectors.
Economic situation by industry sector
The pharmaceuticals market was not affected by the general economic weakness in
2001. Both North America, where substantial price increases were implemented in the
market despite public debate, and Europe contributed to the positive overall picture with
mostly double-digit growth rates.
The market for crop protection products was characterized by stagnating demand
and strong pressure on prices. The BSE and foot-and-mouth crises adversely affected
the animal health market.
The automotive, electronics and construction sectors, which are key customers of
our Polymers business area, have in some cases drastically scaled back production and
reduced inventories. Prices declined sharply in all regions, further increasing the
pressure on margins.
The economy of the chemicals sector also weakened considerably compared with
the previous year in all major foreign markets and downstream industries. The market
environment is characterized by excess capacities and the increasing commoditization
of many products.
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Performance by Region
Europe
€ million 2001 2000 Change
Sales 12,999 12,916 + 0.6%
Operating result before exceptional items 1,707 2,216 – 23.0%
Return on sales before exceptional items 13.1% 17.2% – 4.1
Gross cash flow 2,037 2,096 – 2.8%
CFROI 12.5% 15.2% – 2.7
Sales of our European companies rose by 1 percent to €13.0 billion. By contrast, the
operating result before exceptionals dropped by €509 million to €1.7 billion and the gross
cash flow decreased by €59 million to €2.0 billion. The return on sales declined by
4 percentage points to 13 percent, while the cash flow return on investment (CFROI) was
down 3 percentage points to 12 percent. However, both figures exceed the Group
averages of 6 and 8 percent, respectively. Earnings were also impaired by €0.3 billion in
exceptional charges.
North America
€ million 2001 2000 Change
Sales 9,806 9,699 + 1.1%
Operating result before exceptional items 23 729 – 96.8%
Return on sales before exceptional items 0.2% 7.5% – 7.3
Gross cash flow 632 1,521 – 58.4%
CFROI 4.7% 12.2% – 7.5
The increase in sales of our North American companies to €9.8 billion was due to the
Lyondell polyols acquisition. Operating profit before exceptionals fell 97 percent to 
€23 million, while the gross cash flow receded by 58 percent to €0.6 billion, due mainly
to a cyclical drop in demand and the production problems for our biological products.
The Baycol® withdrawal and restructuring measures, particularly in Polymers, gave rise
to €0.3 billion in exceptional charges.
Performance by Region
Sales Operating
result*
* before exceptionals
Gross
cash flow
Europe
North Amercica
Asia/Pacific
12,999
9,806
3,817
2,316
1,707
23
241
219
2,037
632
312
225
€ million
Latin America/Africa/Middle East
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Asia/Pacif ic
€ million 2001 2000 Change
Sales 3,817 3,761 + 1.5%
Operating result before exceptional items 241 404 – 40.3%
Return on sales before exceptional items 6.3% 10.7% – 4.4
Gross cash flow 312 357 – 12.6%
CFROI 11.3% 14.3% – 3.0
Sales of our companies in the Asia/Pacific region edged up 1 percent to €3.8 billion.
Adverse shifts in exchange rates had a 6 percent negative effect. The operating result
fell by 40 percent to €0.2 billion, and the gross cash flow declined by 13 percent to
€0.3 billion, causing the return on sales and CFROI to drop to 6 and 11 percent,
respectively.
Latin America/Africa/Middle East
€ million 2001 2000 Change
Sales 2,316 2,239 + 3.4%
Operating result before exceptional items 219 213 + 2.8%
Return on sales before exceptional items 9.5% 9.5% + 0
Gross cash flow 225 228 – 1.3%
CFROI 14.5% 16.4% – 1.9
We expanded sales in the Latin America/Africa/Middle East region; sales and operating
profit each rose by 3 percent, and the return on sales was 9 percent. The gross cash flow
dipped by 1 percent to €0.2 billion, and the CFROI was down by 2 percentage points to 
14 percent.
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* before exceptionals
9,833
3,696
10,788
3,749
771
625
434
271
763
713
1,201
379
€ million
Health Care
Agriculture
Polymers
Chemicals
Performance by Business Area
We have pooled the business activities of our 14 business groups in the Health Care,
Agriculture, Polymers and Chemicals business areas according to strategic aspects. In
Health Care, we turned the Biological Products business unit into an independent
business group with effect from January 1, 2002 because it is governed by different
success factors and market structures.
Business Area Business Groups
Health Care Pharmaceuticals; Biological Products; Consumer Care; 
Diagnostics
Agriculture Crop Protection; Animal Health
Polymers Plastics; Rubber; Polyurethanes;
Coatings and Colorants
Chemicals Basic and Fine Chemicals; Specialty Products; H.C. Starck; 
Wolff Walsrode
The Chemicals business area no longer includes the EC Erdölchemie or Haarmann
& Reimer business groups, and Polymers no longer includes Fibers, because these
activities have been classified as discontinuing operations. Our 50 percent interest 
in EC Erdölchemie was sold to Deutsche BP with effect from May 1, 2001.
The four business areas generated total sales of €28.1 billion, achieving operating
profit before exceptional items of €2.1 billion and a gross cash flow of €3.1 billion.
Health Care had the highest operating result in absolute terms, while Polymers
contributed the largest share of Group sales and gross cash flow. Agriculture remained
the business area with the highest return on sales.
Sales Operating
result*
Gross
cash flow
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€ million 2001 2000 Change
Sales 9,833 10,028 – 1.9%
Operating result before exceptional items 771 1,476 – 47.8%
Return on sales before exceptional items 7.8% 14.7% – 6.9
Gross cash flow 763 1,419 – 46.2%
CFROI 8.2% 16.7% – 8.5
Health Care
The Health Care business area achieved sales of €9.8 billion and an operating result
and gross cash flow of €0.8 billion each. The return on sales and CFROI each declined
to 8 percent, due largely to the problems with biological products and the market
withdrawal of Lipobay®/Baycol®. This event and selective restructuring measures led to
exceptional charges of €0.4 billion in addition. Disregarding one-time effects and
exceptional items, the operating result was down 7 percent to €1.4 billion.
Further extensive programs were introduced to enhance profitability in the Health
Care business area, and we expect to achieve total savings of €550 million in the
Pharmaceuticals Business Group alone. Consumer Care also plans to improve the
efficiency of marketing and administration. The steps taken to improve earnings in the
Diagnostics Business Group are already showing initial success.
Sales in € million 2001 2000 Change
Pharmaceuticals 4,784 4,930 – 3.0%
Sales of the Pharmaceuticals Business Group dipped by €0.1 billion, or 3 percent, 
to €4.8 billion. The global market withdrawal of our cholesterol-lowering drug
Lipobay®/Baycol® alone diminished sales by €0.3 billion. Without this effect, sales
were up by 3 percent compared to the previous year.
The antibiotic Ciprobay®/Cipro® registered increased demand in the fourth quarter,
particularly in the United States, due to its approval for treating anthrax, and worldwide
sales of the product advanced by 10 percent to €2.0 billion. Our cardiovascular drug
Adalat® performed well in the market with sales of €1.0 billion, despite intensified
competition from generic products. Sales of our respiratory antibiotic Avalox®/Avelox®
climbed by 37 percent.
Health Care
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In its new drug (proposed tradename: Nuviva®) to treat erectile dysfunction, the
Pharmaceuticals Business Group has a potential new growth driver. The drug has already
been submitted for registration in the United States, Mexico, Japan and Europe, and 
we expect to launch the product in the U.S. and Mexico in the second half of 2002. 
A worldwide co-promotion agreement has been signed with GlaxoSmithKline plc.
The United States Food and Drug Administration (FDA) has approved the new
intravenous presentation of our antibiotic Avalox®/Avelox® for the treatment of
community-acquired pneumonia.
We signed a cooperation agreement in the field of post-genomics with the Italian
biotech company Axxam S.r.l. concerning the development of technology platforms for
drug discovery. In addition, the extremely successful research alliance with U.S.-based
Millennium Pharmaceuticals has been expanded to include the identification of innovative
substances to treat thrombosis, urinary incontinence and benign prostatic hypertrophy. 
To further expand our research platform, we have signed an agreement to cooperate with
the U.S. biotech company CuraGen in the fields of metabolic diseases and genomics
technology. We also plan to sell various generics companies to sharpen the focus on our
core activities.
Sales in € million 2001 2000 Change
Biological Products 945 1,210 – 21.9%
Sales of the Biological Products Business Group dropped by 22 percent, due mainly to
the production problems for Kogenate®. The business group is optimizing processes to
counter these problems. We anticipate considerable growth in output and operating
profit in 2002.
€ million Change
Ciprobay®/Cipro® 1,964 + 10%
Adalat® 975 – 16%
Aspirin® 723 + 2%
Glucometer® Elite 492 + 4%
Baygon® 372 0%
Gamimune® N 343 – 2%
Glucobay® 312 0%
ADVIA® Centaur System 259 + 46%
Kogenate® 250 – 49%
Canesten®/Mycelex®/Bayclear® 206 + 5%
Best-Selling Bayer Health Care Products 
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Sales in € million 2001 2000 Change
Consumer Care 2,095 1,923 + 8.9%
Consumer Care grew faster than the market, with sales moving up by 9 percent. This
was due above all to the good business trend in North America, where Alka-Seltzer Plus®,
following a successful relaunch, and Aleve® Cold & Sinus achieved particularly high
growth rates. Further highlights included strong growth in sales of our Baygon®
household insecticide in Indonesia and the continuing successful expansion of our
business activities in China.
This business group will aim to nearly triple production capacities for non-
prescription drugs at its site in Lerma, Mexico, by the beginning of 2003, giving the
Consumer Care Business Group another world-scale production site in addition to the
solids plant at Bitterfeld, Germany. This decision takes account of favorable conditions
in Mexico and its close proximity to the United States, the world’s largest OTC market.
Sales in € million 2001 2000 Change
Diagnostics 2,009 1,965 + 2.2%
Sales of the Diagnostics Business Group moved ahead by 2 percent year on year to
€2.0 billion, primarily as a result of growth in our nucleic acid diagnostics activities.
Diagnostics has acquired development, manufacturing and marketing rights for
products to detect hepatitis C and HIV antibodies, giving the business group a
comprehensive product range with a view to improving its performance. Bayer also
signed a co-marketing agreement with U.S.-based Cholestech Corporation for 
products to treat diabetes and cardiovascular disease.
€ million 2001 2000 Change
Sales 3,696 3,455 + 7.0%
Operating result before exceptional items 625 558 + 12.0%
Return on sales before exceptional items 16.9% 16.2% + 0.7
Gross cash flow 713 557 + 28.0%
CFROI 15.3% 15.3% 0
Agriculture
BAYER ANNUAL REPORT 200111
Management Report
➔ Table of Contents
Agriculture
Sales of the Agriculture business area grew by 7 percent to €3.7 billion, thanks largely
to the performance of the Crop Protection Business Group, which grew faster than the
market. The operating result improved by 12 percent to €0.6 billion, while the return on
sales moved up by 1 percentage point to 17 percent. The gross cash flow climbed by a
very gratifying 28 percent.
Sales in € million 2001 2000 Change
Crop Protection 2,708 2,456 + 10.3%
The Crop Protection Business Group boosted sales by 10 percent to €2.7 billion, with
6 percentage points of this increase coming from the acquisitions of the FLINT® line of
fungicides and the corn herbicide MIKADO®. The Garden/Professional Care business
unit registered robust growth in North America, while the Insecticides unit grew strongly
in India and Brazil. We signed a five-year extension of the research alliance with
Paradigm Genetics Inc., United States, for the discovery of innovative herbicide targets.
The €7.25 billion acquisition of Aventis CropScience (ACS), including the assumption
of debt, would give Bayer a leadership position in the crop protection market. The
examination by the antitrust authorities is expected to be completed by the end of the
first quarter of 2002. 
Sales in € million 2001 2000 Change
Animal Health 988 999 – 1.1%
Sales of the Animal Health Business Group dipped by 1 percent to €1.0 billion, due
mostly to the divestiture of the U.S. biological products business. The BSE crises in
Europe and Japan and the foot-and-mouth crises in Europe and Latin America also had a
negative effect on sales. The parasiticide Advantage® achieved a gratifying boost in
sales in North America and Japan.
€ million Change
Confidor®/Gaucho®/ Admire®/Provado® 608 + 5%
Folicur®/Raxil® 272 + 5%
Advantage® 211 + 5%
Baytril® 187 + 10%
FLINT® 97
Sencor® 92 + 2%
Drontal®/Drontal Plus®/Droncit® 88 + 11%
Flufenacet 70 + 11%
Tamaron® 65 – 4%
Goltix® 63 – 14%
Best-Selling Bayer Crop Protection and Animal Health Products 
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Polymers
Sales of the Polymers business area declined by 1 percent to €10.8 billion, while the
operating result dropped by 60 percent to €0.4 billion. This sharp decrease in operating
profit was due mainly to much lower margins. Polymers has been particularly affected
by global economic weakness. All important customer industries have scaled back
production and are reducing inventories, while excess capacities are eroding prices in
several areas. Against this background, the operating margin and CFROI fell by 
6 and 4 percentage points, respectively.
With a view to sustained performance enhancement, the business groups have
introduced extensive cost-containment projects that in 2002 should already lead to
savings of at least €300 million.
Sales in € million 2001 2000 Change
Plastics 3,374 3,520 – 4.1%
Sales of the Plastics Business Group dropped by 4 percent to €3.4 billion. This was due
largely to a sharp decline in volumes in Europe and North America and to increasing
pressure on prices in Europe and Asia.
The business group has signed several co-branding agreements for brand positioning
of Makrolon® high-performance polycarbonate. To strengthen Bayer’s competitive
position with this product, the company has formed a joint venture with Shanghai Chlor
Alkali Chemicals Co. Ltd. to build a new production facility in Caojing, China.
This site will produce Makrolon®, its precursor bisphenol A and the polycarbonate/
acrylonitrile-butadiene styrene (ABS) blend Bayblend® for the Asian market. The
investment volume for this production facility will amount to €500 million.
€ million 2001 2000 Change
Sales 10,788 10,892 – 1.0%
Operating result before exceptional items 434 1,078 – 59.7%
Return on sales before exceptional items 4.0% 9.9% – 5.9
Gross cash flow 1,201 1,556 – 22.8%
CFROI 8.1% 11.7% – 3.6
Polymers
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Sales in € million 2001 2000 Change
Rubber 2,207 2,296 – 3.9%
Sales of the Rubber Business Group decreased by 4 percent to €2.2 billion as a result
of the disappointing business trend in North America and Asia.
As part of our portfolio-streamlining strategy, we plan to divest subsidiary Rhein
Chemie Rheinau GmbH, Mannheim, and our 50 percent interest in PolymerLatex GmbH
& Co. KG of Marl, Germany.
Sales in € million 2001 2000 Change
Polyurethanes 3,193 3,130 + 2.0%
The Polyurethanes Business Group had sales of €3.2 billion, with the acquisition of
Lyondell Chemical Company’s polyols business accounting for €0.2 billion of this figure.
Nearly all product groups faced stiff competition and the resulting pressure on margins.
To improve supply chain efficiency, the business group has brought together its
European structures for logistics, marketing and planning within the subsidiary Bayer
Polyurethane Business Service Center GmbH & Co. KG. Extensive site consolidation is
also planned.
Sales in € million 2001 2000 Change
Coatings and Colorants 2,014 1,946 + 3.5%
The Coatings and Colorants Business Group expanded sales by 3 percent to 
€2.0 billion through the acquisition of Sybron Chemicals Inc.
Sales were below expectations particularly in North America, and also in Europe in
the second half of the year.
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Chemicals
The Chemicals business area grew sales by 10 percent to €3.7 billion, chiefly as a
result of acquisitions. Adverse cyclical effects and substantial write-downs of tantalum
inventories at H.C. Starck diminished the operating result by 27 percent and the gross
cash flow by 24 percent. In consequence, the return on sales fell to 7 percent, and the
CFROI to 8 percent.
The Chemicals business area intends to improve its performance through more active
portfolio management and cost-containment programs. The Basic and Fine Chemicals
and Specialty Products business groups anticipate considerable savings already in 2002,
with at least a €200 million cut in annual costs by 2005.
Sales in € million 2001 2000 Change
Basic and Fine Chemicals 1,025 1,006 + 1.9%
Sales of the Basic and Fine Chemicals Business Group advanced by 2 percent, with the
Inorganic Basic Chemicals business unit performing particularly well. In the Fine
Chemicals unit, there are strong indications of above-average growth in the exclusive
synthesis market for the agrochemical and pharmaceutical industries.
The H-acid production facility at Brunsbüttel, Germany, was sold to Rütgers
Elbechemie GmbH with effect from April 1, 2001, while ChemDesign Corporation of the
United States was divested to U.S.-based Chestnut Acquisition Corporation effective
November 30, 2001.
Sales in € million 2001 2000 Change
Specialty Products 1,469 1,312 + 12.0%
Sales of the Specialty Products Business Group rose by 12 percent, with the
acquisitions of Sybron Chemicals Inc. and the paper chemicals business of Cytec
Industries Inc. adding 16 percentage points. The Ion Exchange Resins and Water
Chemicals business unit achieved good growth.
€ million 2001 2000 Change
Sales 3,749 3,410 + 9.9%
Operating result before exceptional items 271 370 – 26.8%
Return on sales before exceptional items 7.2% 10.9% – 3.7
Gross cash flow 379 497 – 23.7%
CFROI 7.7% 11.0% – 3.3
Chemicals
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Sales in € million 2001 2000 Change
H.C. Starck 811 665 + 22.0%
H.C. Starck increased its sales by 22 percent to €0.8 billion through acquisitions.
Significant consolidation in the electronics market depressed sales of the Electronics
and Optics business unit. Sales in the other business units remained steady year on
year.
Sales in € million 2001 2000 Change
Wolff Walsrode 444 427 + 4.0%
Sales of Wolff Walsrode moved up by 4 percent to €0.4 billion. Lower demand in
Western Europe was more than offset by further market share increases in the 
United States, Latin America and eastern Europe. Here the high growth rates of the
methylcellulose business were particularly gratifying.
Effective June 1, 2001, Covexx Films Walsrode was sold to Wipak, part of the 
Wihuri group of Finland.
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Financial Condition
As a globally operating company, we prepare our financial statements according to the
rules issued by the International Accounting Standards Board, London. 
This provides our stockholders and all other interested parties with a reliable,
internationally comparable basis for evaluating our company and its financial
performance. It also serves as the foundation for our value-based corporate controlling,
in which the central profitability indicator is the cash flow return on investment (CFROI).
Liquidity and capital resources
Our internal financing capability is measured by the gross cash flow (GCF). Our
yardstick of performance is the cash value added (CVA). This is the difference between
the GCF and the GCF hurdle which, in turn, is computed from the capital invested, the
cost of capital and the strategic useful life of the assets. The capital invested is the
gross carrying amount of the assets, less interest-free liabilities. 
The €2.8 billion gross cash flow from continuing operations in 2001 amounted to
90 percent of the hurdle for the year, which was €3.1 billion.
€ million (continuing operations) 2001 2000*
Gross cash flow 2,826 3,847
CVA – 298 1,105
CFROI 8.3 % 12.6 %
Average capital invested 34,064 30,646
*2000 figures restated
The profitability of the enterprise and of the individual business groups is measured by
the cash flow return on investment (CFROI), which is the gross cash flow divided by the
average capital invested. The 2001 fiscal year saw considerable growth in the capital
invested, mainly because of acquisitions in the crop protection business.
The decline in the gross cash flow, combined with the increase in the capital
invested, caused the CFROI to drop by 4 percentage points to 8 percent.
€ million 2001 2000*
Gross operating cash flow 2,923 4,164
Changes in working capital 936 (1,073)
Net cash provided by operating activities 3,859 3,091
of which discontinuing operations 159 302
Net cash used in investing activities (2,132) (6,189)
of which discontinuing operations 295 (298)
Net cash provided by (used in) 
financing activities (1,549) 772
of which discontinuing operations 36 11
Change in cash and cash equivalents 178 (2,326)
Cash and cash equivalents at beginning of year 491 2,812
Change due to exchange rate
movements and to changes in scope of 
consolidation 50 5
Cash and cash equivalents at end of year 719 491
*2000 figures restated
Bayer Group Summary Cash Flow Statements
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The cash flow statement shows the cash inflows and outflows from operating,
investing and financing activities. Despite the decrease in the gross cash flow, we
improved the net operating cash flow by €0.8 billion, or 25 percent, to €3.9 billion
through a €0.9 billion reduction in working capital.
The cash outflow for investing activities amounted to €2.1 billion. Net
disbursements of €2.1 billion for intangible assets, property, plant and equipment and
€0.5 billion for acquisitions were partly offset by a total of €0.5 billion in cash receipts
from interest, marketable securities and investments.
The cash outflow of €1.5 billion for financing activities resulted from the dividend
of €1.0 billion and €0.5 billion in interest payments.
Cash and cash equivalents showed a total year-on-year increase of €0.2 billion, to
€0.7 billion. Including marketable securities and other instruments, liquid assets of
€0.8 billion are shown in the balance sheet.
Earnings performance
On sales (including discontinuing operations) of €30.3 billion, the Group recorded an
operating result of €1.6 billion, giving a return on sales of 5 percent.
In continuing operations, sales increased by 1 percent, and the operating result
before exceptional items dropped by €1.4 billion, or 42 percent, to €1.9 billion. The
return on sales was 6 percent.
Exceptional charges totaled €613 million, compared with a net figure of 
€145 million for the previous year. Of the amount for 2001, the Health Care business
area accounted for €379 million, Polymers for €150 million, Chemicals for €68 million
and corporate costs for €16 million.
The operating result after exceptional items fell by €1.8 billion, or 59 percent, to
€1.2 billion.
Of the operating result from discontinuing operations, Haarmann & Reimer
accounted for €73 million, Fibers for minus €37 million, EC Erdölchemie for €17 million
(January to April) and the gain from the sale of the interest in EC Erdölchemie for 
€0.3 billion.
€ million 2001 Change 
in %
Net sales 30,275 – 2.2
Operating result 1,611 – 51.0
of which discontinuing operations 369 + 65.5
Non-operating result (496) – 67.0
Income before income taxes 1,115 – 62.7
Net income 965 – 46.9
Bayer Group Summary Income Statement
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The non-operating result declined by €199 million to minus €496 million. The
previous year’s figure included €207 million in gains from the sale of the interests in
Myriad Genetics and Schein Pharmaceuticals. While net interest expense rose by 
€38 million to €349 million, a net exchange gain of €49 million was recorded,
compared with a net exchange loss of €21 million in the previous year.
Income before income taxes fell by 63 percent to €1.1 billion. Income tax
expense was down by €1.0 billion to €0.2 billion, due to the lower earnings and to tax-
free income. The effective tax rate for the Group was 14 percent, or 34 percent
calculated on taxable income.
Group net income fell by 47 percent to €1.0 billion.
Earnings
1.1
1.5
1.1
1.6
0.8
2.0
1.2
1.8
0.2
1.0
Income taxes
Income after taxes
€ billion 
20012000199919981997
2001 2000
Cost of goods sold (%) Cost of goods sold 57.2 52.7
Net sales
R&D expenses (%) R&D expenses 8.6 8.1
Net sales
Return on sales before Operating result before exceptional items
6.4 11.2
Net sales
Return on stockholders’ equity (%) Income after taxes 5.8 11.8
Average stockholders’ equity
Return on assets (%) Income before income taxes and interest expense 4.3 10.2
Average total assets
The Group’s profitability ratios were as follows:
exceptional items (%)
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Balance Sheet Structure
Assets
2000 2000
Stockholders’ equity
and liabilities
2001
37
59% 56% 45% 46%
16% 17%
12% 12%
23% 25%
8% 7%
2% 2%
17% 15%
18% 20%
36 36 37
Stockholders’ equityNoncurrent assets
Inventories
Receivables
Pension provisions
Other provisions
Financial obligations
Remaining liabilities
€ billion 
2001
Asset and capital structure
Total assets increased compared with the end of 2000 by €0.6 billion, to €37.0 billion.
Changes in the individual items were as follows:
Noncurrent assets grew by €1.4 billion compared with December 31, 2000.
Acquisitions led to an increase of €0.2 billion in intangible assets, to €5.0 billion.
Property, plant and equipment also increased by €0.2 billion. While capital
expenditures amounted to €2.2 billion, depreciation was €1.8 billion, and retirements
and translation losses totaled €0.2 billion. Investments showed an increase of 
€1.0 billion, comprising €0.6 billion from the fair value measurement of securities, 
€0.2 billion from the at-equity valuation of the DyStar Group and €0.2 billion from
acquisitions.
Current assets – including deferred taxes and deferred charges – declined by 
€0.8 billion, or 5 percent. Liquid assets rose by €0.1 billion. The total of inventories
and receivables decreased by €0.9 billion, with inventories down 5 percent and trade
accounts receivable down 13 percent.
Stockholders’ equity grew by €0.8 billion to €16.9 billion. This included 
€965 million added out of Group net income, while the dividend payment for 2000
amounted to €1,022 million. Changes in stockholders’ equity not recognized in income
amounted to €839 million, comprising €294 million in exchange differences and 
€545 million resulting from the revaluation of financial instruments. The equity-to-
assets ratio was 46 percent.
Liabilities declined by €0.1 billion to €20.0 billion. Financial obligations increased
by €0.7 billion due to further utilization of the commercial paper program, whereas the
remaining liabilities were lower by €0.8 billion.
Net debt rose by €0.6 billion to €6.5 billion.
Liquid assets
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€ million Dec. 31, 2001 Dec. 31, 2000
Noncurrent assets 21,702 20,344
Current assets 15,337 16,107
Stockholders’ equity 16,922 16,140
Minority stockholders’ interest 98 237
Liabilities 20,019 20,074
of which discountinuing operations 307 821
Balance sheet total 37,039 36,451
of which discontinuing operations 1,049 2,000
Summary Balance Sheets
2001 2000
Noncurrent assets
58.6 55.8
Total assets
Depreciation
94.2 80.2
Capital expenditures
Net sales
5.2 5.1
Inventories
Net sales
5.6 5.0
Trade accounts receivable
Stockholders’ equity
45.7 44.3
Total assets
Stockholders’ equity
78.0 79.3
Noncurrent assets
Short-term liabilities
51.9 53.8
Total liabilities
Value Added 
Total operating performance of continuing operations rose slightly to €29.6 billion.
The value added was €9.8 billion, which was 10 percent below the previous year due
to higher material and depreciation costs. Of the value added, €7.6 billion was
distributed to employees, €0.8 billion to governments, €0.7 billion to stockholders and
€0.5 billion to lenders; €0.3 billion will be retained by the company.
The balance sheet ratios are as follows:
(%)
(%)
(%)
(%)
(%)
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Source
€ million 2001 Change
in %
Net sales 28,938 + 1.1
Other income 701 – 22.5
Total operating performance 29,639 + 0.4
Cost of materials 11,057 + 10.1
Depreciation 2,403 + 20.8
Other expenses 6,353 + 0.5
Value added 9,826 – 10.1
Distribution
€ million 2001 Share
in %
Stockholders 657 6.7
Employees 7,576 77.1
Governments 826 8.4
Lenders 463 4.7
Earnings retention 304 3.1
Value added 9,826 100.0
Value Added by Continuing Operations
Proposal for Distribution of the Profit
Under German law the dividend is paid out of the balance sheet profit of the parent
company Bayer AG.
The balance sheet profit for 2001 amounted to €0.7 billion. A summary income
statement for Bayer AG is given below.
€ million 2001 2000
Net sales 10,824 10,816
Cost of goods sold 6,963 6,612
Gross profit 3,861 4,204
Selling, R&D and administration expenses 3,848 3,454
Other operating income – net 9 4
Operating result 22 754
Non-operating result 784 1,380
Income before income taxes 806 2,134
Income taxes 149 432
Net income 657 1,702
Bayer AG Summary Income Statement 1)
We will propose to the Annual Stockholders’ Meeting on April 26, 2002 that the
balance sheet profit be used to pay a dividend of €0.90 (2000: €1.40) per share
(730,341,920 shares) on the capital stock of €1,870 million entitled to the dividend for
2001.
1) The complete financial statements of Bayer AG with an unqualified opinion by the auditors are 
published in the “Bundesanzeiger” and have been included in the Commercial Register in Leverkusen.
They are available from Bayer AG in English or German.
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Employees
On December 31, 2001, there were 112,000 people employed in continuing operations of
the Bayer Group, a decline of 1,900 compared to the end of 2000. A breakdown of
employees by segment and region is provided in the notes to the financial statements
on pages 20-22 of this report. The average number of employees increased to 114,100.
Personnel expenses rose by 4 percent to €7.6 billion, and the ratio of personnel
expenses to sales was 26 percent. The value added per employee dropped by €10,200
to €86,100.
Capital Expenditures
We spent a total of €2.6 billion for intangible assets, property, plant and equipment
in 2001, which was well below our budget of €3.1 billion. Europe accounted for 
€1.6 billion, of which 83 percent was spent in Germany.
The breakdown of capital expenditures for property, plant and equipment is as
follows:
€ billion 2001 Change
in %
Capacity expansions 1.2 + 13.8
Replacement and modernization 0.8 – 18.6
Efficiency improvements 0.2 – 17.0
Capital expenditures for property, 
plant and equipment 2.2 – 3.6
Major projects included:
Health Care
Investment volume: €0.7 billion
• Construction of a facility for packaging and storage of biological products, Berkeley,
California
• Expansion of solids plants, Bitterfeld, Germany and Lerma, Mexico
Capital Expenditures
30
1211
43 41
19
17
Health Care Agriculture Polymers Chemicals
by business area in %
27
20002001
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• Construction of research facilities in West Haven, Connecticut, United States and
Kyoto, Japan (completed 2001)
Agriculture
Investment volume: €0.3 billion 
• Construction of a multi-purpose facility for crop protection products, Dormagen,
Germany
• Insecticides production facility, Dormagen, Germany
Polymers
Investment volume: €1.1 billion
• Expansion of polycarbonate capacities (production of bisphenol A and Makrolon®),
Map Ta Phut, Thailand and Uerdingen, Germany
• Expansion of films capacity, Dormagen, Germany
• Construction of a melt polycarbonate facility, Antwerp, Belgium (completed in 2001)
• Construction of a rubber chemicals facility, Brunsbüttel, Germany (completed in 2001)
• Expansion of isocyanate capacities including precursors, Uerdingen and Brunsbüttel,
Germany
• Expansion of coating raw materials production, Leverkusen, Germany
• Expansion of capacity for aqueous dispersions, Dormagen, Germany (brought on
stream in 2001)
• Expansion of dyestuff production for transparent plastics, Leverkusen, Germany
• Construction of a coating raw materials facility, Caojing, China
Chemicals
Investment volume: €0.5 billion
• Construction of a sulfuric acid facility, Leverkusen, Germany
• Expansion/modification of the electrolysis plant, Leverkusen, Germany
• Construction of a polyaspartic acid facility, Leverkusen, Germany
• Expansion of tantalum production, Goslar, Germany and Mito, Japan
BAYER ANNUAL REPORT 200124
Management Report
➔ Table of Contents
• Process technology center, Goslar, Germany (completed in 2001)
• Modernization and expansion of the nitrocellulose facility, Bomlitz, Germany
• Expansion of the molybdenum facility, Laufenburg, Germany
Capital Expenditure Projects
Our planned investment volume for 2002 is €2.4 billion, which is in line with the
planned level of depreciation.
Major projects in 2002 will include:
Health Care
Investment volume: €0.6 billion 
• Sterile filling facility for Factor VIII, Berkeley, California
• Small volume facility with pilot plant for Aspirin® production, Greppin, Germany
Agriculture
Investment volume: €0.2 billion
• Construction of a facility for a new fungicide, Dormagen, Germany
Polymers
Investment volume: €0.9 billion
• MDI plant for polyurethane raw materials, Caojing, China
• Polycarbonate plant (Makrolon®), Caojing, China
• DNT/TDA precursors for TDI-based polyurethane products, Dormagen, Germany
• Capacity expansion for high-performance coating raw materials (Desmodur® W),
Baytown, Texas
Chemicals
Investment volume: €0.4 billion
• Capacity expansion for methylcellulose construction materials additives, Greppin,
Germany
• New manufacturing process for chlorine and sodium hydroxide solution, Uerdingen,
Germany
• Expansion of capacities for tantalum metal powder for electronics applications,
Goslar, Germany and Map Ta Phut, Thailand
Central service divisions
Investment volume: €0.3 billion
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Acquisitions
We spent €0.5 billion on acquisitions in 2001. These included:
• development, manufacturing and marketing rights for products to detect hepatitis C
and HIV antibodies for €116 million
• the MIKADO® corn herbicide from Syngenta for €115 million
• a €93 million equity investment in CuraGen
Procurement
The difficult business conditions in 2001 also posed new challenges in procurement and
logistics. Continuing high prices and limited supply at the beginning of the year were
followed by a drop in prices and excess supply in the second half. Raw materials supply,
in particular, was affected by high petrochemical prices in the first half. A cyclical drop
in demand was already apparent by the second quarter. This trend intensified in the
second half of the year, spreading to organic intermediates, specialty chemicals and
inorganic raw materials.
In the fourth quarter, despite the difficult business environment, many of our
suppliers granted price concessions that were in some cases substantial. In packaging
and technology procurement, we defended against higher price demands in most cases
and in some areas achieved lower price levels.
The implementation of uniform Group-wide procurement and logistics processes will
support the introduction of SAP in our business areas. We place special emphasis on the
systematic networking of processes, integrating measures to reduce working capital, step
up business-to-business activities, utilize new supply tools and complete transactions via
e-business platforms such as cc.chemplorer and Elemica. The use of various e-commerce
applications has been further expanded.
Effective January 1, 2002, we combined our procurement and logistics functions to
form a Procurement and Logistics Division, in a move designed to make the supply of
goods and services to our sites more efficient.
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Research and Development
Future-oriented investment in research and development is a key factor for commercial
success. High-innovation products are crucial to sustained growth and future value
creation in a global market. We spent €2.5 billion on research and development in
2001. A total of 12,000 employees work in R&D at 25 sites around the world.
By consistently applying cutting-edge technologies and steadily expanding our
research infrastructure in all business areas, we plan to score further productivity
improvements that will help in achieving the ambitious goals of our growth strategy.
Particularly in the Pharmaceuticals and Crop Protection business groups, we are
supplementing our internal expertise through numerous strategic alliances and
collaborations with leading research companies and institutes.
Health Care
In 2001 we spent €1.5 billion, or 64 percent of the Group’s research and development
budget, in the Health Care business area. The objective of our research activities is to
secure long-term growth by launching innovative medicines each year. We are working
both to improve known therapies and to develop new substances to treat diseases for
which there is currently no cure. Here we have focused our research activities on a
limited number of indications, including major life-threatening diseases such as cancer
and cardiovascular disorders.
Bayer has gained access to all key innovative technologies. Pharmaceutical
research today is based on knowledge of molecular changes. We are systematically
exploiting the opportunities arising from the mapping of the human genome. The goal is
to identify disease-relevant genes that can serve as targets in the search for tomorrow’s
medicines. The objective of our genomics strategy is to assemble a network of
collaborations with leading high-tech companies in order to boost productivity and
competitiveness.
Research and Development
64 64
17 18 14 13
5 5
Health Care Agriculture Polymers Chemicals
by business area in %
20002001
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Through these strategic alliances and the ongoing evolution of our internal expertise,
we have already achieved a considerable increase in research efficiency and productivity.
The number of development candidates for new drugs has more than doubled since 1998,
with 20 new compounds currently in preclinical testing.
The promising new substance vardenafil (proposed tradename: Nuviva®) to treat
erectile dysfunction was also developed by researchers at Bayer. It has already been
submitted for registration in Europe, North and Central America.
At the end of November, the United States Food and Drug Administration (FDA)
approved the intravenous presentation of Avalox®/Avelox®. Experts believe this product
has the potential to become a leading treatment for community-acquired pneumonia.
Biological Products will remain an important part of our health care business. Our
research activities focus on the continued evolution of Kogenate®, our genetically
engineered blood-clotting Factor VIII, and on developing new plasma products.
Showing particular promise are Gamunex®, an improved immunoglobulin which we
submitted for registration to the FDA in December 2001, and plasmin, an enzyme to
treat thrombosis.
Our research activities in Health Care are complemented by the development of new
medical diagnostic systems. Research in the Diagnostics Business Group is centered
around infectious diseases, allergies and cancer. Our range of test systems for infectious
diseases was greatly strengthened by the addition of new products to diagnose 
hepatitis C and HIV. We also achieved breakthroughs in cancer diagnostics, developing
tests for the early detection of prostate cancer and systems to diagnose and monitor
treatment of breast cancer. These tests enhance patient convenience by obviating the
need for tissue samples.
Genome research is also benefiting the development of diagnostic systems.
Combining our diverse research activities allows us to provide patients with
individualized options for diagnosis, prevention and treatment.
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Agriculture
The Crop Protection and Animal Health business groups accounted for 17 percent of
Group spending on research and development.
Crop Protection is a core competency for Bayer. Combining the innovative capacity
of Bayer’s existing agrochemical activities with those of Aventis CropScience is intended
to create the basis for a long-term growth strategy.
The new genomics technologies will be used in this area, too. Genetic information
from plants, weeds and pests will be used to unlock molecular mechanisms of action
and identify new targets for crop protection agents. By cooperating with competent
external partners, Bayer has successfully established a broadly based high-tech platform
for the development of new herbicides, fungicides and insecticides.
Bayer’s Everest® herbicide, a product to combat weeds in wheat crops, was
discovered still using conventional methods.
Polymers
The Polymers business groups invested €0.3 billion in R&D in 2001 to strengthen our
position as a technology leader and global supplier of customized, high-quality materials
and system solutions.
In the Plastics Business Group, our Makrolon® polycarbonate is characterized by high
transparency, good flow properties and excellent mechanical strength, and special grades
of the material can be sterilized using gamma rays without yellowing. Thanks to this
outstanding property profile, Makrolon® is being used in medical technology as a material
for injection ampoules whose contents are administered not with a needle, but using a
short burst of high pressure in a virtually painless procedure. The new chlorine and
bromine-free flame retardant Bayblend® FR 3000 generation meets strict environmental
standards and is used particularly for business machine housings.
Additional Bayer plastics entering domains previously reserved for other materials
include black, laser-weldable Durethan® grades and electrostatically coatable Triax®, the
first thermoplastic suitable for automotive bodywork components that are painted online.
The software tool Design & Processing Properties, which allows component and
process-dependent materials data to be incorporated into component development, trims
our customers’ development times and costs.
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With the development of the reversion protection agent Vulcuren®, experts from
Bayer’s Rubber Business Group have succeeded both in increasing the heat resistance of
rubber products and allowing faster and more cost-effective vulcanization of large-volume
parts. Bayer’s Therban® family of high-performance elastomers has been supplemented by
the XT grade, which features specially good adhesion to reinforcing materials. Therban® XT
is used for such items as automotive timing belts. Another highlight is the Levamelt®-
based self-adhesive film used, for example, to protect new vehicles during transit. We have
great expectations for our polar-modified rubber grades, which are currently being tested
for the production of easy-tread tires with good wet grip. We also have extensive know-
how in new measurement methods for material testing, which helps our customers save
time and money.
Our Polyurethanes research centers around improving production processes –
particularly the development of a new polymer polyol process - and optimizing the
processability of established polyurethane systems. One market innovation is the 
Baytec® RT polyurethane spray system, which is used as an alternative to glass-fiber-
reinforced plastics in the manufacture of large molded parts.
Researchers in our Coatings and Colorants Business Group have developed
environmentally friendly soft-touch coatings for plastic surfaces. Applications for these
coatings include cell phone housings and automotive interior parts. Another new
development is Bayoxide® E33 iron oxide granules for removing arsenic from drinking
water.
The November 2001 inauguration of our new Polymer Technical Center in Pudong
highlighted China’s importance to Bayer in terms of polymers research as well as
manufacturing.
Chemicals
The focus is on innovation in our Chemicals business area, too, where we spent 
€0.1 billion in 2001 to optimize processes and develop high-tech products with
significant potential for the future.
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Our Baypure® DS 100 dispersing and sequestering agent was developed by
researchers in the Basic and Fine Chemicals Business Group. As a dispersing agent 
in paper production or a water-softening agent in detergents, Baypure® DS 100 has
considerable advantages over conventional products due to its very good
biodegradability. The biodegradable chelating agent Baypure® CX 100 won the
“Presidential Green Chemistry Challenge Award” of the United States Environmental
Protection Agency. The Baypure®-based Danish product Groen Linie Maskinvask
Color/Ultra became the first laundry detergent in the world to receive the European
Union’s “EU Flower” ecolabel.
The Specialty Products Business Group also markets products used to enhance 
in-process environmental protection. The enzyme-based textile processing chemicals
Baylase® EVO and Baylase® RP save considerable time, energy and chemicals during
cotton pretreatment and washing-off after dyeing. The new chrome-free leather
waterproofing agents XERODERM® P-AF and XERODERM® S-AF were well received at
the leather fair in Bologna, Italy, in the fall of 2001.
We have also developed groundbreaking dye systems for a new generation of
rewritable optical data storage media presented by our partner Sony at the ISOM
electronics fair in Taiwan in October.
H.C. Starck also supplies the electronics sector with innovative products. A novel
process allowed our subsidiary to produce even finer tantalum powder that should
double the capacitance of the next capacitor generation.
At the cellulosics competence center of Wolff Walsrode, research and development
is carried out for methylcellulose, which is used in a wide variety of applications from
construction materials to pharmaceutical products.
Risk Management
As a global company, Bayer is exposed to a wide variety of risks in the course of its
worldwide activities. Even before Germany’s “Law on Corporate Supervision and
Transparency” went into effect on May 1, 1998, Bayer AG operated an effective system
for identifying, communicating and dealing with risks at an early stage. The principles
behind that system are spelled out in the Risk Management Guidelines approved by
the Board of Management and valid throughout the Bayer Group. In line with our
corporate responsibility to deal adequately with risks, our goal is to identify as early and
as fully as possible the potential risks associated with our activities, assess the possible
consequences of their materialization and take suitable measures to mitigate them. The
identification and assessment of these risks are crucial to the company’s commercial
success. The various processes and instruments used depending on the respective risk
profile are constantly being improved, supplemented and optimized in line with statutory
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requirements and the expectations of Bayer’s management. Effective risk management
ensures the efficient use of these processes and instruments. 
Risk management is an integral part of all decisions and business processes in the
Bayer Group. The management structure, the planning system, and the reporting and
information systems, in particular, form the basis for the organizational integration of
risk management into business processes.
Reporting plays a central role in monitoring the economic risks of our everyday
business, as it ensures that the business performance of individual Group companies is
described and reported to Group headquarters according to uniform guidelines. In addi-
tion to the data on which external reports are based, internal reports are produced each
month to ensure that the Board of Management and the various management levels are
fully alerted to possible risks in a timely fashion. Bayer’s Enterprise Accounting and
Reporting Division supports these activities and works to increase the responsiveness
and efficiency of the reporting system.
To ensure that the risk management system is functional at all times, we employ
highly effective monitoring and control mechanisms based on established standard soft-
ware. These mechanisms are the subject of continuous improvement and are adjusted
immediately to changes in circumstances.
The internal audit department examines at regular intervals the risk management
system’s efficiency and functionality. In addition, possible risks are identified and docu-
mented with respect to their quantitative effects and the likelihood of their materiali-
zation so that precautionary measures can be taken.
The Law on Corporate Supervision and Transparency requires our external auditors
to periodically evaluate our risk management system. The Board of Management and the
Supervisory Board are regularly briefed on the results of this evaluation.
Our business activities involve the following primary risks:
As a manufacturing company active in numerous areas of the health care and chemi-
cals industry, we are subject to the procurement market risk that the raw materials
and utilities needed to manufacture our products may not be available, or that their
quality or quantity may be insufficient. Here we have the international network of our
Procurement and Logistics Division at our disposal.
This enables us to identify risks on the procurement markets at an early stage,
respond to changes and ensure a constant supply of raw materials, as well as achieve
more favorable prices and supply terms for the Group as a whole.
We guard against exchange and interest rate risks by financing our business in
local currencies or by hedging currency and interest positions using derivative financial
instruments. Such instruments are employed according to the respective risk assess-
ments and on the basis of detailed guidelines. To a limited extent, these guidelines also
allow us to hedge against currency risks of anticipated transactions.
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We address product and environmental risks by way of suitable quality assurance
measures. These include certifying our operations to international standards, continu-
ously upgrading our plants and processes, and developing new and improved products.
Strict quality requirements are met by applying uniform standards throughout the world.
We also aim to ensure the safety of our products and their proper usage by
customers. For example, when we received a growing number of reports of side effects
associated with our cholesterol-lowering drug Lipobay®/Baycol®, especially in patients
who had been prescribed the active substance gemfibrozil concomitantly despite
specific warnings and a contraindication in the product information, we voluntarily
withdrew all dosages of the product from the market in August 2001 in the interest of
patient safety despite the adverse financial consequences for the enterprise.
We are committed to the international Responsible Care initiative of the chemical
industry and to our own safety and environmental management system, which we report
on at regular intervals. Specially developed guidelines on product stewardship,
occupational safety and environmental protection are designed to ensure that all of our
employees act competently and responsibly.
To guard against possible liability risks and compensation claims, we have
concluded insurance agreements to keep the potential consequences within reasonable
limits or exclude them completely. The level of insurance cover is continuously
reexamined and adjusted where necessary.
Even if there can be no guarantee that the sums insured cover all conceivable risks,
we assume that any claims would not affect the Group’s assets, financial position or
earnings situation to the extent of jeopardizing the company’s existence.
To counter risks that could arise from the numerous tax, competition, patent,
antitrust and environmental regulations and laws, we make our decisions and engineer
our business processes on the basis of comprehensive legal advice provided both by our
own experts and by acknowledged external specialists. We establish provisions in the
balance sheet for any risks resulting from new laws or legal judgments that apply
retroactively.
Business risks also include those pertaining to acquisitions, capital expenditures
and research and development activities. These future-oriented activities are vital to the
continued existence of the Group, yet they also harbor risks because of the related
uncertainties.
We control and mitigate operating risks by exercising due diligence prior to such
activities and by tracking their progress. For example, we investigate whether budgets
can be adhered to, whether original forecasts can be met and whether additional
financial or technological risks are likely to emerge.
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The future success of our business depends in no small part on the dedication,
motivation and skills of our employees. We must be capable at all times of attracting
suitably qualified technical and managerial personnel, successfully integrating them into
our operations and ensuring that they stay with us over the long term.
With this goal in mind, we offer our employees internal education and training
opportunities, as well as attractive remuneration systems that include, for example, our
stock compensation programs. To ensure that our employees act responsibly from both
a professional and a legal point of view within their respective fields of work, we have
promulgated a worldwide legal compliance program. Supported by thorough training,
this behavioral code obligates employees to observe laws and regulations. Complying
with the rules at all times and monitoring the way employees handle risks are among the
basic duties of all managers and supervisors throughout the Group. Binding guidelines
and instructions are distributed throughout the enterprise to help ensure that our
employees act consistently and safely.
After assessing the current risk situation, we have concluded that we carry sufficient
insurance cover and that the provisions established in the balance sheet are adequate.
We have not identified any risks that could jeopardize the existence of the Bayer Group.
Furthermore, we believe we are capable of countering future risks.
Subsequent Events 
Bayer AG has sold most of its real estate holdings to TreuHandStelle GmbH (THS) of
Essen, Germany. Under the terms of the agreement signed by both companies, Bayer
transferred 94.9 percent of its interest in Bayer Wohnungen GmbH (BayWoGe) 
to THS on March 1, 2002.
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Strategy
The Bayer Group is currently undergoing a process of strategic realignment and
corporate reorganization aimed at improving our earnings performance for the long
term. At the center of this process are plans to fundamentally reorganize the enterprise.
Under the umbrella of a management holding company, four independent operating
subsidiaries for HealthCare, CropScience, Polymers and Chemicals would be formed,
along with three service companies. It is planned to implement this new structure step
by step, subject to the approval of the Annual Stockholders’ Meetings in 2002 and
2003.
The aim in forming independent operating units is to achieve greater flexibility, which
in turn should accelerate portfolio management, technology development, identification
of market opportunities and response to customer needs. The new structure would
make Bayer a more focused enterprise, unlocking additional innovative potential and
problem-solving expertise for the benefit of our customers.
Finally, setting up separate corporate entities would enhance transparency, making it
easier to identify businesses as drivers or destroyers of value.
The effect would be to boost Bayer’s competitiveness in our various markets and
create the necessary conditions for strategic partnerships.
We believe the enterprise has major potential for further development in the fields of
HealthCare, CropScience, Polymers and Chemicals.
It is planned to place the Pharmaceuticals, Biological Products, Consumer Care,
Diagnostics and Animal Health business groups into what should prove to be a strong-
performing health care company. To achieve critical mass and round out our portfolio,
we are actively looking for strategic partnerships for the entire business area or for
individual business units or niche markets.
To improve the efficiency of our pharmaceutical research and development, we
have assembled an extensive network of external collaborations in the search for drug
targets and potential active ingredients for new drugs. Long-term alliances with leading
biotechnology companies give us access to state-of-the-art technologies and leading-
edge expertise. Our goal is to identify at least 20 new active substance candidates each
year with the help of this research platform, and thus to create a solid basis for the
efficient development of new medicines.
In Consumer Care, we are looking to strengthen sales of our Aspirin®, Alka-Seltzer®
and Canesten® brands. Diagnostics has a major strategic focus on oncology.
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Our Crop Protection Business Group already boasts an outstanding product
portfolio in insecticides and fungicides. The acquisition of Aventis CropScience (ACS),
assuming it receives regulatory approval, would strengthen our position in herbicides,
the main growth driver in the world crop protection market. We would also gain access
to cost-effective application of green biotechnology. Overall we would have leadership
positions in all major sectors of the agrochemical industry, whose three pillars – crop
protection, green biotechnology and seeds – are expected to increasingly converge and
support each other.
We plan to expand our research platform of enabling technologies not only through
the integration of ACS, but also through alliances with competent external partners. We
expect to develop a steady stream of new products to market maturity in the coming
years.
In Polymers, we are already a market leader in many areas of business. We have an
excellent global position following the Lyondell polyols acquisition and the purchase of
Sybron. We are committed to long-term expansion plans for core products such as our
Makrolon® high-tech polycarbonate, the polyurethane precursors MDI and TDI, and our
coating raw materials. In the short and medium term, however, the focus will be on
improving margins. Apart from the need to expand our presence in North America and
Europe, the growth markets of Asia are of great strategic importance. In China we have
announced our largest single investment program ever, with a planned volume of 
€3.4 billion.
In Chemicals, we are concentrating on our specialty, fine and electronic chemicals
activities. We must continue to optimize cost structures and streamline the portfolio,
particularly in basic chemicals. In view of continuing industry consolidation, we are
prepared to enter a strategic partnership that could lead to a joint venture with a
similarly structured company. In the medium term, we are looking to enter an alliance
that would add to our technological expertise, expand our marketing activities and
strengthen our presence in the main economic regions.
Bayer’s corporate strategy is geared to achieving a sustained increase in value
through our active portfolio management, which will continue to focus on strong organic
growth and strategic acquisitions. Our goal is to substantially increase the cash 
value added. To do so, we are consistently applying the principles of value-based
management, which involve setting specific operating targets for all areas of the
company. The stock compensation program and variable remuneration of our employees
are linked to the achievement of these targets.
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Outlook
Global economic trend
We anticipate that the economy of the United States will gain momentum during the
second half of 2002. In conjunction with stimulus from monetary policy and declining
pressure on prices, this should have a positive effect on the euro zone economy. We are
less optimistic about the trend in Japan.
Objectives for 2002
In Health Care, we expect the situation in Biological Products to improve over the course
of the year. However, this will not entirely compensate for the loss of revenues caused
by the Lipobay®/Baycol® withdrawal.
The planned acquisition of Aventis CropScience would further strengthen our crop
protection business, with 2002 being a year of integration. We expect the new company
Bayer CropScience to achieve a 20 percent operating margin by 2005 – an estimate
based on a strong market position, a well stocked product pipeline and the prospect of
rising earnings from green biotechnology.
For Polymers, we anticipate continued price erosion due to overcapacities, resulting
in stiffer competition. Orders received for January and February 2002 show a slight
improvement compared to the fourth quarter of 2001, though they remain well below the
previous year’s level.
Our Chemicals business should come out stronger as a result of active portfolio
management and structural changes, coupled with the opportunities arising from the
changing corporate structure.
We expect Group net income for 2002 to show a distinct year-on-year improvement.
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Management’s Statement of Responsibility 
for Financial Reporting
The consolidated financial statements of the Bayer Group have been prepared by the
management, which is responsible for the substance and objectivity of the information
contained therein. The same applies to the management report, which is consistent with
the financial statements.
Our financial reporting takes place according to the rules issued by the International
Accounting Standards Board, London. 
Effective internal monitoring procedures instituted by Group management at the con-
solidated companies along with appropriate staff training ensure the propriety of our
reporting and its compliance with legal provisions. Integrity and social responsibility
form the basis of our corporate principles and of their application in areas such as envi-
ronmental protection, quality, product safety, plant safety and adherence to local laws
and regulations. The worldwide implementation of these principles and the reliability and
effectiveness of the monitoring procedures are continuously verified by our Corporate
Auditing Department.
These measures in conjunction with a uniform reporting system throughout the
Group ensure that Group companies present the management with an accurate view of
their business operations, enabling us to discern risks to our assets or fluctuations in
the economic performances of Group companies at an early stage and at the same time
providing a reliable basis for the consolidated financial statements and management
report.
The Board of Management conducts the business of the Group in the interests of the
stockholders and in awareness of its responsibilities toward employees, communities
and the environment in all the countries in which we operate. Our declared aim is to
deploy the resources entrusted to us in order to increase the value of the Bayer Group
as a whole.
In accordance with the resolution of the Annual Stockholders’ Meeting, the
Supervisory Board appointed PwC Deutsche Revision Aktiengesellschaft as independent
auditors of the consolidated financial statements and of the statements’ compliance
with the International Accounting Standards. The scope of the auditors’ report, which
appears on the following page, also includes Bayer’s risk management system, which
they have audited in light of the German Law on Corporate Supervision and
Transparency. The consolidated financial statements, the management report and the
auditors’ report were discussed in detail, in the presence of the auditors, by the
Presidial Committee of the Supervisory Board and at a plenary meeting of the
Supervisory Board. The Report of the Supervisory Board appears elsewhere. 
The Board of Management
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Independent Auditors’ Report
We have audited the consolidated financial statements of the Bayer Group, comprising
the income statement, the balance sheet, the statement of changes in stockholders’
equity and the statement of cash flows as well as the notes to the financial statements
for the financial year from January 1 through December 31, 2001. The preparation and
the content of the financial statements according to the International Accounting
Standards of the IASB (IAS) are the responsibility of the Board of Management of 
Bayer AG. Our responsibility is to express an opinion, based on our audit, about whether
the consolidated financial statements are in accordance with IAS. 
We conducted our audit of the consolidated financial statements in accordance with
German auditing standards, the German principles for the auditing of financial state-
ments promulgated by the Institut der Wirtschaftsprüfer (IDW) (German Institute of
Certified Public Accountants), and the International Standards on Auditing (ISA). Those
standards require that we plan and perform the audit to obtain reasonable assurance
about whether the consolidated financial statements are free of material misstatements.
The evidence supporting the amounts and disclosures in the consolidated financial
statements is examined on a test basis within the framework of the audit. The audit
includes assessing the accounting principles used and significant estimates made by the
Board of Management, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that our audit provides a reasonable basis for our 
opinion. 
In our opinion, based on our audit, the consolidated financial statements as of
December 31, 2001 give a true and fair view of the net worth, financial position, results
of operations and cash flows of the Bayer Group for the financial year in accordance
with IAS. 
Our audit, which – according to German auditing regulations – also extends to the
Group management report prepared by the Board of Management for the financial year
from January 1 through December 31, 2001, has not led to any objections. In our opin-
ion, the management report provides, on the whole, a fair understanding of the Group’s
position and adequately presents the risks related to its future development. In addition,
we confirm that the consolidated financial statements of the Bayer Group and the Group
management report for the financial year from January 1 through December 31, 2001
satisfy the conditions required for the company’s exemption from its obligation to pre-
pare the consolidated financial statements and the Group management report in accor-
dance with the German Commercial Code. 
Essen, February 26, 2002
PwC Deutsche Revision
Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft
P. Albrecht J. Schilling 
(Certified Public Accountant) (Certified Public Accountant)
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Bayer Group Consolidated Statements of Income
Note 2001 2000
€ million € million
Net sales [1] 30,275 30,971
Net sales from discontinuing operations [6] (1,337) (2,356)
Net sales from continuing operations 28,938 28,615
Cost of goods sold (16,542) (15,077)
Gross profit 12,396 13,538
Selling expenses [2] (6,980) (6,637)
Research and development expenses [3] (2,488) (2,319)
General administration expenses (988) (885)
Other operating income [4] 480 425
Other operating expenses [5] (1,178) (1,058)
Operating result from continuing operations 1,242 3,064
Operating result from discontinuing operations [6] 369 223
Operating result [7] 1,611 3,287
Income from investments in affiliated companies – net [8] 54 283
Interest expense – net [9] (349) (311)
Other non-operating expenses – net [10] (201) (269)
Non-operating result (496) (297)
Income before income taxes 1,115 2,990
Income taxes [11] (154) (1,148)
Income after taxes 961 1,842
Minority stockholders’ interest [13] 4 (26)
Net income 965 1,816
Earnings per share (€) [14] 1.32 2.49
* 2000 figures restated
*
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Bayer Group Consolidated Balance Sheets *Note Dec. 31, 2001 Dec.31,2000
€ million € million
ASSETS
Noncurrent assets
Intangible assets [18] 5,014 4,843
Property, plant and equipment [19] 13,543 13,345
Investments [20] 3,145 2,156
21,702 20,344
Current assets
Inventories [21] 5,818 6,095
Receivables and other assets
Trade accounts receivable [22] 5,415 6,244
Other receivables and other assets [23] 2,447 2,414
7,862 8,658
Liquid assets [24]
Marketable securities and other instruments 52 213
Cash and cash equivalents 719 491
771 704
14,451 15,457
Deferred taxes [11] 608 413
Deferred charges [25] 278 237
37,039 36,451
of which discontinuing operations [35] 1,049 2,000
STOCKHOLDERS’ EQUITY AND LIABILITIES
Stockholders’ equity
Capital stock of Bayer AG 1,870 1,870
Capital reserves of Bayer AG 2,942 2,942
Retained earnings 9,841 9,047
Net income 965 1,816
Other comprehensive income
Currency translation adjustment 759 465
Miscellaneous items 545 0
[26] 16,922 16,140
Minority stockholders’ interest [27] 98 237
Liabilities
Long-term liabilities
Long-term financial obligations [30] 3,071 2,803
Miscellaneous long-term liabilities [32] 140 196
Provisions for pensions and other post-employment benefits [28] 4,407 4,254
Other long-term provisions [29] 1,288 1,208
8,906 8,461
Short-term liabilities
Short-term financial obligations [30] 4,309 3,862
Trade accounts payable [31] 1,993 2,016
Miscellaneous short-term liabilities [32] 1,832 2,274
Short-term provisions [29] 1,477 1,701
9,611 9,853
18,517 18,314
of which discontinuing operations [35] 307 821
Deferred taxes [11] 1,238 1,595
Deferred income [34] 264 165
37,039 36,451
* 2000 figures restated
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Bayer Group Consolidated Statements of Changes in Stockholders’ Equity
Capital Capital Retained Net Currency Miscel- Total
stock of reserves of earnings income translation laneous
Bayer AG Bayer AG adjustment items 
€ million € million € million € million € million € million € million
Dec. 31, 1999 1,870 2,942 7,965 2,002 227 0 15,006
Changes in stockholders’ equity 
resulting from capital contributions 
and dividend payments
Capital contributions 0
Dividend payments (949) (949)
(949) (949)
Other changes in stockholders’ equity 
not recognized in income
Exchange differences 238 238
Other differences 29 29
29 238 267
Changes in stockholders’ equity 
recognized in income 
Allocation to retained earnings 1,053 (1,053) 0
Income after taxes for 2000 1,816 1,816
1,053 763 1,816
Dec. 31, 2000 1,870 2,942 9,047 1,816 465 0 16,140
Changes in stockholders’ equity 
resulting from capital contributions 
and dividend payments
Capital contributions 0
Dividend payments (1,022) (1,022)
(1,022) (1,022)
Other changes in stockholders’ equity 
not recognized in income
Exchange differences 294 294
Other differences 545 545
294 545 839
Changes in stockholders’ equity 
recognized in income
Allocation to retained earnings 794 (794) 0
Income after taxes for 2001 965 965
794 171 965
Dec. 31, 2001 1,870 2,942 9,841 965 759 545 16,922
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Bayer Group Consolidated Statements 
of Cash Flows *
* 2000 figures restated
Note 2001 2000
€ million € million
Operating result 1,611 3,287
Income taxes currently payable (637) (873)
Depreciation and amortization 2,516 2,139
Change in long-term provisions (193) (316)
Gains on retirements of noncurrent assets (374) (73)
Gross cash provided by operating activities 2,923 4,164
(Increase) Decrease in inventories 146 (750)
(Increase) Decrease in trade accounts receivable 638 (548)
Increase in trade accounts payable 73 351
Changes in other working capital 79 (126)
Net cash provided by operating activities [39] 3,859 3,091
of which discontinuing operations [42] 159 302
Cash outflows for additions to property, plant and equipment (2,617) (2,647)
Cash inflows from sales of property, plant and equipment 521 322
Cash inflows related to investments 109 (45)
Cash outflows for acquisitions (502) (4,125)
Interest and dividends received 138 191
Cash inflows from marketable securities 219 115
Net cash used in investing activities [40] (2,132) (6,189)
of which discontinuing operations [42] 295 (298)
Capital contributions 0 2
Bayer AG dividend and dividend payments 
to minority stockholders (1,028) (953)
Issuances of debt 2,514 3,952
Retirements of debt (2,551) (1,893)
Interest paid after taxes (484) (336)
Net cash provided by (used in) financing activities [41] (1,549) 772
of which discontinuing operations [42] 36 11
Change in cash and cash equivalents 
due to business activities 178 (2,326)
Cash and cash equivalents at beginning of year 491 2,812
Change in cash and cash equivalents due to changes 
in scope of consolidation 42 (3)
Change in cash and cash equivalents 
due to exchange rate movements 8 8
Cash and cash equivalents at end of year [43] 719 491
Marketable securities and other instruments 52 213
Liquid assets as per balance sheets 771 704
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The consolidated financial statements of the Bayer Group are prepared – pursuant to
Article 292a of the German Commercial Code – in accordance with the rules of the
International Accounting Standards Board (IASB), London, in effect at the closing date.
They comply with the European Union’s guidelines on consolidation of financial state-
ments (Directive 83/349/EEC).
The financial statements of the consolidated companies are prepared according to
uniform recognition and valuation principles. Valuation adjustments made for tax rea-
sons are not reflected in the Group statements. The individual companies’ statements
are prepared as of the closing date for the Group statements.
In compliance with IAS 37, provisions are established for contingent liabilities if 
available information indicates that an asset has been impaired or a liability has been
incurred, and the amount of the impairment loss can be estimated with sufficient 
reliability.
Certain income statement and balance sheet items are combined for the sake of
clarity, as explained in the Notes. A distinction is made in the balance sheet between
long-term and short-term liabilities in accordance with IAS 1 (Presentation of Financial
Statements). Liabilities are stated as short-term if they mature within one year. Income
received such as royalties, rental income, interest income or dividend income is recog-
nized on an accrual basis.
Changes in recognition and valuation principles are explained in the Notes. The pre-
vious year’s figures are restated accordingly. Accounting policies for individual cate-
gories of items in the income statement and balance sheet are included in the relevant
notes.
In a few instances, estimates and assumptions have to be made. These affect the
classification and valuation of assets, liabilities, income, expenses and contingent liabili-
ties. The actual values may vary from the estimates.
Notes to the Consolidated Financial Statements 
of the Bayer Group
A C C O U N T I N G
P O L I C I E S
The consolidated financial statements of the Bayer Group for the 2001 fiscal year com-
ply with the following new or revised International Accounting Standards (IAS) and inter-
pretations of the Standing Interpretations Committee (SIC) that the Group implemented
for the first time in 2001:
IAS 12 (Revised 2000) Income Taxes
IAS 19 (Revised 2000) Employee Benefits
IAS 39 Financial Instruments: Recognition and Measurement
IAS 40 Investment Property
SIC-17 Equity – Cost of an Equity Transaction
SIC-19 Reporting Currency – Measurement and Presentation of
Financial Statements under IAS 21 and IAS 29
The adoption of these standards did not have any significant impact on Bayer’s financial
position or its results of operations during 2001 or on the comparability of its 2001 and
2000 consolidated financial statements.
E F F E C T  O F  N E W
A C C O U N T I N G
P R O N O U N C E M E N T S
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The following new interpretations will be implemented in 2002:
SIC-27 Evaluating the Substance of Transactions Involving the Legal Form of a Lease
SIC-28 Business Combinations – “Date of Exchange” and Fair Value of Equity
Instruments
SIC-29 Disclosure – Service Concession Arrangements
SIC-30 Reporting Currency – Translation from Measurement Currency to Presentation
Currency
SIC-31 Revenue – Barter Transactions Involving Advertising Services
SIC-33 Consolidation and Equity Method – Potential Voting Rights and Allocation of
Ownership Interests
A series of related transactions legally amounting to a lease contract should be
accounted for as a single transaction according to SIC-27 (Evaluating the Substance of
Transactions Involving the Legal Form of a Lease). This applies particularly in cases
where the substance of the transactions cannot be adequately understood without 
reference to the series of transactions as a whole.
If a company pays for an acquisition with its own shares, determination of the “date
of exchange” is crucial to valuation. According to SIC-28 (Business Combinations –
“Date of Exchange” and Fair Value of Equity Instruments), the “date of exchange” is the
day on which the agreed transaction is executed and the acquirer gains control over the
net assets and business activities of the acquired unit. The cost of acquisition is based
on the publicly quoted price of the equity instruments on that day.
The disclosure requirements for agreements under which the reporting enterprise is
granted a concession to provide public services such as drinking water supplies are
defined in SIC-29 (Disclosure – Service Concession Arrangements). All aspects of such
concession arrangements should be disclosed.
Where a company’s financial statements are published in a currency other than the
measurement currency, SIC-30 (Reporting Currency – Translation from Measurement
Currency to Presentation Currency) provides that the statements be translated by the
method specified in IAS 21 for foreign companies whose activities are not an integral
part of those of the reporting enterprise (“foreign entities”).
Rules for realizing revenues from advertising-related barter transactions are given in
SIC-31 (Revenue – Barter Transactions Involving Advertising Services).
According to SIC-33 (Consolidation and Equity Method – Potential Voting Rights and
Allocation of Ownership Interests), potential voting rights that currently can be exercised
without restriction, such as those conferred by stock subscription rights or stock pur-
chase options, must be taken into account in determining whether one company 
controls or significantly influences another. However, the actual ownership interests held
must continue to be used for the consolidation.
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The financial statements of the Bayer Group as of December 31, 2001 include Bayer AG
and 49 German and 189 foreign consolidated subsidiaries in which Bayer AG, directly or
indirectly, has a majority of the voting rights. The total number of consolidated compa-
nies has risen by 10 from the previous year. Excluded from consolidation are 85 sub-
sidiaries that in aggregate are immaterial to the net worth, financial position and earn-
ings of the Bayer Group; they account for less than 1 percent of Group sales. 
We have included 12 joint ventures – 29 fewer in total than in the previous year – by
proportionate consolidation in compliance with IAS 31 (Financial Reporting of Interests
in Joint Ventures). The decline in the number of included joint ventures is due mainly to
the inclusion of DyStar GmbH, Frankfurt am Main, Germany, by the equity method start-
ing in 2001. The effect of joint ventures on the Group balance sheet and income state-
ment is as follows:
While 11 companies are stated at equity, 58 companies that in aggregate are of minor
importance are stated at their carrying amounts.
Consolidated for the first time are 27 companies, including those that belonged to
the Cleveland, Ohio-based CSM group, which we acquired at the end of 2000. As a
consequence of divestitures and mergers the number of consolidated companies was
reduced by 47.
Acquisitions are accounted for by the purchase method. Accordingly, the results of
operations of the acquired businesses are included in the consolidated financial
statements as of the respective dates of acquisition. The purchase prices of the foreign
acquisitions are translated at the exchange rates in effect at the respective dates of
acquisition. 
In 2001 a total of €514 million was spent on acquisitions, which were paid for in
cash, not with shares of the company. These acquisitions led to goodwill of €50 million,
including €45 million in additional goodwill resulting from the Lyondell polyols
acquisition. The goodwill amounts are being amortized by the straight-line method over
periods not exceeding 20 years.
In June 2001, Bayer Corporation, United States, acquired at a cost of €116 million
development, manufacturing and distribution rights for products to detect antibodies to
the hepatitis C virus (HCV) and HIV from the strategic cooperation between Ortho-
Clinical Diagnostics Inc., Raritan, New Jersey, and Chiron Corporation, Emeryville,
California. This acquisition expands the Diagnostics Business Group’s portfolio of
immunodiagnostic agents, strengthening its laboratory testing segment. The rights are
being amortized over an estimated useful life of 12 years.
Bayer expanded its crop protection business in Europe on February 1, 2001 by
acquiring MIKADO®, a leading corn herbicide, from Syngenta AG, Basel, Switzerland, for
€115 million. The transaction covers business in the European Union and EFTA
S C O P E  O F  
C O N S O L I D AT I O N
€ million 
Noncurrent assets 230
Current assets 184
Pension provisions (7)
Other provisions (10)
Financial obligations (77)
Remaining liabilities (78)
Net assets 242
€ million
Income 499
Expenses 443
Income after taxes 56
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(European Free Trade Association) countries as well as patents, registrations, trademark
rights, and production and formulation expertise. The acquired intangible assets are
being amortized over an estimated useful life of 10 years.
Bayer AG has purchased a €93 million equity interest in CuraGen Corporation, New
Haven, Connecticut, a leading biotech company. The objective of the collaboration
agreement concluded with CuraGen in mid-January 2001 is to jointly develop and market
novel drugs to treat obesity and diabetes. The intention is also to use special genomics-
based technologies to evaluate substances in Bayer’s early pharmaceutical research
pipeline regarding their suitability for further clinical development.
On May 1, 2001, Bayer Corporation, United States, increased its equity ownership in
PharmaNetics Inc., Raleigh, North Carolina, by a further €25 million for the Diagnostics
Business Group. The existing distribution agreement with PharmaNetics was expanded
to cover Theranostic tests (rapid diagnostic testing during drug therapy), a core
component of the technology platform offered by PharmaNetics Inc. The agreement
includes non-exclusive rights in the U.S. and exclusive rights elsewhere for the
Diagnostics Business Group to distribute Theranostic tests.
In February 2001, Bayer acquired a €17 million equity interest in PPL Therapeutics
plc, Edinburgh, United Kingdom. PPL Therapeutics is a biotech company involved in the
discovery, development, production and marketing of genetically modified proteins for
therapeutic purposes and food products. The Pharmaceuticals Business Group and PPL
Therapeutics have concluded an agreement under which Bayer will pursue the clinical
development of, and acquire, global exclusive marketing rights to the company’s major
product, rAAT (recombinant alpha-1-antitrypsin). PPL Therapeutics intends to
manufacture the product in a new facility currently scheduled for construction.
On February 12, 2001, the Pharmaceuticals Business Group purchased a €16 million
equity interest in Avigen Inc., Alameda, California, a leading biotech company. The
investment gives Bayer global, exclusive marketing and distribution rights to the gene
therapy Coagulin-B™ developed by Avigen Inc. for the treatment of hemophilia B by gene
transfer. Avigen Inc. intends to meet global demand for Coagulin-B™ from manufacture
in a new production facility scheduled for construction.
On March 15, 2001, Bayer Corporation concluded an agreement on HIV and hepatitis
C virus (HCV) tests with the biotech company Innogenetics N.V., Ghent, Belgium, for the
Diagnostics Business Group. For €12 million Bayer acquired exclusive worldwide
distribution and marketing rights, including rights to further developments in the future,
for the HIV and HCV product lines manufactured by Innogenetics. These intangible
assets are being amortized over an estimated useful life of 10 years.
H.C. Starck GmbH, Goslar, Germany, a subsidiary of Bayer AG, acquired TeCe
Technical Ceramics GmbH & Co. KG, Selb, Germany from Deutsche Shell GmbH for 
€9 million effective January 1, 2001. The acquisition complements H.C. Starck’s
activities in surface technology and ceramics. The very good manufacturing conditions
and geographical advantages support H.C. Starck’s aim of expanding its position in the
U.S. market. The acquired goodwill of €4 million is being amortized in the Bayer Group
financial statements over an estimated useful life of 5 years.
In December 2001, the Consumer Care Business Group of Bayer’s Mexican
subsidiary Bayer de México, S.A. de C.V. purchased the marketing rights to Cevalin®, 
a leading vitamin C brand, and the well-known disinfectant Merthiolate® from Eli Lilly.
The rights will be amortized over an estimated useful life of 10 years.
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Significant divestitures in 2001 were as follows:
Bayer sold its 50 percent interest in EC Erdölchemie GmbH, Cologne, Germany to
the other joint venture partner Deutsche BP AG, Hamburg, Germany, effective May 1,
2001, following approval from the E.U. Commission. The proceeds of the sale amounted
to €476 million. Future raw material supplies from Erdölchemie to Bayer are
contractually assured, as is the provision of services by Bayer to Erdölchemie.
Bayer Group company Wolff Walsrode AG sold its subsidiary Covexx Films, Walsrode,
Germany, a company specializing in high-performance films, to Wipak, part of the Wihuri
group of Finland, effective June 1, 2001.
Effective April 1, 2001, Bayer AG sold the H-acid production facilities on its
Brunsbüttel site to Rütgers Elbechemie GmbH, a subsidiary of Rütgers VTF AG.
Bayer sold its interest in ChemDesign Corporation, Fitchburg, Massachusetts, to
Chestnut Acquisition Corporation, Mendham, New Jersey, a subsidiary of Chestnut
Investments LLC, Mendham, New Jersey, effective November 30, 2001. ChemDesign
manufactures organic chemicals mainly for the agrochemical and photographic
industries.
As part of the planned divestiture of Bayer’s fibers activities, the Dralon® business
was sold to the Fraver group of Biella, Italy, at the beginning of the year.
Acquisitions and divestitures of businesses affected the Group’s assets and liabilities
as of the dates of acquisition or divestiture as follows:
Lists of Bayer AG’s direct and indirect holdings have been included in the
Leverkusen commercial register. They also are available directly from Bayer AG on
request.
The following domestic subsidiaries availed themselves in 2001 of certain
exemptions granted under Articles 264, paragraph 3 and 264 b, No. 4 of the German
Commercial Code regarding the preparation, auditing and publication of financial
statements: Bayer Bitterfeld GmbH, Greppin; Bayer Handelsges. mbH, Leverkusen; Bayer
Buna GmbH, Marl; Bayer-Kaufhaus GmbH, Leverkusen; Bayer Kautschuk GmbH,
Leverkusen; Generics Holding GmbH, Leverkusen; IAB Ionenaustauscher GmbH,
Greppin; KVP Pharma + Veterinär Produkte GmbH, Kiel; iSL-Chemie GmbH & Co. KG,
Kürten.
The principal companies included in the consolidated financial statements are listed
in the following table: 
€ million Acquisitions Divestitures
Noncurrent assets 505 366
Current assets (excluding liquid assets) 18 357
Liquid assets – –
Assets 523 723
Pension provisions – (88)
Other provisions (1) (50)
Financial obligations – (5)
Remaining liabilities (8) (12)
Liabilities (9) (155)
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Company Name and Place of Business Bayer’s
interest %
Germany
H.C. Starck GmbH, Goslar 100
Wolff Walsrode AG, Walsrode 100
Bayer Chemie Service GmbH, Cologne 100
Bayer Vital GmbH & Co. KG, Leverkusen 100
Bayer Industrieprodukte GmbH & Co. KG, Leverkusen 100
Bayer Buna GmbH, Marl 100
Other European Countries
Bayer Hispania, S.A., Spain 100
Bayer S.p.A., Italy 100
Química Farmacéutica Bayer, S.A., Spain 100
Bayer Rubber N.V., Belgium 100
Bayer plc, United Kingdom 100
Bayer Antwerpen N.V., Belgium 100
Bayer Pharma S.A., France 99.9
Bayer International S.A., Switzerland 99.7
Bayer S.A., France 99.9
Bayer B.V., Netherlands 100
Bayer A/S, Denmark 100
North America
Bayer Corporation, United States 100
Bayer Inc., Canada 100
Asia/Pacific
Bayer (India) Ltd., India 55.3
Bayer Yakuhin, Ltd., Japan 100
Sumika Bayer Urethane Co. Ltd., Japan 60
Bayer Ltd., Japan 100
Bayer Australia Ltd., Australia 99.9
Bayer (South East Asia) Pte Ltd., Singapore 100
Nihon Bayer Agrochem K.K., Japan 99.5
Bayer Thai Co. Ltd., Thailand 100
Bayer China Co. Ltd., Hong Kong 99.3
Latin America/Africa/Middle East
Bayer de México, S.A. de C.V., Mexico 100
Bayer S.A., Argentina 99.9
Bayer S.A., Brazil 99.9
Bayer (Proprietary) Ltd., South Africa 100
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Foreign currency translation 
The financial statements for 2001 are drawn up in euros (€).
In the financial statements of the individual consolidated companies, foreign curren-
cy receivables and payables are translated at closing rates, irrespective of whether they
are exchange-hedged. Forward contracts that, from an economic point of view, serve as
a hedge against fluctuations in exchange rates are stated at fair value.
The majority of foreign consolidated companies are to be regarded as foreign enti-
ties since they are financially, economically and organizationally autonomous. Their func-
tional currencies according to IAS 21 (The Effects of Changes in Foreign Exchange
Rates) are thus the respective local currencies. The assets and liabilities of these com-
panies are therefore translated at closing rates, income and expense items at average
rates for the year.
Where the operations of a foreign company are integral to those of Bayer AG, the
functional currency is the euro. 
Property, plant and equipment, intangible assets, investments in affiliated companies
and other securities included in investments are translated at the historical exchange
rate on the date of addition, along with any relevant amortization, depreciation and
write-downs. All other balance sheet items are translated at closing rates. Income and
expense items (except amortization, depreciation and write-downs) are translated at
average rates for the year.
Companies operating in hyperinflationary economies prepare their statements in
hard currency and thus, in effect, by the temporal method described above. 
Exchange differences arising from the translation of foreign companies’ balance
sheets are shown in a separate stockholders’ equity item. In case of divestiture, the
respective exchange differences are reversed and recognized in income.
The exchange rates for major currencies against the euro varied as follows:
€ Closing rate Average rate
2001 2000 2001 2000
U.S.A. USD 0.88 0.93 0.90 0.93
U.K. GBP 0.61 0.62 0.62 0.61
Japan JPY 115.33 106.92 108.74 99.74
Canada CAD 1.41 1.40 1.39 1.37
Switzerland CHF 1.48 1.52 1.51 1.56
Management’s
Statement
Independent
Auditors’
Report
Statements 
of Income
Balance
Sheets
Statements of
Changes in 
Stockholders’
Equity
Statements of
Cash Flows
NotesFinancial
Statements
Table of Contents
BAYER ANNUAL REPORT 200115
Consolidation methods 
Capital consolidation is performed according to IAS 22 (Business Combinations) by off-
setting investments in subsidiaries against the underlying equities at the dates of acqui-
sition. The identifiable assets and liabilities of subsidiaries and joint ventures are includ-
ed at their fair values in proportion to Bayer’s interest. Remaining differences are recog-
nized as goodwill.
Where the statements of individual consolidated companies reflect write-downs or
write-backs of investments in other consolidated companies, these are reversed for the
Group statements.
Intragroup sales, profits, losses, income, expenses, receivables and payables are
eliminated.
Deferred taxes are recognized for temporary differences related to consolidation
entries.
Joint ventures are included by proportionate consolidation according to the same
principles. 
The consolidated financial statements include the accounts of those material sub-
sidiaries in which Bayer AG is able to exercise operational control, generally through an
ownership interest greater than 50 percent. 
The equity method is used to account for investments in material entities in which
Bayer AG exerts significant influence, generally through an ownership interest between
20 and 50 percent.
Intercompany profits and losses on transactions with companies included at equity
were immaterial in 2001 and 2000.
Cash flow statement 
The cash flow statement shows how the liquidity of the Bayer group was affected by the
inflow and outflow of cash and cash equivalents during the year. The effects of acquisi-
tions, divestitures and other changes in the scope of consolidation are eliminated. Cash
flows are classified by operating, investing and financing activities in accordance with
IAS 7 (Cash Flow Statements). An adjustment is shown to reconcile cash and cash
equivalents at the end of the year to the liquid assets reflected in the balance sheet.
The amounts reported by foreign consolidated companies are translated at average
exchange rates for the year, with the exception of cash and cash equivalents, which are
translated at closing rates as in the balance sheet. The effect of changes in exchange
rates on cash and cash equivalents is shown separately.
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[1] Net sales
Sales are recognized upon delivery of goods or rendering of services to third parties and
are reported net of sales taxes and rebates. Revenues from contracts that contain cus-
tomer acceptance provisions are deferred until customer acceptance occurs or the con-
tractual acceptance period has lapsed. Allocations to provisions for rebates to cus-
tomers are recognized in the period in which the related sales are recorded based on
the contract terms. Payments relating to the sale or outlicensing of technologies or
technological expertise – once the respective agreements have become effective – are
immediately recognized in income if all rights to the technologies and all obligations
resulting from them have been relinquished under the contract terms. However, if rights
to the technologies continue to exist or obligations resulting from them have yet to be
fulfilled, the payments received are recorded in line with the actual circumstances.
While total reported sales declined by €0.7 billion compared with 2000, to 
€30.3 billion, sales from continuing operations increased by €0.3 billion. A €0.9 billion
decrease due to lower volumes was offset by positive contributions of €0.3 billion 
from higher selling prices, €0.1 billion from favorable shifts in exchange rates and 
€0.8 billion from the net effect of acquisitions and divestitures. Acquisitions and dives-
titures during 2001 and 2000 affected the comparison between the two years’ sales 
figures by the following amounts:
Breakdowns of net sales by segment and by region are given in the table on 
pages 20 - 22.
N O T E S  T O  T H E  
S TAT E M E N T S  
O F  I N C O M E
€ million
Acquisitions
Sybron Chemicals Inc. (polymers and specialty chemicals) 
(acquired in 2000) 206
Polyols business of Lyondell Chemical Company (acquired in 2000) 202
CSM Group (acquired in 2000) 133
Fungicide product lines, primarily FLINT® 104
Full consolidation of Sumika Bayer Urethane Co. Ltd., Japan 99
Paper chemicals business of Cytec Industries Inc. (acquired in 2000) 83
MIKADO® corn herbicide 46
Other 110
983
Divestitures 
Covexx Films (61)
U.S. livestock vaccines business to 
Intervet International (divested in 2000) (30)
Other (33)
(124)
Net effect on sales from continuing operations 859
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[2] Selling expenses
Selling expenses include €782 million (2000: €776 million) in shipping and handling
costs.
They also include advertising and promotion costs, expensed in the period in which
they are incurred. These costs amount to €1,389 million (2000: €1,331 million).
[3] Research and development expenses
According to IAS 38 (Intangible Assets), research costs cannot be capitalized;
development costs can only be capitalized if specific conditions are fulfilled.
Development costs must be capitalized if it is sufficiently certain that the future
economic benefits to the company will cover not only the usual production, selling and
administrative costs but also the development costs themselves. There are also several
other criteria relating to the development project and the product or process being
developed, all of which have to be met to justify asset recognition. As in previous years,
these conditions are not satisfied.
[4] Other operating income
Among the items of other operating income from continuing operations for 2001 are
€68 million (2000: €83 million) from reversals of unutilized provisions, €74 million
(2000: €74 million) from retirements of noncurrent assets, and €25 million (2000: 
€25 million) from sideline operations. The cost of goods sold incurred for sideline
operations has been offset against the corresponding revenues to more clearly reflect
the earnings position. Also included here is €45 million in income resulting from an
agreement concluded with Syngenta to settle a patent dispute over thiomethoxam.
[5] Other operating expenses
Included in other operating expenses for continuing operations in 2001 are €90 million
(2000: €35 million) in write-downs of receivables, €94 million (2000: €77 million) in
amortization of acquired goodwill and €15 million (2000: €25 million) in losses from the
sale of property, plant and equipment. 
In addition, €214 million (2000: €200 million) was spent on restructuring. Further
details of restructuring expenses are given in Note 29.
[6] Discontinuing operations
Bayer sold its 50 percent interest in EC Erdölchemie GmbH, Cologne, to the joint
venture partner Deutsche BP AG, Hamburg, effective May 1, 2001. The operating result
of Erdölchemie for 2001 shown in the following table comprises the result of the
business group’s operations up to the date of divestiture and the income from the sale
of the 50 percent interest.
In April 2001 Bayer decided to divest the remaining activities of its Fibers Business
Group, including the production facilities for Dorlastan® spandex fibers and Perlon®
monofilaments.
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In the course of its reorganization Bayer plans to divest the Haarmann & Reimer
business group, whose activities it now regards as non-core. It is therefore intended to
sell the wholly owned subsidiary Haarmann & Reimer GmbH, a manufacturer of
fragrances and flavors based in Holzminden, Germany.
The non-operating results and the income taxes attributable to Haarmann & Reimer,
Fibers, Erdölchemie and DyStar are reflected in the corresponding items of the income
statement.
A breakdown of the results of discontinuing operations is given below.
[7] Operating result
Breakdowns of the operating result by segment and by region are given in the table on
pages 20 – 22. 
€ million Erdölchemie Fibers H & R DyStar Total
2001 2000 2001 2000 2001 2000 2000 2001 2000
Net sales 233 635 232 506 872 865 350 1,337 2,356
Cost of goods sold (196) (481) (205) (383) (481) (489) (223) (882) (1,576) 
Selling expenses (16) (45) (26) (50) (199) (197) (68) (241) (360) 
Research and 
development expenses (–) (2) (8) (9) (63) (54) (9) (71) (74) 
General administration 
expenses (3) (9) (11) (8) (38) (39) (21) (52) (77) 
Other operating income 316 7 1 10 23 14 6 340 37 
Other operating expenses (1) (6) (20) (15) (41) (32) (30) (62) (83) 
Operating result 
from discontinuing 
operations 333 99 (37) 51 73 68 5 369 223
Non-operating result (1) (1) (1)   1 (4) (6) (18) (6) (24)
Income (Loss) before 
income taxes 332 98 (38) 52 69 62 (13) 363 199
Income taxes (6) – (3) (2) (35) (30) 1 (44) (31)
Income (Loss) 
after taxes 326 98 (41) 50 34 32 (12) 319 168
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Notes on segment reporting
In accordance with IAS 14 (Segment Reporting), a breakdown of certain data in the
financial statements is given by segment and geographical region. The segments and
regions are the same as those used for internal reporting. The aim is to provide users of
the financial statements with information regarding the profitability and future prospects
of the Group’s various activities. To allow a more accurate appraisal of continuing
operations, the discontinuing operations are shown separately.
The Bayer Group is managed on the basis of business groups, which are aggregated
into reportable segments according to economic characteristics, products, production
processes, customer relationships and methods of distribution. There are currently 
14 business groups, which are aggregated here into 7 reportable segments.
The segments shown as continuing operations embrace the following activities:
Segment Activity
Health Care
Pharmaceuticals & Development and marketing of ethical pharmaceuticals
Biological Products
Consumer Care & Development and marketing of over-the-counter medications, 
Diagnostics nutritional supplements, insecticides and insect repellents and
diagnostic products for central laboratory, near patient testing,
and self-testing applications
Agriculture
Crop Protection Development and marketing of insecticides, fungicides and
herbicides for all climate zones
Animal Health Development and marketing of veterinary medicines, nutritionals
and grooming products for companion animals and livestock
Polymers
Plastics & Rubber Manufacturing and marketing of engineering plastics and a
variety of raw materials for the rubber and tire industries
Polyurethanes, Development, manufacturing and marketing of a range of 
Coatings & Colorants polyurethane raw materials for a wide variety of applications, as
well as coating and adhesive raw materials and colorants
Chemicals Manufacture and marketing of bulk and specialty chemicals,
metal and ceramic powders and cellulosics
The reconciliation eliminates intersegment items and reflects income and expenses not
allocable to segments, such as central R&D expenses, corporate costs, and revenues
and expenses from sideline operations. It also reflects non-allocable assets and
liabilities.
Business activities that Bayer has already divested or intends to divest are shown as
discontinuing operations. These are the Haarmann & Reimer, Erdölchemie and Fibers
business groups. 
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K e y  D ata  by  S e g m e n t  ( 1 )
Segments Pharmaceuticals & Consumer Care & Crop Protection Animal Health 
Biological Products Diagnostics
€ million 2001 2000 2001 2000 2001 2000 2001 2000
Net sales (external) 5,729 6,140 4,104 3,888 2,708 2,456 988 999
• Change in € – 6.7% +22.7% +5.6% +15.6% +10.3% +12.8% –1.1% +8.9%
• Change in local currencies – 6.7% +11.9% +5.0% +5.4% +10.7% +3.9% –1.1% –1.4%
Intersegment sales 38 39 2 0 102 97 5 6
Other operating income 62 90 49 51 102 38 13 41
Operating result before exceptionals 383 1,165 388 311 453 401 172 157
Return on sales before exceptionals 6.7% 19.0% 9.5% 8.0% 16.7% 16.3% 17.4% 15.7%
Exceptional items (332) (5) (47) (134) 0 1 0 25
Operating result 51 1,160 341 177 453 402 172 182
Return on sales 0.9% 18.9% 8.3% 4.6% 16.7% 16.4% 17.4% 18.2%
Gross cash flow 229 1,048 534 371 550 397 163 160
Capital invested 5,352 5,267 3,799 3,650 3,884 3,664 645 725
CFROI 4.2% 21.3% 14.0% 10.4% 13.9% 14.0% 22.8% 20.0%
Equity-method income 0 0 0 0 0 0 0 0
Equity-method investments 16 20 0 0 0 0 0 0
Total assets 5,303 5,291 3,956 3,480 3,488 3,218 734 768
Capital expenditures 415 553 267 192 215 233 49 50
Amortization and depreciation 364 273 291 256 247 143 40 40
Liabilities 1,869 2,202 1,271 1,158 1,130 947 379 337
Research and development expenses 1,242 1,096 252 266 292 276 98 94
Number of employees (as of Dec. 31) 26,800 27,200 14,900 15,100 10,900 11,000 3,900 3,900
Health Care Agriculture
Segments Plastics & Polyurethanes, Chemicals
Rubber Coatings &
Colorants
€ million 2001 2000 2001 2000 2001 2000
Net sales (external) 5,581 5,816 5,207 5,076 3,749 3,410
• Change in € – 4.0% +25.7% +2.6% +30.0% +9.9% +19.4%
• Change in local currencies –5.0% +19.5% +2.1% +23.4% +10.0% +13.3%
Intersegment sales 116 122 138 462 456 466
Other operating income 87 28 51 42 53 35
Operating result before exceptionals 288 560 146 518 271 370
Return on sales before exceptionals 5.2% 9.6% 2.8% 10.2% 7.2% 10.9%
Exceptional items (50) (45) (100) (45) (68) 24
Operating result 238 515 46 473 203 394
Return on sales 4.3% 8.9% 0.9% 9.3% 5.4% 11.6%
Gross cash flow 587 802 614 754 379 497
Capital invested 6,405 6,456 8,051 8,011 4,774 4,665
CFROI 8.9% 12.7% 7.5% 10.7% 7.7% 11.0%
Equity-method income 0 (1) 0 0 0 5
Equity-method investments 27 23 773 616 13 18
Total assets 5,867 6,176 7,493 7,568 4,216 4,421
Capital expenditures 592 652 492 359 483 424
Amortization and depreciation 482 446 604 466 334 293
Liabilities 1,339 1,696 2,311 1,737 1,797 1,813
Research and development expenses 134 128 186 151 114 105
Number of employees (as of Dec. 31) 17,900 18,500 15,100 16,100 19,500 20,500
Polymers Chemicals
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K e y  D ata  by  S e g m e n t  ( 2 )
Segments Reconciliation Continuing Discontinuing Bayer Group
operations operations
€ million 2001 2000 2001 2000 2001 2000 2001 2000
Net sales (external) 872 830 28,938 28,615 1,337 2,356 30,275 30,971
• Change in € +1.1% +21.4% – 2.2% +13.4%
• Change in local currencies +0.8% +12.1% – 2.5% +4.5%
Intersegment sales (857) (1,192)
Other operating income 63 100 480 425 340 37 820 462
Operating result before exceptionals (246) (273) 1,855 3,209 76 247 1,931 3,456
Return on sales before exceptionals 6.4% 11.2% 6.4% 11.2%
Exceptional items (16) 34 (613) (145) 293 (24) (320) (169)
Operating result (262) (239) 1,242 3,064 369 223 1,611 3,287
Return on sales 4.3% 10.7% 5.3% 10.6%
Gross cash flow (230) (182) 2,826 3,847 97 317 2,923 4,164
Capital invested 556 441 33,466 32,879 1,392 2,183 34,858 35,062
CFROI 8.3% 12.6% 8.2% 12.7%
Equity-method income 12 (5) 12 (1) 14 72 26 71
Equity-method investments 158 182 987 859 179 487 1,166 1,346
Total assets 4,933 3,529 35,990 34,451 1,049 2,000 37,039 36,451
Capital expenditures 40 23 2,553 2,486 64 161 2,617 2,647
Amortization and depreciation 41 73 2,403 1,990 113 149 2,516 2,139
Liabilities 9,616 9,363 19,712 19,253 307 821 20,019 20,074
Research and development expenses 170 203 2,488 2,319 71 74 2,559 2,393
Number of employees (as of Dec. 31) 3,000 1,600 112,000 113,900 4,900 8,200 116,900 122,100
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K e y  D ata  by  R e g i o n
Regions Europe North America Asia/Pacific Latin America/
Africa/Middle East
€ million 2001 2000 2001 2000 2001 2000 2001 2000
Net sales (external) – by market 11,659 11,299 9,473 9,352 4,660 4,819 3,146 3,145
Net sales (external) – by point of origin 12,999 12,916 9,806 9,699 3,817 3,761 2,316 2,239
• Change in € +0.6% +11.4% +1.1% +29.6% +1.5% +42.2% +3.4% +20.6%
• Change in local currencies +0.5% +10.9% – 1.9% +14.1% +7.3% +26.5% +2.5% +7.8%
Interregional sales 3,154 3,018 1,927 1,603 226 228 116 98
Other operating income 312 256 70 62 48 64 50 43
Operating result before exceptionals 1,707 2,216 23 729 241 404 219 213
Return on sales before exceptionals 13.1% 17.2% 0.2% 7.5% 6.3% 10.7% 9.5% 9.5%
Exceptional items (272) 20 (278) (144) (14) (21) (30) 0
Operating result 1,435 2,236 (255) 585 227 383 189 213
Return on sales 11.0% 17.3% – 2.6% 6.0% 5.9% 10.2% 8.2% 9.5%
Gross cash flow 2,037 2,096 632 1,521 312 357 225 228
Capital invested 16,355 15,849 12,808 13,025 2,711 2,628 1,607 1,433
CFROI 12.5% 15.2% 4.7% 12.2% 11.3% 14.3% 14.5% 16.4%
Equity-method income 12 0 0 0 0 (1) 0 0
Equity-method investments 351 255 618 582 2 2 16 20
Total assets 17,298 15,988 12,652 12,859 3,132 3,085 1,834 1,723
Capital expenditures 1,620 1,440 560 749 255 199 118 98
Amortization and depreciation 1,227 971 918 818 150 118 104 83
Liabilities 9,769 8,736 6,407 6,627 1,382 1,489 673 672
Research and development expenses 1,559 1,342 690 681 68 83 9 10
Number of employees (as of Dec. 31) 64,600 65,700 23,200 24,100 12,600 12,100 11,000 11,400
Regions Reconciliation Continuing Discontinuing Bayer Group
operations operations
€ million 2001 2000 2001 2000 2001 2000 2001 2000
Net sales (external) – by market 28,938 28,615 1,337 2,356 30,275 30,971
Net sales (external) – by point of origin 28,938 28,615 1,337 2,356 30,275 30,971
• Change in € +1.1% +21.4% –2.2% +13.4%
• Change in local currencies +0.8% +12.1% –2.5% +4.5%
Interregional sales (5,423) (4,947)
Other operating income 480 425 340 37 820 462
Operating result before exceptionals (335) (353) 1,855 3,209 76 247 1,931 3,456
Return on sales before exceptionals 6.4% 11.2% 6.4% 11.2%
Exceptional items (19) 0 (613) (145) 293 (24) (320) (169)
Operating result (354) (353) 1,242 3,064 369 223 1,611 3,287
Return on sales 4.3% 10.7% 5.3% 10.6%
Gross cash flow (380) (355) 2,826 3,847 97 317 2,923 4,164
Capital invested (15) (56) 33,466 32,879 1,392 2,183 34,858 35,062
CFROI 8.3% 12.6% 8.2% 12.7%
Equity-method income 12 (1) 14 72 26 71
Equity-method investments 987 859 179 487 1,166 1,346
Total assets 1,074 796 35,990 34,451 1,049 2,000 37,039 36,451
Capital expenditures 0 0 2,553 2,486 64 161 2,617 2,647
Amortization and depreciation 4 0 2,403 1,990 113 149 2,516 2,139
Liabilities 1,481 1,729 19,712 19,253 307 821 20,019 20,074
Research and development expenses 162 203 2,488 2,319 71 74 2,559 2,393
Number of employees (as of Dec. 31) 600 600 112,000 113,900 4,900 8,200 116,900 122,100
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The segment data are calculated as follows:
• The intersegment and interregional sales reflect intragroup transactions effected at
transfer prices fixed on an arm’s-length basis.
• Comparability of the operating results of different years may be restricted by
exceptional items relating particularly to restructuring measures and acquisitions or
divestitures of companies or businesses. The operating result before exceptional
items is therefore shown in addition.
• The return on sales before exceptional items is the ratio of the operating result before
exceptional items to external sales.
• Expenses included in exceptional items mainly relate to restructuring measures.
• The return on sales is the ratio of the operating result after exceptional items to
external sales.
• Gross cash flow is the excess of cash receipts over cash disbursements before
application of funds.
• The capital invested comprises all the assets that serve a segment and are required to
yield a return, less interest-free liabilities. It is stated as of December 31.
• The CFROI is the ratio of the gross cash flow to the average capital invested for the
year.
• The equity items are those reflected in the balance sheet and income statement. They
are allocated to the segments where possible. Equity-method income reconciles to
the income statement line “Income from investments in affiliated companies – net” as
follows:
• Capital expenditures, amortization and depreciation relate to intangible assets,
property, plant and equipment.
€ million 2001 2000
Equity-method income 26 71
Dividends and similar income 15 18
Income from profit and loss transfer agreements • 1
Gains from the sale of investments in affiliated companies 16 204
Losses from the sale of investments in affiliated companies (3) (1)
Write-downs of investments in affiliated companies 0 (10)
Income from investments in affiliated 
companies – net 54 283
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[8] Income from investments in affiliated companies - net 
This comprises the following items:
In the previous year this item contained the €65 million gain from the sale of the 
11 percent interest in Myriad Genetics, Salt Lake City, Utah and the €142 million gain 
from the sale of the 25 percent interest in Schein Pharmaceutical Inc., Florham Park, 
New Jersey.
[9] Interest expense - net
Interest income and expense comprises:
Finance leases are capitalized under property, plant and equipment in compliance with
IAS 17 (Leases). The interest portion of the lease payments, amounting to €9 million in
2001, is reflected in interest expense. 
Interest expense incurred to finance the construction phase of major investment
projects is not included here. Such interest expense, amounting in 2001 to €30 million
(2000: €28 million), is capitalized as part of the cost of acquisition or construction of
the property, plant or equipment concerned, based on an average capitalization rate of 
5 percent. 
€ million 2001 2000
Dividends and similar income 15 18
• of which €12 million (2000: €8 million) from subsidiaries 
Income from profit and loss transfer agreements • 1
• of which € • million (2000: €1 million) from subsidiaries 
Equity-method income (expense) 26 71
Gains from the sale of investments in affiliated companies 16 204
Losses from the sale of investments in affiliated companies (3) (1)
Write-downs of investments in affiliated companies 0 (10)
54 283
€ million 2001 2000
Income from other securities and loans 
included in investments 9 10
Other interest and similar income 108 143
• of which €1 million (2000: €4 million) from subsidiaries
Interest and similar expenses (466) (464)
• of which €5 million (2000: €24 million) to subsidiaries
(349) (311)
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[10] Other non-operating expense – net
This item comprises:
Miscellaneous non-operating income includes €25 million (2000: €18 million) in gains
from the sale of marketable securities.
[11] Income taxes
This item comprises the income taxes paid or accrued in the individual countries, plus
deferred taxes. Deferred taxes arise from temporary differences between the carrying
amounts of assets or liabilities in the accounting and tax balance sheets, from
consolidation measures and from realizable loss carryforwards. Deferred taxes are
calculated at the rates which – on the basis of the statutory regulations in force, or
already enacted in relation to future periods, as of the closing date – are expected to
apply in the individual countries at the time of realization.
The breakdown of pre-tax income and income tax expense by origin is as follows:
A valuation allowance is recognized against tax loss carryforwards when it is not
sufficiently certain that this income will be realized.
Changes in tax rates diminished deferred tax expense for 2001 by €8 million (2000:
€21 million). 
€ million 2001 2000
Interest portion of interest-bearing provisions (274) (272)
Net exchange gain (loss) 49 (21)
Miscellaneous non-operating expenses (28) (18)
Miscellaneous non-operating income 52 42
(201) (269)
€ million 2001 2000
Income before income taxes
- Germany 971 1,482
- Other countries 144 1,508
1,115 2,990
Income taxes paid or accrued
- Germany 122 442
- Other countries 502 321
624 763
Deferred taxes
- from temporary differences (272) 383
- from loss carryforwards (198) 2
(470) 385
154 1,148
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Deferred taxes – computed according to IAS 12 (Income Taxes) – result primarily from
temporary differences between the accounting and tax balance sheets of the individual
consolidated companies with regard to the recognition and/or valuation of certain items.
The deferred tax assets and liabilities are allocable to the various balance sheet
items as follows:
In 2001, deferred tax assets of €9 million and deferred tax liabilities of €10 million
relate to changes in the scope of consolidation. Utilization of tax loss carryforwards
from previous years diminished the amount of income taxes paid or accrued in 2001 by
€88 million (2000: €7 million). 
The value of existing loss carryforwards by expiration date is as follows:
Deferred tax assets of €204 million (2000: €15 million) are recognized on the 
€540 million (2000: €48 million) of loss carryforwards that represent income likely to
be realized in the future. Recognition of these deferred tax assets results in deferred tax
income of €198 million.
€ million Dec. 31, 2001 Dec. 31, 2000
Deferred Deferred Deferred Deferred
tax assets tax liabilities tax liabilities tax liabilities
Intangible assets 438 177 87 72
Property, plant and equipment 243 1,672 68 1,745
Investments 20 88 2 79
Inventories 267 86 298 86
Receivables 122 53 116 51
Other current assets 11 189 51 132
Pension provisions 357 247 327 202
Other provisions 166 74 144 46
Other liabilities 158 30 163 40
Loss carryforwards 282 – 82 –
Valuation allowance for 
loss carryforwards 78 – 67 –
1,986 2,616 1,271 2,453
Set-off * (1,378) (1,378) (858) (858)
608 1,238 413 1,595
* According to IAS 12 (Income
Taxes), deferred tax assets and
deferred tax liabilities should,
under certain conditions, be
offset if they relate to income
taxes levied by the same taxa-
tion authority.
€ million Dec. 31, 2001 Dec. 31, 2000
One year 6 3
Two years 11 20
Three years 16 11
Four years 50 22
Five years or more 653 196
736 252
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Deferred tax liabilities have not been recognized for temporary differences
associated with investments in foreign subsidiaries of €3,030 million (2000: 
€2,887 million) as Bayer has determined that the profits concerned will not be
distributed in the foreseeable future. If deferred taxes were recognized for these
temporary differences, the liability would be based on the respective withholding tax
rates only. For most countries, double taxation agreements ensure that any withholding
taxes paid can be deducted from the tax base or the tax to be paid in Germany. 
The actual income tax expense for 2001 of €154 million (2000: €1,148 million) is
€259 million (2000: €31 million) less than the €413 million (2000: €1,179 million) that
would result from applying to the pre-tax income of the Group a tax rate of 37.1 percent
(2000: 39.5 percent), which is the weighted average of the theoretical tax rates for the
individual Group companies. 
The reconciliation of theoretical to actual income tax expense for the Group is as
follows:
[12] Other taxes
Other taxes amounting to €247 million (2000: €229 million) are included in the cost of
goods sold, selling expenses, research and development expenses or general
administration expenses. These are mainly property-related taxes.
[13] Minority stockholders’ interest
Minority interest in income amounts to €6 million (2000: €29 million), and minority
interest in losses to €10 million (2000: €3 million), adding €4 million to (2000:
subtracting €26 million from) income after taxes.
[14] Earnings per share
Earnings per share are determined according to IAS 33 (Earnings Per Share) by dividing
the net income by the average number of shares. 
In 2001, as in 2000, the number of shares remained constant at 730,341,920.
Earnings per share were €1.32 (2000: €2.49). 
There were no subscription rights outstanding in 2001 or 2000, and therefore no
dilutive potential shares. 
[15] Cost of materials
The total cost of materials for continuing operations amounted to €11,057 million
(2000: €10,040 million), comprising €10,361 million (2000: €9,380 million) in expenses
2001 2000
€ million % € million %
Theoretical income tax expense 413 100 1,179 100
Lower taxes due to 
tax-free income (283) (68) (151) (13)
Higher taxes due to 
non-tax-deductible expenses 47 11 93 8
Other tax effects (23) (5) 27 2
Actual income tax expense 154 38 1,148 97
Effective tax rate in % 13.8 38.4
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for raw materials, supplies and goods purchased for resale, and €696 million (2000:
€660 million) in expenses for purchased services. 
The cost of materials for the discontinuing operations was €533 million (2000: 
€1,168 million). While Erdölchemie incurred costs of €153 million (2000: €545 million)
entirely for raw materials and supplies, Haarmann & Reimer accounted for €344 million
(2000: €393 million), including €10 million (2000: €10 million) for purchased services.
Fibers accounted for €36 million (2000: €126 million), including €10 million (2000: 
€23 million) for purchased services. In 2000, DyStar accounted for €104 million, which
included €1 million for purchased services.
[16] Personnel expenses
Personnel expenses for continuing operations rose in 2001 by €281 million to 
€7,576 million. Of the increase, €43 million is due to exchange rate fluctuations. 
The breakdown of personnel expenses is as follows:
[17] Number of employees 
The average number of employees in continuing operations, classified by corporate
functions, was as follows:
The employees of joint ventures are included in the above figures in proportion to
Bayer’s interests in the respective companies. The total number of people employed by
our joint ventures in 2001 was 1,075 (2000: 1,048).
The figures in the above table do not include people employed in discontinuing
operations. In 2001, Haarmann & Reimer employed on average 3,660 people (2000:
3,742); Fibers employed on average 1,169 people (2000: 1,643).
€ million Continuing Discontinuing operations
operations Erdölchemie Fibers H & R DyStar
2001 2000 2001 2000 2001 2000 2001 2000 2000
Wages and salaries 6,005 5,814 18 55 32 54 188 184 67
Social expenses 1,571 1,481   5 15 6 13   47 39   13
- of which 
pension expenses (430) (397) (2) (5) (•) (3) (14) (8) (3)
7,576 7,295   23 70   38 67   235 223   80
2001 2000
Marketing 33,768 33,191
Technology 60,168 59,923
Research 11,150 11,007
Administration 8,972 9,426
114,058 113,547
of which trainees 2,641 2,667
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[18] Intangible assets
Acquired intangible assets other than goodwill are recognized at cost and amortized by
the straight-line method over a period of 4 to 15 years, depending on their estimated
useful lives. Write-downs are made for impairment losses. Assets are written back if the
reasons for previous years’ write-downs no longer apply.
Goodwill, including that resulting from capital consolidation, is capitalized in
accordance with IAS 22 and amortized on a straight-line basis over a maximum estimated
useful life of 20 years. The value of goodwill is reassessed regularly based on impairment
indicators and written down if necessary. In compliance with IAS 36 (Impairment of
Assets), such write-downs of goodwill are measured by comparison to the discounted
cash flows expected to be generated by the assets to which the goodwill can be ascribed.
Self-created intangible assets are not capitalized.
Certain development costs relating to the application development stage of 
internally developed software are capitalized in the Group balance sheet. These costs 
are amortized over their useful life from the date they are placed in service.
Changes in intangible assets in 2001 were as follows: 
The exchange differences are the differences between the carrying amounts at the
beginning and the end of the year that result from translating foreign companies’ figures
at the respective different exchange rates and changes in their assets during the year at
the average rate for the year.
N O T E S  T O  T H E  
B A L A N C E  S H E E T S
€ million Acquired Advance Total
goodwill payments
Gross carrying amounts, Dec. 31, 2000 4,566 1,289 71 5,926
Exchange differences 146 31 2 179
Changes in scope of consolidation (17) 50 – 33
Acquisitions 266 50 – 316
Capital expenditures 362 – 44 406
Retirements (155) (22) (2) (179)
Transfers 72 1 (73) – 
Gross carrying amounts, Dec. 31, 2001 5,240 1,399 42 6,681
Accumulated amortization 
and write-downs, Dec. 31, 2000 772 311 –  1,083
Exchange differences 27 7 – 34
Changes in scope of consolidation (9) (3) – (12)
Amortization and write-downs in 2001 554 115 – 669
• of which write-downs [2] [–] [–] [2]
Write-backs (1) – – (1)
Retirements (100) (6) – (106)
Transfers – – – – 
Accumulated amortization and 
write-downs, Dec. 31, 2001 1,243 424 – 1,667
Net carrying amounts, Dec. 31, 2001 3,997 975 42 5,014
Net carrying amounts, Dec. 31, 2000 3,794 978 71 4,843
Acquired concessions,
industrial property rights,
similar rights and assets,
and licenses thereunder
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[19] Property, plant and equipment
Property, plant and equipment is carried at the cost of acquisition or construction.
Assets subject to depletion are depreciated over their estimated useful lives. Write-
downs are made for any declines in value that go beyond the depletion reflected in
depreciation. In compliance with IAS 36 (Impairment of Assets), such write-downs are
measured by comparing the carrying amounts to the discounted cash flows expected to
be generated by the respective assets. Where it is not possible to estimate the
impairment loss for an individual asset, the loss is assessed on the basis of the
discounted cash flow for the cash-generating unit to which the asset belongs. Assets are
written back if the reasons for previous years’ write-downs no longer apply. 
The cost of construction of self-constructed property, plant and equipment
comprises the direct cost of materials, direct manufacturing expenses, appropriate
allocations of material and manufacturing overheads, and an appropriate share of the
depreciation and write-downs of assets used in construction. It includes the shares of
expenses for company pension plans and discretionary employee benefits that are
attributable to construction.
If the construction phase of property, plant or equipment extends over a long period,
the interest incurred on borrowed capital up to the date of completion is capitalized as
part of the cost of acquisition or construction.
Expenses for the repair of property, plant and equipment are normally charged
against income, but they are capitalized if they result in an enlargement or substantial
improvement of the respective assets.
Property, plant and equipment is depreciated by the straight-line method, except
where the declining-balance method is more appropriate in light of the actual utilization
pattern.
When assets are closed down, sold, or abandoned, the difference between the net
proceeds and the net carrying amount of the assets is recognized as a gain or loss in
other operating income or expenses, respectively.
The following depreciation periods, based on the estimated useful lives of the
respective assets, are applied throughout the Group:
In accordance with IAS 17 (Leases), assets leased on terms equivalent to financing a
purchase by a long-term loan (finance leases) are capitalized at the lower of their fair
value or the present value of the minimum lease payments. The leased assets are
depreciated over their estimated useful life except where subsequent transfer of title is
uncertain, in which case they are depreciated over their estimated useful life or the
respective lease term, whichever is shorter. The future lease payments are recorded as
financial obligations.
Buildings 20 to 50 years
Outdoor infrastructure 10 to 20 years
Plant installations 6 to 20 years
Machinery and apparatus 6 to 12 years
Laboratory and research facilities 3 to 5 years
Storage tanks and pipelines 10 to 20 years
Vehicles 4 to 8 years
Computer equipment 3 to 5 years
Furniture and fixtures 4 to 10 years
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Changes in property, plant and equipment in 2001 were as follows:
The exchange differences are as defined for intangible assets.
Capitalized property, plant and equipment includes assets with a total net value of
€588 million (2000: €199 million) held under finance leases. The gross carrying
amounts of these assets total €1,229 million (2000: €277 million). These assets are
mainly machinery and technical equipment with a carrying amount of €425 million
(gross amount €975 million) and buildings with a carrying amount of €106 million
(gross amount €141 million). In the case of buildings, either the present value of the
minimum lease payments covers substantially all of the cost of acquisition, or title
passes to the lessee on expiration of the lease.
Also included are products leased to other parties under operating leases with a
carrying amount of €381 million (2000: €247 million), the gross carrying amount of the
assets concerned being €753 million (2000: €717 million). However, if under the
relevant agreements the lessee is to be regarded as the economic owner of the assets
and the lease therefore constitutes a finance lease as defined in IAS 17 (Leases), a
receivable is recognized in the balance sheet in the amount of the discounted future
lease payments.
€ million Land and buildings Machinery Furniture, Construction in Total
and fixtures and progress and
technical other advance
equipment equipment payments to
vendors and
contractors
Gross carrying amounts, Dec. 31, 2000 7,978 19,986 2,513 1,262 31,739
Exchange differences 91 318 20 32 461
Changes in scope of consolidation (165) (991) (51) (60) (1,267)
Acquisitions – – – – – 
Capital expenditures 78 373 250 1,510 2,211
Retirements (144) (732) (349) (29) (1,254)
Transfers 310 590 117 (1,017) – 
Gross carrying amounts, Dec. 31, 2001 8,148 19,544 2,500 1,698 31,890
Accumulated depreciation 
and write-downs, Dec. 31, 2000 4,092 12,583 1,712 7 18,394
Exchange differences 31 153 12 – 196
Changes in scope of consolidation (114) (811) (41) – (966)
Depreciation and write-downs in 2001 274 1,276 286 11 1,847
• of which write-downs [–] [38] [1] [11] [50]
Write-backs – – – – – 
Retirements (118) (710) (296) – (1,124)
Transfers 3 (5) 2 – – 
Accumulated depreciation 
and write-downs, Dec. 31, 2001 4,168 12,486 1,675 18 18,347
Net carrying amounts, Dec. 31, 2001 3,980 7,058 825 1,680 13,543
Net carrying amounts, Dec. 31, 2000 3,886 7,403 801 1,255 13,345
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€ million Investments Loans to Investments in other Loans to Other Other Total
in subsidiaries subsidiaries affiliated companies other securities loans
Associated Other affiliated
companies companies companies
Gross carrying 
amounts, Dec. 31, 2000 232 3 1,469 157 14 150 243 2,268
Fair value, Jan. 1, 2001 – – – 1,328 – 4 – 1,332
Exchange differences 3 – 34 2 (1) 6 1 45
Changes in scope
of consolidation (98) (3) 105 4 – 1 (13) (4)
Changes in fair value – – – (768) – (4) – (772)
Acquisitions 8 – 24 140 – – – 172
Other additions 41 – 158 35 – 37 31 302
Retirements (4) – (37) (20) – (18) (35) (114)
Transfers – – (463) 463 – 20 (20) –
Gross carrying 
amounts, Dec. 31, 2001 182 – 1,290 1,341 13 196 207 3,229
Accumulated 
write-downs, Dec. 31, 2000 14 – 83 – – 1 14 112
Exchange differences – – – – – – (1) (1)
Changes in scope of 
consolidation – – (25) – – – – (25)
Write-downs in 2001 – – 2 – – 2 – 4
Write-backs – – (2) – – – (1) (3)
Retirements – – – – – (3) – (3)
Transfers – – – – – 3 (3) –
Accumulated write-
downs, Dec. 31, 2001 14 – 58 – – 3 9 84
Net carrying amounts, 
Dec. 31, 2001 168 – 1,232 1,341 13 193 198 3,145
Net carrying amounts, 
Dec. 31, 2000 218 3 1,386 157 14 149 229 2,156
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[20] Investments
Investments in non-consolidated subsidiaries and other affiliated companies are
generally carried individually at cost. Where other affiliated companies or other
securities included in investments are classified as held-to-maturity investments or
available-for-sale financial assets, they are recognized in compliance with IAS 39
(Financial Instruments: Recognition and Measurement) at amortized cost or fair value.
Where evidence exists that such assets may be impaired, they are written down as
necessary on the basis of an impairment test. Investments are written back if the
reasons for previous years’ write-downs no longer apply. 
The cost of acquisition of investments in companies included at equity is adjusted
annually in line with any changes in these companies’ total stockholders’ equity.
In the first-time consolidation, differences between the cost of acquisition and the
underlying equities at the dates of acquisition of the investments are allocated to assets
or liabilities by the same method applied to fully consolidated subsidiaries. 
Loans receivable that are interest-free or bear low rates of interest are carried at
present value; other loans receivable are carried at nominal value.
Changes in investments in 2001 were as follows:
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The exchange differences are as defined for intangible assets. 
The additions to investments in associated companies relate mainly to a
manufacturing company being established jointly with Lyondell and the first-time
inclusion of DyStar GmbH at equity. The difference between the equity interest in the
underlying net assets of companies included at equity and their at-equity accounting
values is €45 million (2000: €91 million). It relates primarily to goodwill. Since Bayer no
longer exerts significant influence over Agfa-Gevaert N.V., Belgium, Bayer’s 30 percent
interest in this company, which was previously valued at equity, is included at fair value
under investments in other companies.
[21] Inventories
Raw materials, supplies, and goods purchased for resale are valued at the cost of
acquisition; work in process and finished goods are valued at the cost of production. 
If the inventory values are lower at the closing date because of a drop in market prices,
for example, the lower amounts are shown. Of the €5,818 million in inventories carried
as of December 31, 2001 (2000: €6,095 million), €824 million (2000: €431 million)
represents those included at their net realizable value.
Inventories are normally valued by the weighted-average method.
The cost of production comprises the direct cost of materials, direct manufacturing
expenses, appropriate allocations of material and manufacturing overheads, and an
appropriate share of the depreciation and write-downs of assets used for production. 
It also includes the shares of expenses for company pension plans and discretionary
employee benefits that are attributable to production. Administrative costs are included
where they are attributable to production.
Work in process and finished goods are grouped together in light of the production
sequences characteristic of the chemical industry.
Inventories are comprised as follows:
The changes in inventory write-downs are as follows:
€ million Dec. 31, 2001 Dec. 31, 2000
Raw materials and supplies 1,179 1,041
Work in process, finished goods and goods
purchased for resale 4,626 5,046
Advance payments 13 8
5,818 6,095
€ million Dec. 31, 2001 Dec. 31, 2000
Balance at beginning of year (241) (248)
Additions charged to expenses (362) (218)
Exchange differences (2) (9)
Changes in scope of consolidation 17 –
Deductions due to utilization 154 234
Balance at end of year (434) (241)
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[22] Trade accounts receivable
Trade accounts receivable are stated at nominal value, less write-downs of €222 million
(2000: €204 million) for amounts unlikely to be recovered. 
Trade accounts receivable as of December 31, 2001 include €5,413 million (2000:
€6,236 million) maturing within one year and €2 million (2000: €8 million) maturing
after one year. Of the total, €18 million (2000: €11 million) is receivable from
subsidiaries, €66 million (2000: €87 million) from other affiliated companies and
€5,331 million (2000: €6,146 million) from other customers. 
[23] Other receivables and other assets
Other receivables and other assets are stated at nominal value, less write-downs of 
€4 million (2000: €4 million). 
They are comprised as follows:
Interest receivable on loans consists mainly of interest earned in the fiscal year but not
due to be received until after the balance sheet date.
Total other receivables and other assets include €66 million (2000: €149 million)
pertaining to subsidiaries and €124 million (2000: €44 million) pertaining to other
affiliated companies.
Total other receivables and other assets in the amount of €444 million (2000: 
€442 million) mature in more than one year. Of this amount, €30 million (2000: 
€31 million) pertains to subsidiaries.
Changes in write-downs of receivables are as follows:
€ million Dec. 31, 2001 Dec. 31, 2000
Claims for tax refunds 448 662
Short-term loans – other 102 153
Lease payments receivable 94 96
Receivables from derivative financial instruments 72 –
Short-term loans 41 87
Payroll receivables 47 47
Interest receivable on loans 19 23
Other receivables 1,624 1,346
2,447 2,414
€ million Dec. 31, 2001 Dec. 31, 2000
Balance at beginning of year (204) (173)
Additions charged to expenses (94) (42)
Exchange differences (5) (5)
Changes in scope of consolidation 5 – 
Deductions due to utilization 76 16
Balance at end of year (222) (204)
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Lease agreements in which the other party, as lessee, is to be regarded as the economic
owner of the leased assets (finance leases) give rise to accounts receivable in the
amount of the discounted future lease payments. These receivables amount to 
€94 million (2000: €96 million), while the interest portion pertaining to future years
amounts to €29 million (2000: €23 million). The lease payments are due as follows:
[24] Liquid assets
As of 2001, securities are recognized at fair value in compliance with IAS 39 (Financial
Instruments: Recognition and Measurement). Their total fair value at the closing date
amounts to €52 million (2000: €247 million) and exceeds the lower of cost and market
by €13 million (2000: €34 million). Financial instruments with original maturities of up
to three months are recognized as cash equivalents in view of their high liquidity.
[25] Deferred charges
Deferred charges as of December 31, 2001 include unamortized debt discounts of 
€9 million (2000: €17 million). The debt discounts are amortized annually over the lives
of the underlying liabilities.
Total deferred charges include €183 million that is expected to be used up in 2002.
[26] Stockholders’ equity
The capital stock of Bayer AG amounts to €1,870 million, as in the previous year, and is
divided into 730,341,920 no-par bearer shares of a single class.
Authorized capital totaling €256 million was approved by the Annual Stockholders’
Meeting on April 30, 1997. It expires on April 30, 2002. The authorized capital can be
used to increase the capital stock by issuing new shares against cash contributions.
Subscription rights for existing stockholders are excluded with respect to €102 million of
this authorized capital.
Further authorized capital in the amount of €374 million was approved by the
Annual Stockholders’ Meeting on April 27, 2001. This authorized capital, which expires
on April 27, 2006, can be used to increase the capital stock by issuing new shares
against non-cash contributions. Subscription rights for existing stockholders are excluded.
€ million Lease Of which Account
payments interest receivable
2002 41 8 33
2003 28 6 22
2004 23 6 17
2005 18 5 13
2006 11 4 7
After 2006 2 0 2
123 29 94
€ million Dec. 31, 2001 Dec. 31, 2000
Marketable securities and other instruments 52 213
Cash and cash equivalents 719 491
771 704
Conditional capital of €83 million existed at December 31, 2001. This capital may only
be utilized to the extent necessary to issue the requisite number of shares as and when
conversion or subscription rights are exercised by the holders of convertible bonds or of
warrants conferring subscription rights, respectively, that may be issued by Bayer AG or
a wholly owned direct or indirect subsidiary through April 29, 2004.
Capital reserves include the paid-in surplus from the issuance of shares and
subscription rights by Bayer AG. 
The retained earnings contain prior years’ undistributed income of consolidated
companies.
The changes in the various components of stockholders’ equity during 2001 and
2000 are shown in the statements of changes in stockholders’ equity.
The dividend per share amounts paid for the 2000 and 1999 fiscal years were
€1.40 and €1.30, respectively. 
[27] Minority interest
Minority interest mainly comprises third parties’ shares in the equity of the consolidated
subsidiaries Sumika Bayer Urethane Co. Ltd., Japan; the Makroform GmbH group; Bayer
(India) Ltd.; and Bayer ABS Ltd., India.
[28] Provisions for pensions and other post-employment benefits
Group companies provide retirement benefits for most of their employees, either directly
or by contributing to independently administered funds. The way these benefits are
provided varies according to the legal, fiscal and economic conditions of each country,
the benefits generally being based on the employees’ remuneration and years of service.
The obligations relate both to existing retirees' pensions and to pension entitlements of
future retirees. Group companies provide retirement benefits under defined contribution
and/or defined benefit plans. 
In the case of defined contribution plans, the company pays contributions to publicly
or privately administered pension insurance plans on a mandatory, contractual or voluntary
basis. Once the contributions have been paid, the company has no further payment
obligations. The regular contributions constitute net periodic costs for the year in which
they are due and as such are included in the cost of goods sold, selling expenses, research
and development expenses or general administration expenses, and thus in the operating
result. In 2001, these expenses totaled €312 million (2000: €437 million).
All other retirement benefit systems are defined benefit plans, which may be either
unfunded, i.e. financed by provisions (accruals), or funded, i.e. financed through pension
funds. In 2001, expenses for defined benefit plans amounted to €301 million (2000:
€326 million). These net periodic costs – except for the interest portion – are generally
included in the cost of goods sold, selling expenses, research and development
expenses, general administration expenses or other operating income. For the most
important defined benefit plans they are comprised as follows: 
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Defined benefit plans
€ million Dec. 31, 2001 Dec. 31, 2000
Service cost 265 210
Past service cost 10 1
Interest cost 669 589
Return on plan assets (640) (526)
Amortization of actuarial amounts (34) (14)
270 260
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The pension provisions for defined benefit plans are calculated in accordance with
IAS 19 (Employee Benefits) by the projected unit credit method. The future benefit
obligations are valued by actuarial methods on the basis of an appropriate assessment of
the relevant parameters. 
Benefits expected to be payable after retirement are spread over each employee’s
entire period of employment, allowing for future changes in remuneration.
The legally independent fund “Bayer Pensionskasse VvaG” (Bayer Pensionskasse) is a
private insurance company and is therefore subject to the German Law on the Supervision
of Private Insurance Companies. Since Bayer guarantees the commitments of the Bayer
Pensionskasse, it is classified as a defined benefit plan for IAS and U.S. GAAP purposes.
All defined benefit plans necessitate actuarial computations and valuations. These are
based not only on life expectancy but also on the following parameters, which vary from
country to country according to economic conditions:
The status of unfunded and funded defined benefit obligations, computed using the
appropriate parameters, is as follows:
The adjustments, as yet unrecognized in the income statement, represent the difference
between the defined benefit obligation – after deducting the fair value of plan assets –
and the net liability recognized in the balance sheet. They arise mainly from actuarial
gains or losses caused by differences between actual and previously assumed trends in
employee turnover and remuneration. Pension assets in excess of the obligation are
reflected in other receivables, subject to the asset limitation specified in IAS 19
(Employee Benefits). In accordance with IAS 19, the amounts reflected in the balance
sheet will be recognized in the income statement over the expected average remaining
Parameters
Dec. 31, 2001 Dec. 31, 2000
Discount rate 2.5% to 7.0% 3.0% to 7.3%
Projected future remuneration increases 2.0% to 4.8% 1.0% to 7.0%
Projected future pension increases 2.0% to 3.3% 1.0% to 4.5%
Projected employee turnover
(according to age and gender) empirical data
Projected return on plan assets 2.0% to 8.5% 3.0% to 8.5%
€ million Dec. 31, 2001 Dec. 31, 2000
Defined benefit obligation (11,303) (9,535)
Fair value of plan assets 8,126 7,847
Funded status (3,177) (1,688)
Unrecognized transition liability (asset) (31) (11)
Unrecognized actuarial (gain) loss 1,366 (203)
Asset limitation due to uncertainty of 
obtaining future benefits (1,215) (1,249)
Net recognized liability (3,057) (3,151)
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working lives of existing employees. The portion of the net actuarial gain or loss to be
recognized in the income statement is determined by the corridor method.
The net liability under these defined benefit plans changed as follows:
Funds and benefit obligations are valued on a regular basis at least every three years.
For all major funds, comprehensive actuarial valuations are performed annually.
Provisions are also set up under this item for the obligations of Group companies,
particularly in the United States, to provide health care to their retirees. For health care
costs, the valuation is based on the assumption that they will increase at an annual rate
of 5 percent in the long term. Early retirement and certain other benefits to retirees are
also included, since these obligations are similar in character to pension obligations.
Like pension obligations, they are valued in line with international standards. In 2001,
provisions for early retirement and other post-retirement benefits amounted to 
€635 million (2000: €637 million). The resulting expenses for 2001 amounted to 
€63 million (2000: €214 million), comprising €23 million (2000: €192 million) for
service cost, €58 million (2000: €52 million) for interest cost, €31 million (2000: 
€30 million) for expected return on plan assets and €13 million (2000: €0 million) for
actuarial losses. 
[29] Other provisions
Other provisions are valued in accordance with IAS 37 (Provisions, Contingent
Liabilities and Contingent Assets) and, where appropriate, IAS 19 (Employee Benefits),
using the best estimate of the extent of the obligation. Long-term portions of provisions
are discounted to their present value. The Group sets up and maintains provisions for
probable and on-going litigation cases when a reasonable estimate can be made. These
provisions include all estimated legal fees and costs of settlement. The amounts are
based upon written notification and reasonable settlement cost estimates provided by
the Group’s attorneys. Periodically, but at least quarterly, the provisions are reviewed
with the Group’s attorneys and updated.
€ million 2001 2000
Net liability recognized at the beginning of the year (3,151) (3,191)
Pension benefit (cost) income (270) (260)
Employer contributions 313 255
Divestitures 87 20
Change in asset limitation (33) 12
Changes in scope of consolidation • 11
Changes in currency translation (3) 2
Net liability recognized at end of year (3,057) (3,151)
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The breakdown of provisions is as follows:
Personnel commitments mainly include annual bonus payments, service awards and
other personnel costs. Reimbursements to be received from the German government
under the pre-retirement part-time work program are recorded as receivables and
recognized in income as soon as the criteria for such reimbursements are fulfilled. Trade-
related commitments mainly include rebates, as well as obligations relating to services
already received but not yet invoiced.
Changes in provisions were as follows:
Stock compensation program
Bayer’s three-tier stock compensation program was first launched in 2000. It consists 
of a Stock Option Program for the members of the Board of Management and senior
executives, a Stock Incentive Program for middle management and equivalent employees,
and a Stock Participation Program for junior management and other employees. To be
eligible for the Stock Option Program, Stock Incentive Program or Module 1 of the Stock
Participation Program, participants must place Bayer AG shares of their own into a
special deposit account. Participants do not pay an exercise price for the shares they
receive under these programs. Rather, they receive the shares as bonus shares or, in the
case of Module 2 of the Stock Participation Program, have the opportunity to purchase
shares at a discounted price. 
€ million Dec. 31, 2001 Dec. 31, 2000
Total Maturing Total Maturing
in 2002 in 2001
Provisions for taxes 524 151 537 370
Provisions for personnel 
commitments 923 451 1,044 555
Provisions for environmental 
remediation 200 19 230 12
Provisions for restructuring 145 79 131 69
Provisions for trade-related 
commitments 438 426 411 397
Miscellaneous provisions 535 351 556 298
2,765 1,477 2,909 1,701
€ million Jan. 1, 2001 Changes Currency Allocation Utilization Reversal Dec. 
in scope effects 31, 2001
of con-
solidation
Provisions for taxes 537 1 – 465 (402) (77) 524
Provisions for personnel commitments 1,044 (24) 9 493 (560) (39) 923
Provisions for environmental remediation 230 (15) 3 19 (34) (3) 200
Provisions for restructuring 131 – 7 98 (91) – 145
Provisions for trade-related commitments 411 (10) 10 583 (542) (14) 438
Miscellaneous provisions 556 (17) 13 454 (425) (46) 535
Total 2,909 (65) 42 2,112 (2,054) (179) 2,765
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Stock Option Program 
Members of the Board of Management and senior executives who wish to participate in
the Stock Option Program must place Bayer AG shares of their own in a special deposit
account. We determine on an individual basis the maximum number of shares each
participant may deposit; the participant receives one option right for each 20 shares
deposited. These deposited shares are “locked up”; the participant may not sell them
during the following three years. After the end of these three years, a two-year exercise
period begins. During this period, the participant may exercise the option rights if he or
she has fulfilled the performance criteria. Any unexercised option rights expire at the
end of this two-year period. To determine whether the participant is eligible to exercise
option rights and, if so, the number of shares received upon exercise, we apply three
performance criteria. Two of these measure the relative performance of the Bayer AG
share; the third measures the individual contribution of the participant. If the participant
fails to meet minimum standards under these criteria, he or she receives no shares
under the program. At December 31, 2001, no options were exercisable. No options
expired, nor were any options cancelled, during fiscal 2001. 
If it is not possible to issue shares under the Stock Option Program to participants
at the time they are entitled to exercise their option rights, the option rights would
function as share appreciation rights. Instead of shares, the participant would receive
the cash value of the shares to which the option rights would otherwise entitle him or
her, based on the trading price of the Bayer AG share at the time of exercise. 
Stock Incentive Program
Like the Stock Option Program, our Stock Incentive Program for middle management
requires participants to deposit Bayer AG shares of their own in a special deposit
account. Each participant may deposit shares with a maximum aggregate value of half
his or her performance-related bonus for the preceding fiscal year. The number of
incentive shares the participant receives depends on the number deposited at the
launch of the program as well as on the overall performance of Bayer stock. Unlike the
Stock Option Program, the Stock Incentive Program does not “lock up” deposited
shares. Participants may sell their deposited shares during the term of the program, but
any deposited shares they sell are no longer counted in calculating the number of
incentive shares for subsequent distribution dates. The Stock Incentive Program has a
ten-year term. There are three incentive share distribution dates during this period. On
these dates, the participant receives incentive shares as follows: 
Distribution date at end of Incentive shares received 
(per 10 deposited shares)
Second year 2
Sixth year 4
Tenth year 4
10
Issuance of incentive shares to employees in the Stock Incentive Program
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Participants receive incentive shares only if Bayer stock has outperformed the Dow
Jones EURO STOXX 50 index on the relevant distribution date, as calculated from the
beginning of the program.
Stock Participation Program
Our Stock Participation Program has two components, Module 1 and Module 2.
Employees not covered by the Stock Option Program or Stock Incentive Program may
participate in both Module 1 and Module 2. The Module 1 program, like the Stock
Incentive Program, requires participants to deposit Bayer AG shares of their own in a
special account. As with the Stock Incentive Program, participants in the Stock
Participation Program may sell their deposited shares during the term of the program;
any shares they sell are no longer counted in calculating the number of bonus shares on
subsequent distribution dates. 
Module 1 has a term of ten years and entitles the participant to receive incentive
shares on three distribution dates based on the number of shares he or she has
deposited. Unlike the Stock Incentive Program, Module 1 does not impose a share
performance criterion. The participant receives incentive shares as follows on the
distribution dates: 
In addition, under Module 2 each participant may purchase 10 Bayer AG shares per 
year at a tax-free discount of €15.34 (2000: €15.34) per share to the market price.
Participants may not include shares that they purchase under Module 2 among the
shares they deposit under Module 1. Each participant may take up both modules up to a
maximum aggregate value of half his or her performance-related bonus in the year he or
she enters the program. 
The Stock Option Program, the Stock Incentive Program and Module 1 of the Stock
Participation Program are accounted for as follows: Since participants are entitled to
receive shares of Bayer AG stock bought in the capital market, subject to certain
performance criteria, compensation expense for potential share distributions is recorded
when there is a reasonable basis on which to estimate whether the performance criteria
will ultimately be met. Compensation expense is recorded at each balance sheet date by
estimating the number of rights outstanding multiplied by the current quoted market
price of Bayer AG shares. The related personnel provisions on December 31, 2001
amounted to €12 million. 
Distribution date at end of Incentive shares received 
(per 10 deposited shares)
Second year 1
Sixth year 2
Tenth year 2
5
Issuance of incentive shares to employees in the 
Stock Participation Program
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For Module 2 of the Stock Participation Program, the difference between the quoted
market price of Bayer AG stock and the discounted price paid by participants at the date
of purchase is expensed immediately. During the year ended December 31, 2001,
participants in Module 2 received 252,652 shares at a total price of €7.8 million,
resulting in personnel expenses of €3.9 million. The discount to the price of Bayer AG
stock was 33.2 percent.
Environmental provisions
The Group’s activities are subject to extensive laws and regulations in the jurisdictions
in which it does business and maintains properties. Our compliance with environmental
laws and regulations may require us to remove or mitigate the effects of the disposal or
release of chemical substances at various sites. Under some of these laws and
regulations, a current or previous owner or operator of property may be held liable for
the costs of removal or remediation of hazardous substances on, under, or in its
property, without regard to whether the owner or operator knew of, or caused the
presence of the contaminants, and regardless of whether the practices that resulted in
the contamination were legal at the time they occurred. As many of our production sites
have an extended history of industrial use, it is impossible to predict precisely what
effect these laws and regulations will have on us in the future.
As is typical for companies involved in the chemical and related industries, soil and
groundwater contamination has occurred in the past at some of our sites, and might
occur or be discovered at other sites. We are subject to claims brought by United States
Federal or State regulatory agencies and other private entities and individuals regarding
the remediation of sites that we own, formerly owned or operated, where materials were
produced specifically for us by contract manufacturers or where waste from our
operations was treated, stored or disposed. In particular, we have a potential liability
under the U.S. Federal Comprehensive Environmental Response, Compensation, and
Liability Act, commonly known as “Superfund”, the U.S. Resource Conservation and
Recovery Act and related state laws for investigation and remediation costs at a number
of sites. At most of these sites, numerous companies, including Bayer, have been
notified that the U.S. Environmental Protection Agency, state governing body or private
individuals consider such companies to be potentially responsible parties under
Superfund or related laws. At other sites, Bayer is the sole responsible party. The
proceedings relating to these sites are in various stages. In most cases remediation
measures have already been initiated.
Provisions for environmental remediation as of December 31, 2001 amounted to
€200 million (2000: €230 million). The material components of the provisions for
environmental remediation costs primarily relate to land reclamation, rehabilitation of
contaminated sites, recultivation of landfills, and redevelopment and water protection
measures. The provisions for environmental remediation costs are recorded on a
discounted basis where environmental assessments or clean-ups are probable, the costs
can be reasonably estimated and no future economic benefit is expected to arise from
these measures. The above amount of provisions represents anticipated future
remediation payments totaling €265 million (2000: €304 million), discounted at risk-
free rates of 0.5 percent to 5.5 percent. 
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These discounted amounts will be paid out over the period of remediation of the
relevant sites, which is expected to be 15 years. Costs are estimated based on
significant factors such as previous experience in similar cases, environmental
assessments, development of current costs and new circumstances with major
influences on expenses, our understanding of current environmental laws and
regulations, the number of other potentially responsible parties at each site and the
identity and financial position of such parties in light of the joint and several nature of
the liability, and the remediation methods expected to be employed.
It is difficult to estimate the future costs of environmental protection and
remediation because of many uncertainties, particularly with regard to the status of
laws, regulations and the information available about conditions in the various countries
and at the individual sites. Subject to these factors, but taking into consideration our
experience to date regarding environmental matters of a similar nature, we believe that
the provisions are adequate based upon currently available information. However, given
the inherent difficulties in estimating liabilities in this area, it cannot be guaranteed that
additional costs will not be incurred beyond the amounts accrued. It is possible that
final resolution of these matters may require us to make expenditures in excess of
established provisions, over an extended period of time and in a range of amounts that
cannot be reasonably estimated. Management nevertheless believes that such
additional amounts, if any, would not have a material adverse effect on the Group’s
financial position, results of operations or cash flows.
Legal risks
As a global company with a heterogeneous business portfolio, Bayer is exposed to
numerous legal risks, particularly in the areas of product liability, patent disputes, tax
assessments, competition and antitrust law, and environmental matters. We cannot
predict with certainty the outcome of any proceedings in which we are or may become
involved. It is therefore possible that legal judgments give rise to expenses that are not
fully covered by insurers’ compensation payments and significantly affect our revenues
and earnings.
In the opinion of the management, however, currently pending litigation is unlikely to
result in judgments that would materially affect the Group’s financial position or results
of operations. 
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Restructuring charges
Charges incurred for restructuring programs during 2001 were €214 million,
including €98 million in provisions that are expected to be used as the related actions
under the plans are completed. The total charges comprise €57 million in severance
payments, €61 million in accelerated amortization/depreciation and write-downs of
intangible assets, property, plant and equipment, and €96 million in other expenses.
Of the restructuring charges in 2001, a total of €39 million is related to the
integration of the polyols business acquired from Lyondell, with severance payments
accounting for €13 million, other expenses for €19 million and asset write-downs for
€7 million. The greater part of the severance payments and other expenses for 2001
will lead to disbursements in 2002.
The restructuring of our styrenics business in North America and Europe led to a
further €43 million in charges, including €19 million for write-downs and €24 million
for other expenses. In the second half of 2001 we announced plans to restructure our
styrenics operations in Camacari, Brazil, resulting in charges of €22 million, comprising
€16 million in write-offs of assets no longer utilized and €5 million in other expenses.
In 2001, a further €15 million in restructuring charges was incurred in the U.S. for
the restructuring of the Consumer Care Business Group in Elkhart, Indiana, including 
€9 million in write-downs and €6 million in other expenses.
In the second half of 2001 we initiated restructuring measures to enhance the
efficiency of our U.S. production facilities in Baytown, Texas and New Martinsville, West
Virginia. The €35 million in charges comprises €21 million in severance payments and
€13 million in other expenses. We also announced plans to close down a facility in West
Virginia, resulting in €10 million in write-offs of assets no longer utilized and €3 million
in severance payments.
The ongoing restructuring programs to improve profitability in the Pharmaceuticals
Business Group gave rise to €26 million in charges, comprising €7 million in severance
payments and €19 million in other expenses.
Further charges relate to various small-scale restructuring programs.
Changes in provisions and expenses for restructuring were as follows:
The other costs are mainly demolition expenses and other charges related to the
abandonment of production facilities.
€ million Severance Asset Other costs Total
payments write-downs 
Status, Dec. 31, 2000 86 13 32 131
Additions 57 61 96 214
Utilization (69) – (64) (133)
Transfers – (74) – (74)
Exchange differences 5 0 2 7
Status, Dec. 31, 2001 79 0 66 145
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[30] Financial obligations
Financial obligations that are not the hedged item in a permissible hedge accounting
relationship are carried at the higher of nominal and redemption value. They comprise
the following:
The maturities of financial obligations existing at December 31, 2001 were as follows: 
Maturing in € million
2002 4,309
2003 291
2004 1,665
2005 355
2006 86
2007 or later 674
7,380
The financial obligations are predominantly in U.S. dollars, which account for 
€5.1 billion (2000: €4.0 billion). U.S. dollar borrowings represent 69 percent (2000: 
61 percent) of total financial obligations.
Short-term borrowings (excluding the short-term portion of debentures) amounted to
€3,528 million (2000: €3,579 million) with a weighted average interest rate of 
5.4 percent (2000: 6.6 percent). The Bayer Group’s financial obligations are primarily
unsecured and of equal priority.
€ million Dec. 31, 2001 Dec. 31, 2000
Total Maturing Total Maturing
in 2002 in 2002
Debentures 2,592 781 2,168 283
Liabilities to banks 1,122 829 1,458 932
Liabilities under lease agreements 881 99 199 34
Liabilities from the issuance of promissory notes 84 84 2 2
Commercial paper 1,365 1,365 1,812 1,812
Liabilities from derivative financial instruments 180 169 – –
Other financial obligations 1,156 982 1,026 799
7,380 4,309 6,665 3,862
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The other debentures totaling €37 million are due between 2002 and 2011; their average
interest rate is 10.9 percent.
In July 1987, Bayer Capital Corporation B.V. issued CHF 250 million of 2.50 % Bonds
with warrants in Switzerland. The Bonds have a term of 15 years and mature in July
2002. The issue price of the Bonds was 100 %, and interest is paid annually in July. The
warrants attached expired on August 28, 1997.
In October 1995, Bayer Corporation issued USD 400 million of 6.50 % Notes to
qualified institutional buyers. The Notes have a term of 7 years and mature in October
2002. Interest is paid semi-annually in April and October. The Group recorded a discount
of USD 2.7 million, which includes commissions paid to underwriters.
In October 1995, Bayer Corporation issued USD 200 million of 7.125 % Notes to
qualified institutional buyers. The Notes have a term of 20 years and mature in October
2015. Interest is paid semi-annually in April and October. The Group recorded a discount
of USD 2.4 million, which includes commissions paid to underwriters.
In April 1997, Bayer Corporation issued CHF 200 million of 2.25 % Bonds in
Switzerland. The Bonds have a term of 5 years and mature in April 2002. Interest is paid
annually in April. The Group recorded a discount of USD 0.4 million, which includes
commissions paid to underwriters. This debt was swapped into U.S. dollars at a floating
interest rate. At December 31, 2001, the effective U.S. dollar interest rate was 2.17 %.
In March 1997, Bayer Corporation issued USD 20.6 million of Revenue Bonds to U.S.
institutional buyers. The interest rate is reset daily with monthly interest payments. The
Revenue Bonds have a term of 12 years and mature in May 2009.
Debentures include the following:
Effective Stated Volume
Dec.31,2001 Dec.31,2000
rate rate € million € million
Bayer Capital Corporation B.V.
2.820% 2.500% Bonds with Warrants Attached CHF 250.0 million 169 164
1987/2002
Bayer Corporation
6.735% 6.500% Notes 1995/2002 USD 400.0 million 454 430
7.323% 7.125% Notes 1995/2015 USD 200.0 million 227 215
6.784% 6.750% Notes 1996/2001 USD 250.0 million – 269
2.166% 2.250% Bonds 1997/2002 CHF 200.0 million 135 131
3.500% 3.500% Revenue Bonds 1997/2009 USD 20.6 million 23 22
4.000% 4.000% Revenue Bonds 1997/2027 USD 25.0 million 28 27
6.761% 6.650% Notes 1998/2028 USD 350.0 million 397 376
6.391% 6.200% Bonds1998/2028 USD 250.0 million 284 269
4.750% 4.750% Money Market Puttable 
Reset Securities 2001/2011 USD 500.0 million 568 –
Bayer Ltd., Japan
3.869% 3.750% Bonds 2000/2005 CHF 400.0 million 270 239
Other debentures 37 26
2,592 2,168
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In May 1997, Bayer Corporation issued USD 25 million of Revenue Bonds to U.S.
institutional buyers. The interest rate is reset daily with monthly interest payments. The
Revenue Bonds have a term of 30 years and mature in May 2027.
In February 1998, Bayer Corporation issued USD 350 million of 6.65 % Notes to
qualified institutional buyers. The Notes have a term of 30 years and mature in February
2028. Interest is paid semi-annually in August and February. The Group recorded a
discount of USD 1.9 million, which includes commissions paid to underwriters. The
Notes will be redeemable, in whole or in part, at the option of Bayer Corporation at any
time, upon less than 30 but not more than 60 days’ notice, at a redemption price equal
to the greater of (i) 100 % of the principal amount or (ii) as determined by an
independent investment banker.
In February 1998, Bayer Corporation issued USD 250 million of 6.20 % Bonds to
qualified institutional buyers. The Bonds have combined call and put options giving the
lead manager the right to repurchase them, and the investors the right to cash them,
after 10 years. At that time the lead manager can reset the interest rate and remarket
the Bonds for a further period of 20 years such that they would mature in 2028. If the
lead manager does not exercise its call option and the investors exercise their put
option, the Bonds will be redeemed in 2008. Interest is paid semi-annually in August and
February. The Group recorded a discount of USD 0.6 million which includes
commissions paid to underwriters. The redemption provision on the 1998 6.65 % Notes
also applies for these Bonds.
In April 2000, Bayer Ltd., Japan, issued CHF 400 million of 3.75 % Bonds in
Switzerland. The Bonds have a term of 5 years and mature in April 2005. Interest is paid
annually in April. The Group recorded a discount of CHF 1.2 million. The debt was
swapped into yen at a floating interest rate.
In March 2001, Bayer Corporation issued USD 500 million of 4.75 % Money Market
Puttable Reset Securities to qualified institutional buyers, due in 2011. The Bonds have
combined call and put options giving the lead manager the right to repurchase them,
and the investors the right to cash them, on each anniversary date of the original
marketing of the securities.
At December 31, 2001, the Group had approximately €6.2 billion (2000: 
€5.6 billion) in total lines of credit, of which €1.1 billion (2000: €1.5 billion) was used
and €5.1 billion (2000: €4.1 billion) were unused and available for borrowing on an
unsecured basis.
Liabilities under finance leases are recognized as financial obligations if the leased
assets are capitalized under property, plant and equipment. They are stated at present
values. Lease payments totaling €1,174 million (2000: €285 million), including 
€293 million (2000: €86 million) in interest, are to be made to the respective lessors 
in future years. 
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The liabilities associated with finance leases mature as follows:
Lease payments in 2001 in connection with operating leases amounted to €244 million
(2000: €162 million).
The other financial obligations include €85 million (2000: €42 million) to non-
consolidated subsidiaries.
[31] Trade accounts payable
Trade accounts are payable mainly to third parties; they are carried at the higher of
nominal and redemption value. As last year, the entire amount is due within one year. 
Trade accounts payable as of December 31, 2001 include €1,991 million (2000:
€2,013 million) maturing within one year and €2 million (2000: €3 million) maturing
after one year. Of the total, €8 million (2000: €8 million) is payable to subsidiaries, 
€7 million (2000: €16 million) to other affiliated companies and €1,978 million (2000:
€1,992 million) to other suppliers.
[32] Miscellaneous liabilities
Miscellaneous liabilities are carried at the higher of nominal and redemption value. 
They are comprised as follows:
€ million Dec. 31, 2001 Dec. 31, 2000
Total Maturing Total Maturing
in 2002 in 2001
Payroll liabilities 443 320 537 422
Tax liabilities 281 280 291 289
Liabilities for social expenses 144 144 114 114
Accrued interest on liabilities 125 125 73 46
Advance payments received 25 25 24 24
Liabilities from the acceptance of drafts 17 17 14 14
License liabilities 56 56 32 32
Other miscellaneous liabilities 881 865 1,385 1,333
1,972 1,832 2,470 2,274
€ million Lease Of which Liability
payments interest
2002 130 26 104
2003 149 38 111
2004 126 34 92
2005 101 26 75
2006 79 22 57
2007 or later 589 147 442
1,174 293 881
Management’s
Statement
Independent
Auditors’
Report
Statements 
of Income
Balance
Sheets
Statements of
Changes in 
Stockholders’
Equity
Statements of
Cash Flows
NotesFinancial
Statements
Table of Contents
BAYER ANNUAL REPORT 200149
Tax liabilities include not only Group companies’ own tax liabilities, but also taxes
withheld for paying over to the authorities on behalf of third parties.
Liabilities for social expenses include, in particular, social insurance contributions
that had not been paid over by the closing date.
The other miscellaneous liabilities comprise mainly guarantees, commissions to
customers, and expense reimbursements.
The total of miscellaneous liabilities includes €42 million (2000: €76 million) to 
non-consolidated subsidiaries and €3 million (2000: €12 million) to other affiliated
companies.
[33] Further information on other liabilities
Other liabilities (financial obligations, trade accounts payable and miscellaneous
liabilities) include €1,779 million (2000: €1,636 million) maturing in more than five
years. 
Of the total, €334 million (2000: €283 million) was secured, mainly by mortgages of
€256 million (2000: €256 million).
Included is €125 million (2000: €123 million) in accrued interest, representing
expenses attributable to the fiscal year but not due to be paid until after the closing
date.
[34] Deferred income
In accordance with IAS 20 (Accounting for Government Grants and Disclosure of
Government Assistance), grants and subsidies that serve to promote investment are
reflected in the balance sheet as deferred income. The amounts are gradually reversed
during the useful lives of the respective assets and recognized in income. 
The main component of deferred income as of December 31, 2001 comprises 
€111 million (2000: €113 million) in such grants and subsidies received from
governments; the amount reversed and recognized in income was €17 million (2000:
€13 million).
[35] Discontinuing operations
Assets and liabilities include the following amounts pertaining to the discontinuing
operations of Haarmann & Reimer and Fibers:
€ million Fibers H & R Erdöl- DyStar Total
Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, Dec. 31, 
2001 2000 2001 2000 2000 2000 2001 2000
Noncurrent assets 130 143 419 423 200 89 549 855
Current assets 
(excluding liquid assets) 99 195 384 390 199 320 483 1,104
Liquid assets – – 17 30 – 11 17 41
Assets 229 338 820 843 399 420 1,049 2,000
Pension provisions 28 53 74 69 59 16 102 197
Other provisions 17 35 43 62 39 28 60 164
Financial obligations – – 12 15 5 76 12 96
Remaining liabilities 29 82 104 101 59 122 133 364
Liabilities 74 170 233 247 162 242 307 821
chemie
Management’s
Statement
Independent
Auditors’
Report
Statements 
of Income
Balance
Sheets
Statements of
Changes in 
Stockholders’
Equity
Statements of
Cash Flows
NotesFinancial
Statements
Table of Contents
BAYER ANNUAL REPORT 200150
[36] Commitments and contingencies
Contingent liabilities as of December 31, 2001 – almost all of which exist toward third
parties – amount to €193 million. They result from: 
The respective items refer to potential future obligations where the occurrence of the
future events would create an obligation, the existence of which is uncertain at the
balance sheet date. The warranties mainly relate to contractual terms encountered in
the ordinary course of business.
In addition to provisions, other liabilities and contingent liabilities, there are other
financial commitments resulting primarily from long-term lease and rental agreements. 
Minimum non-discounted future payments relating to operating leases total 
€557 million (2000: €598 million). The respective payment obligations mature as
follows: 
Maturing in € million
2002 188
2003 91
2004 69
2005 56
2006 86
2007 or later 67
557
Financial commitments resulting from orders already placed under purchase agreements
related to planned or ongoing capital expenditure projects total €354 million (2000: 
€446 million). The respective payments are due almost entirely in 2002. 
Under collective agreements on part-time work arrangements for certain older
employees, we have to accept applications for such arrangements from a certain quota
of the work force. Other financial obligations that may arise from such work
arrangements in the future cannot be quantified, since the quota has already been
exceeded.
In addition, the Group has entered into research agreements with a number of third
parties under which Bayer has agreed to fund various research projects or has assumed
other commitments based on the achievement of certain milestones or other specific
conditions. The total amount of such funding and other commitments is €732 million
(2000: €683 million). At December 31, 2001, the remaining payments expected to be
made to these parties, assuming the milestones or other conditions are met, were as
follows: 
€ million Dec. 31, 2001 Dec. 31, 2000
Issuance and endorsement of bills 22 23
Guarantees 53 44
Warranties 118 148
193 215
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Maturing in € million
2002 218
2003 215
2004 88
2005 81
2006 84
2007 or later 46
732
[37] Related parties
Transactions with related persons and companies, which are invariably performed on an
arm’s length basis, are mainly trade transactions. The related receivables and payables
have been included in the respective notes to the financial statements as required by
European Union directives. The revenue and expenses related to these transactions are
immaterial to the consolidated financial statements as a whole.
[38] Financial instruments
Financial instruments entail contractual claims on financial assets. Under IAS 32
(Financial Instruments: Disclosure and Presentation), financial instruments include both
primary instruments, such as trade accounts receivable and payable, investments, and
financial obligations; and derivative financial instruments, which are used to hedge risks
arising from changes in currency exchange and interest rates. 
Primary financial instruments
Primary financial instruments are reflected in the balance sheet. In compliance with 
IAS 39 (Financial Instruments: Recognition and Measurement), asset instruments are
categorized as “held for trading”, “held to maturity”, or “available for sale” and,
accordingly, recognized at fair value or amortized cost. Changes in fair value are
recognized in stockholders’ equity. In the event of impairment losses, the assets are
written down and the write-downs are recognized in income. Financial instruments
constituting liabilities are carried at the higher of nominal and redemption value.
Fair value
The fair value of a primary financial instrument is the price at which it could be
exchanged in a current transaction between knowledgeable, willing parties in an active
market. The fair values of other securities included in investments and of marketable
securities are derived from their market prices and reflected in the financial statements.
Financial obligations are valued mainly on the basis of quoted prices, or in some cases
by discounting future cash flows. Their total fair value is €83 million less than their
carrying value. The remaining receivables and liabilities and the liquid assets have such
short terms that there is no significant discrepancy between their fair values and
carrying amounts.
Credit risk 
Credit risk arises from the possibility of asset impairment occurring because
counterparties cannot meet their obligations in transactions involving financial
instruments.
Since we do not conclude master netting arrangements with our customers, the total
of the amounts recognized in assets represents the maximum exposure to credit risk.
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Currency risk
Currency risk is the potential decline in the value of financial instruments due to
exchange rate fluctuations. Exposure to currency risk arises mainly when receivables
and payables are denominated in a currency other than the company's local currency or
will be denominated in such a currency in the planned course of business.
Such risks may be naturally hedged, as when a receivable in a given currency is
matched, for example between Group companies, by one or more payables in the same
amount, and having an equivalent term, in the same currency. They may also be hedged
using derivative financial instruments. 
All currency risks arising on financial transactions, including interest, are generally
fully hedged. The instruments used are mainly currency swaps, interest and principal
currency swaps and forward exchange contracts. Currency risks relating to operating
activities are systematically monitored and analyzed. The level of hedging is regularly
reviewed. 
The position at year end was as follows:
In some cases forecasted transactions are also hedged to further reduce the related
anticipated currency risk. At December 31, 2001 the total notional amount of the hedging
instruments concerned – mainly forward exchange contracts for the sale of U.S. dollars
or Japanese yen and all maturing before December 31, 2002 – was €497 million, which
is not included in the hedged amount of €2.5 billion. These hedging relationships
amount to cash flow hedges as defined in IAS 39. The contracts are concluded monthly
so that they run for one year and mature in the middle of each month. On these dates
the results of the transactions are recognized in income. In 2001, the differences resulting
from fair value measurement and initially recognized in equity amounted to €1.9 million.
On the asset side, 62 percent of currency risks relate to the U.S. dollar and 10
percent to the Japanese yen. On the liabilities side, 60 percent of foreign currency risks
relate to the U.S. dollar, while only 4 percent relate to euro risk positions of subsidiaries
domiciled outside the euro zone. The remaining exposure involves liabilities in British
pounds (3 percent), Japanese yen (5 percent) and a number of other currencies outside
the dollar and euro zones. The U.S. dollar accounts for 77 percent of the asset volume
hedged through derivative financial instruments, while the pound accounts for 8 percent
and the yen for 6 percent. Of the hedged liabilities, 59 percent are in U.S. dollars, 
7 percent in yen, 5 percent in British pounds and 29 percent in other currencies. The
need for hedging within the euro zone ceased at the beginning of 1999 due to the
permanent fixing of exchange rates. When economically hedging exchange rate risk on
recorded foreign currency operating items, we do not aim for hedge accounting
treatment. Changes in the fair values of the respective hedging instruments are
therefore recognized immediately in income. 
The other securities included in investments are almost exclusively denominated in
the currency used by the Group company making the investment, so no currency risk is
involved. Similarly, the other loans are made only to borrowers in the same currency
zone. Where intragroup loans exposed to currency risk have no natural hedge, they are
hedged through derivative financial instruments. 
€ million Dec. 31, 2001 Dec. 31, 2000
Primary asset instruments exposed to currency risk 3,657 2,813
Primary liability instruments exposed to currency risk 2,314 2,159
Amount naturally hedged (3,011) (1,102)
Amount hedged through derivative financial instruments (2,527) (2,205)
Residual unhedged currency exposure 433 1,665
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Interest rate risk
An interest rate risk – the possibility that the value of a financial instrument will change
due to movements in market rates of interest – applies mainly to receivables and
payables with maturities of over one year. 
Items with such long maturities are not of material significance on the operating side
but are relevant in the case of investments and financial commitments. Here, derivative
financial instruments are used as the main method of interest rate hedging, though in
some cases interest rate risk is not hedged if attractive fixed interest rates can be
obtained.
The other securities included in investments are mostly floating rate investments at
market rates of interest. Interest rate swaps are not used to convert floating rate
investments into fixed rate investments.
The other loans chiefly comprise loans to employees, generally at market-oriented,
fixed interest rates. Such loans are exposed to an interest rate risk which, however, is
not hedged since it was entered into for specific reasons. More than three-quarters of
employee loans are for terms of more than five years. 
Derivative financial instruments
The derivatives we use are mainly over-the-counter instruments, particularly forward
foreign exchange contracts, option contracts, interest rate swaps, and interest and
principal currency swaps. We deal only with banks of high credit standing. The
instruments are employed according to uniform guidelines and are subject to strict
internal controls. Their use is confined to the hedging of the operating business and of
the related investments and financing transactions. “Regular way” purchases and sales
of financial assets are recorded at the settlement date in compliance with IAS 39. The
main objective in using derivative financial instruments is to reduce fluctuations in cash
flows and earnings associated with changes in interest and foreign exchange rates.
Market risk
Market risk arises from the fact that the value of financial instruments may be positively
or negatively affected by fluctuating prices on the financial markets. The fair values
quoted are the current values of the derivative financial instruments, disregarding any
opposite movements in the values of the respective hedged transactions. The fair value
is the repurchase value of the derivatives on the closing date, based on quoted prices or
determined by standard methods. The notional amount is the total volume of the
contracted purchases or sales of the respective derivatives. 
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The notional amounts and fair values of the derivative financial instruments held at
the closing date were as follows: 
Gains and losses from changes in fair values are immediately recognized in income,
except where the strict conditions for the recognition of a hedge accounting relationship
are present. This is also the case with fair value hedges, where the gain or loss on both
the hedging contract and the hedged item are recognized in income. However, gains or
losses incurred through cash flow hedge accounting are recognized initially in equity and
subsequently in the income for the year in which the term of the respective hedging
contract is completed.
Credit risk
Credit risk exposure is €139 million (2000: €227 million), this amount being the total of
the positive fair values of derivatives that give rise to claims against the other parties to
the instruments. It represents the losses that could result from non-performance of
contractual obligations by these parties. We minimize this risk by imposing a limit on the
volume of business in derivative financial instruments transacted with individual parties.
Currency risk
Exchange hedging instruments in the notional amount of €2.7 billion (2000: 
€3.3 billion) mature within one year, while instruments in the amount of €0.3 billion
(2000: €0.2 billion) have longer remaining terms.
Interest rate risk
Short-term interest rate hedging contracts (including interest and principal currency
swaps) total €2.0 billion (2000: €0.3 billion). Those maturing after more than one year
total €2.5 billion (2000: €3.2 billion).
Hedge accounting
Most interest rate swaps and interest and principal currency swaps are performed to
allow the company to maintain a target range of floating rate debt. All swap contracts
amount to permissible hedge accounting relationships and there is no ineffectiveness
related to these hedges. Changes in the fair values of derivatives that hedge interest
€ million Notional amount Fair value
Dec. 31, Dec. 31, Dec. 31, Dec. 31, 
2001 2000 2001 2000
Forward foreign 
exchange contracts 2,740 3,219 (28) 145
Currency options 279 87 • 1
Currency swaps 9 196 • (12)
Interest rate hedging 
contracts (including interest 
and principal currency swaps) 4,485 3.495 (60) (133)
7,513 6,997 (88) 1
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rate risk are recorded as interest expense for the respective periods, as are offsetting
changes in the fair value of the related hedged debt items. Fair value hedge accounting
is not used in any other circumstances. Some interest rate or interest and principal
currency instruments involve a swap from variable to fixed interest rates. Such contracts
are accounted for as cash flow hedges as defined in IAS 39. However, most of the cash
flow hedges are entered into to protect future operating revenues against currency
fluctuations, as explained earlier.
[39] Net cash provided by operating activities
The cash flow statement starts from the operating result. The gross cash flow for 2001
of €2.9 billion (2000: €4.2 billion) is the cash surplus from operating activities before
any changes in working capital. Breakdowns of the gross cash flow by segment and
region are given in the table on pages 20 - 22. The net cash flow of €3.9 billion (2000:
€3.1 billion) takes into account changes in working capital.
[40] Net cash used in investing activities
Additions to property, plant and equipment and intangible assets in 2001 resulted in a
cash outflow of €2.6 billion (2000: €2.6 billion). Cash outflows for acquisitions amount-
ed to €0.5 billion (2000: €4.1 billion). Sales of property, plant and equipment led to a
cash inflow of €0.5 billion (2000: €0.3 billion), while that from interest and dividend
receipts and from marketable securities amounted to €0.4 billion (2000: €0.3 billion).
[41] Net cash provided by (used in) financing activities
The net cash outflow of €1.5 billion in 2001 mainly comprises the €1.0 billion dividend
payment for 2000 (2000: €1.0 billion dividend payment for 1999) and €0.5 billion
(2000: €0.3 billion) in interest payments.
[42] Discontinuing operations
Discontinuing operations affected the Group cash flow statements as follows:
N O T E S  T O  T H E  
S TAT E M E N T S  
O F  C A S H  F L O W S
€ million Erdölchemie Fibers H & R DyStar Total
2001 2000 2001 2000 2001 2000 2000 2001 2000
Net cash provided by 
operating activities 13 38 28 114 118 84 66 159 302
Net cash provided by 
(used in) investing 
activities 474 (87) (16) (30) (163) (116) (65) 295 (298)
Net cash provided by 
(used in) financing 
activitiest 0 0 (41) • 77 (7) 18 36 11
Change in cash and 
cash equivalents 487 (49) (29) 84 32 (39) 19 490 15
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[43] Cash and cash equivalents
Cash and cash equivalents as of December 31, 2001 amounted to €0.7 billion (2000:
€0.5 billion). The liquid assets of €0.8 billion (2000: €0.7 billion) shown in the balance
sheet also include marketable securities and other instruments.
The remuneration of the Board of Management for 2001 amounted to €8,153,562.
Emoluments to retired members of the Board of Management and their surviving
dependents amounted to €8,355,270.
Pension provisions for these individuals, amounting to €69,341,493 are reflected in
the balance sheet of Bayer AG.
The remuneration of the Supervisory Board amounted to €1,293,750.
There were no loans to members of the Board of Management or the Supervisory
Board outstanding as of December 31, 2001, nor any repayments of such loans during
the year.
Leverkusen, February 26, 2002
Bayer Aktiengesellschaft
The Board of Management
TOTAL REMUNER ATION 
OF THE BOARD OF
MANAGEMENT AND THE
SUPERVISORY BOARD,
ADVANCES AND LOANS
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Report of the Supervisory Board
During 2001 the Supervisory Board monitored the conduct of the company's business
and acted in an advisory capacity. We performed these functions on the basis of
detailed reports from the Board of Management received at our meetings. In
addition, the Chairman of the Supervisory Board and the Chairman of the Board of
Management maintained a constant exchange of information and ideas. In this way
the Supervisory Board was kept continuously informed about:
• the company’s business strategy; 
• corporate planning, including financial, investment and human resources
planning;
• the company’s earnings performance; and
• the general state of the business.
The documents relating to Board of Management decisions or actions requiring the
approval of the Supervisory Board were inspected by the Supervisory Board at its plenary
meetings, sometimes after preparatory work by its committees. In certain cases the
Supervisory Board gave its approval on the basis of documents circulated to its members.
We discussed at length the business trends described in the reports from the Board of
Management and the prospects for the development of the Bayer Group, the individual
business groups and the principal affiliated companies in Germany and abroad. 
Figuring prominently in these discussions was the question of reorganizing the
company and the Group, which was discussed in great detail with the Board of
Management. Another major focus of our deliberations was the acquisition of Aventis
CropScience Holding S.A., with its global crop protection and bioscience business.
Further matters dealt with by the Supervisory Board included:
• the sale of the 50 percent interest in EC Erdölchemie GmbH;
• the divestiture of Haarmann & Reimer GmbH, Rhein Chemie Rheinau GmbH and
Bayer’s 50 percent interest in PolmerLatex GmbH & Co. KG;
• the sale of 94.9 percent of the real-estate company Bayer-Wohnungen GmbH.
Other major topics reported to us and discussed during the year included:
• the withdrawal of Lipobay®/Baycol® and its effects on the pharmaceuticals business
and the entire enterprise;
• the problems with the production process for Kogenate® and the resulting shortfalls
in revenue and earnings.
At its meeting on September 13, 2001, the Supervisory Board decided to appoint
Werner Wenning to the position of Chairman of the Board of Management, effective
from the end of the 2002 Annual Stockholders’ Meeting.
The Supervisory Board is assisted in its work by the Presidial Committee, the Affiliates
Committee and Extended Affiliates Committee, the Human Resources Committee and the
Social Policy Committee. During the fiscal year there were five plenary meetings of the
Supervisory Board, one meeting of the Affiliates Committee convened in the form of the
Extended Affiliates Committee, one meeting of the Presidial Committee and two meetings
of the Human Resources Committee.
Hermann J. Strenger
Chairman of the 
Supervisory Board
1
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Report of the Supervisory Board
The consolidated financial statements of the Bayer Group were drawn up according
to the International Accounting Standards (IAS). These statements, as well as the
financial statements of Bayer AG and the management reports of the Bayer Group and
Bayer AG, have been examined by the auditors PwC Deutsche Revision Aktiengesellschaft
Wirtschaftsprüfungsgesellschaft, Essen. The conduct of the audit is explained in the
Independent Auditors’ Report. The auditors find that Bayer has fully complied with the
International Accounting Standards and issue an unqualified opinion to the consolidated
financial statements of the Bayer Group. The financial statements and management
report of Bayer AG, the consolidated financial statements and management report of the
Bayer Group, and the audit reports were submitted to all members of the Supervisory
Board. They were discussed in detail by the Presidial Committee and at a plenary
meeting of the Supervisory Board. The auditors submitted a report on both occasions
and were present during the discussions.
We examined the financial statements and management report of Bayer AG, the
proposal for distribution of the profit, and the consolidated financial statements and
management report of the Bayer Group. We found no objections, thus we concur with
the result of the audit.
We have approved the financial statements of Bayer AG prepared by the Board of
Management. These financial statements are thus confirmed. We are in agreement with
the management report of Bayer AG and, in particular, with the assessment of the
company’s future development.
We also concur with the dividend policy and the allocations to retained earnings. We
assent to the proposal for distribution of the profit, which provides for payment of a
dividend of €0.90 per share. 
Detlef Fahlbusch relinquished his seat on the Supervisory Board on April 30, 2001.
Our sincere thanks go to him for his dedicated service. His place was taken, effective 
May 1, 2001, by Siegfried Wendlandt.
Dr. Pol Bamelis retired from the Board of Management at the end of the 2001
Annual Stockholders’ Meeting. We would like to take this further opportunity to thank
him for his valuable service to the company.
Leverkusen, March 2002
For the Supervisory Board
Hermann J. Strenger
Chairman
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Corporate Officers
S U P E R V I S O R Y B O A R D
B O A R D O F M A N A G E M E N T
Prof. Dr. Herbert Grünewald
Honorary Chairman, Leverkusen
Prof. Dr. Kurt Hansen †
Honorary Chairman, Leverkusen
Members of the Supervisory Board – in addition to
performing individual supervising functions at
companies affiliated to those in which they hold
legal offices – hold offices as members of the super-
visory board or a comparable supervising body of
the corporations listed (as of December 31, 2001):
Hermann Josef Strenger
Former Chairman of the Company’s 
Board of Management, Leverkusen
Chairman
Agfa-Gevaert N.V.
Commerzbank AG
Linde AG (until May 29, 2001)
Erhard Gipperich
Lathe Operator, Leverkusen
Vice Chairman
Petra Brayer
Chemical Laboratory Assistant, Dormagen
Karl-Josef Ellrich
Health Insurance Fund Economist, Dormagen
Detlef Fahlbusch (until April 30, 2001)
North Rhine District Secretary of the German Mine,
Chemical and Power Workers Union, Düsseldorf
mg technologies AG (until March 31, 2001)
RAG Immobilien AG (until March 31, 2001)
Rheinbraun AG (until March 31, 2001)
Dr. h. c. Martin Kohlhaussen
Chairman of the Supervisory Board of Commerzbank
AG, Frankfurt (Main) 
(effective May 25, 2001)
Assicurazioni Generali S.p.A. (until April 28, 2001)
Heraeus Holding GmbH 
Hochtief AG
Infineon Technologies AG
Karstadt Quelle AG
Linde AG
RHEINHYP Rheinische Hypothekenbank AG (until May 11, 2001)
Schering AG
ThyssenKrupp AG (effective June 21, 2001)
Verlagsgruppe Georg von Holtzbrinck GmbH (effective May 15, 2001)
Hilmar Kopper
Chairman of the Supervisory Board 
of Deutsche Bank AG, Frankfurt (Main)
Akzo-Nobel N.V.
DaimlerChrysler AG 
Solvay S.A.
Unilever N.V. 
Xerox Company
Petra Kronen
Chemical Laboratory Assistant, Krefeld
Dr.-Ing. Manfred Lennings
Management Consultant, Essen-Kettwig
B.U.S. Berzelius Umwelt-Service AG (until November 30, 2001)
Deutsche Post AG
Gildemeister AG
Heitkamp-Deilmann-Haniel GmbH
IVG Holding AG
Privatbrauerei Diebels GmbH (until August 22, 2001)
Dr. h. c. André Leysen
Chairman of the Board of Directors 
of Gevaert N.V., Mortsel, Belgium
Agfa-Gevaert AG
Agfa-Gevaert N.V.
Deutsche Telekom AG
e.on AG
GIB Group N.V. (until June 30, 2001)
Schenker AG
Tessenderlo Chemie N.V. (until June 30, 2001)
Dr. h. c. Helmut Oswald Maucher 
Honorary Chairman of Nestlé S.A., Frankfurt (Main)
Koc Holding A.S. 
Qualiclick.com AG 
Ravensburger AG
Union Bancaire Privée S.A
Rolf Nietzard 
Chemical Laboratory Technician, Leverkusen
Dr. Heinrich v. Pierer 
President and Chief Executive Officer, 
Siemens AG, Munich
Hochtief AG
Münchener Rückversicherungs-Gesellschaft
Volkswagen AG
Waltraud Schlaefke 
Chemical Laboratory Technician, Bomlitz 
Wolff Walsrode AG
Hubertus Schmoldt 
Chairman of the German Mine, 
Chemical and Power Workers Union, Hannover
Buna Sow Leuna Olefinverbund GmbH
e.on AG
RAG Coal International AG
Dieter Schulte 
Chairman of the German 
Unions Federation, Berlin
Hermes Kreditversicherungs-AG
Kreditanstalt für Wiederaufbau
ThyssenKrupp AG 
Dr. Eugen Velker
Chemist, Dormagen
Lodewijk Christiaan van Wachem 
Chairman of the Supervisory 
Board of Royal Dutch Petroleum Company, 
The Hague, Netherlands
Akzo Nobel N.V.
ATCO Ltd.
BMW AG
IBM Corporation
Philips Electronics N.V.
Zürich Financial Services
Siegfried Wendlandt (effective May 1, 2001)
Wholesale Clerk, Düsseldorf
North Rhine District Secretary of the German
Mine, Chemical and Power Workers Union
RWE Rheinbraun AG
Rütgers AG
HT Troplast AG
Prof. Dr. Ernst-Ludwig Winnacker 
President of the German Research 
Association, Bonn
Elegene AG (effective January 1, 2001)
MediGene AG
Nascacell AG
Therascope AG
Dr. Hermann Wunderlich 
Former Vice Chairman of the Company’s 
Board of Management, Odenthal
Babcock-Borsig AG (until July 12, 2001)
Freudenberg & Co.
Members of the Board of Management – in addition
to performing individual supervising functions at
affiliated companies – hold offices as members of
the supervisory board or a comparable supervising
body of the corporations listed 
(as of December 31, 2001):
Dr. Manfred Schneider
Chairman
Allianz AG 
DaimlerChrysler AG 
Linde AG (effective May 29, 2001)
Metro AG
RWE AG
Dr. Pol Bamelis (until April 30, 2001)
Agfa-Gevaert AG
Agfa-Gevaert N.V.
Bekaert N.V.
Crop Design N.V.
Oleon N.V.
Evotec oAi AG
Fortis Equity
MediGene AG
Dr. Attila Molnar 
Dr. Frank Morich
Dr. Udo Oels
Agfa-Gevaert AG
EC Erdölchemie GmbH (until May 1, 2001)
Haarmann & Reimer GmbH
Wolff Walsrode AG
Werner Spinner
Bayer Faser GmbH 
Verwaltungsrat GfK 
Werner Wenning
Agfa-Gevaert AG
Agfa-Gevaert N.V.
Dresdner Bank Lateinamerika AG
EC Erdölchemie GmbH (until May 1, 2001) 
Gerling-Konzern Allgem. Versicherungs-AG (until December 31, 2001)
Gerling-Konzern Versicherungs-Beteiligungs-AG (effective May 31, 2001) 
RHEINHYP Rheinische Hypothekenbank AG
Dr. Gottfried Zaby
Beteiligungs- und Kunststoffverwertungs GmbH
Bayer Industrieprodukte GmbH & Co. KG
Bayer Vital GmbH (effective March 27, 2001)
Deutsche Gesellschaft für Kunststoffrecycling mbH
Mannesmann Plastics Machinery AG
Haarmann & Reimer GmbH
H.C. Starck GmbH 
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Ten-Year Financial Summary
*) continuing operations
Bayer Group (€ million) 1992 1993 1994 1995 1996
Net sales 21,063 20,967 22,200 22,793 24,853
Sales outside Germany 78.7% 81.0% 81.6% 80.5% 82.2%
Sales of foreign consolidated companies 61.2% 64.5% 65.3% 63.4% 65.4%
Operating result 1,419 1,200 1,656 2,102 2,306
Income before income taxes 1,377 1,204 1,684 2,140 2,282
Income after taxes 799 701 1,029 1,238 1,405
Noncurrent assets 7,987 8,256 8,563 9,437 10,689
Intangible assets 161 164 386 488 729
Property, plant and equipment 7,262 7,506 7,548 7,966 8,974
Investments 564 586 629 983 986
Current assets 11,610 12,283 13,097 13,211 14,593
Inventories 4,355 4,176 4,261 4,762 5,144
Receivables 5,336 5,427 5,881 5,787 7,028
Liquid assets 1,919 2,680 2,955 2,662 2,421
Stockholders’ equity 8,759 9,089 8,488 9,109 10,531
Capital stock of Bayer AG 1,681 1,715 1,772 1,803 1,851
Capital reserves and retained earnings 6,303 6,695 5,709 6,082 7,287
Net income 775 679 1,007 1,224 1,393
Minority stockholders’ interest 212 220 232 248 234
Liabilities 10,626 11,230 12,940 13,291 14,517
Provisions 5,657 6,003 6,788 6,923 7,057
Other liabilities 4,969 5,227 6,152 6,368 7,460
Total assets 19,597 20,539 21,660 22,648 25,282
Proportion of total assets
Noncurrent assets 40.8% 40.2% 39.5% 41.7% 42.3%
Current assets 59.2% 59.8% 60.5% 58.3% 57.7%
Stockholders’ equity 44.7% 44.3% 39.2% 40.2% 41.7%
Liabilities 54.2% 54.7% 59.7% 58.7% 57.4%
Financial obligations 2,528 2,691 3,209 3,205 3,520
• Long-term 1,568 1,319 1,259 1,436 1,615
• Short-term 960 1,372 1,950 1,769 1,905
Interest income (expense) – net (92) (26) 45 6 (44)
Noncurrent assets financed 
by stockholders’ equity 109.7% 110.1% 99.1% 96.5% 98.5%
Noncurrent assets and inventories financed by
stockholders’ equity and long-term liabilities 120.3% 123.0% 114.9% 110.7% 113.4%
Return on sales 6.7% 5.7% 7.5% 9.2% 9.3%
Return on stockholders’ equity 9.1% 7.7% 11.4% 13.7% 14.0%
Operating cash flow (gross) 2,401 2,481 2,529 2,751 2,959
Capital expenditures 1,462 1,614 1,794 1,620 1,931
Depreciation and amortization 1,305 1,374 1,243 1,184 1,326
Depreciation and amortization in
percent of capital expenditures 89.3% 85.2% 69.3% 73.1% 68.7%
Personnel expenses (including pension expenses) 7,380 7,315 7,392 7,477 7,718
Number of employees (year end) 156,400 150,400 146,700 142,900 142,200
Research and development expenses 1,583 1,614 1,624 1,666 1,845
Bayer AG
Income after taxes/Net income 446 418 476 592 695
Allocation to retained earnings 77 41 15 51 66
Total dividend payment 369 377 461 541 629
Dividend per share (€) 0.56 0.56 0.66 0.77 0.87
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Ten-Year Financial Summary
*) Continuing Operations
Bayer Group (€ million) 1997 1998 1999 2000 2001
Net sales 28,124 28,062 27,320 30,971 30,275
Sales outside Germany 83.9% 83.6% 84.3% 85.6% 85.6%
Sales of foreign consolidated companies 67.0% 67.5% 68.3% 69.0% 70.9%
Operating result 3,077 3,155 3,357 3,287 1,611
Income before income taxes 2,611 2,728 2,836 2,990 1,115
Income after taxes 1,509 1,615 2,018 1,842 961
Noncurrent assets 12,230 13,981 15,614 20,344 21,702
Intangible assets 1,051 1,909 2,213 4,843 5,014
Property, plant and equipment 10,307 10,970 11,986 13,345 13,543
Investments 872 1,102 1,415 2,156 3,145
Current assets 15,467 15,396 15,665 16,107 15,337
Inventories 5,424 5,781 4,992 6,095 5,818
Receivables 7,588 7,894 7,533 9,308 8,748
Liquid assets 2,455 1,721 3,140 704 771
Stockholders’ equity 12,009 12,568 15,006 16,140 16,922
Capital stock of Bayer AG 1,867 1,867 1,870 1,870 1,870
Capital reserves and retained earnings 8,638 9,087 11,134 12,454 14,087
Net income 1,504 1,614 2,002 1,816 965
Minority stockholders’ interest 223 211 176 237 98
Liabilities 15,465 16,598 16,097 20,074 20,019
Provisions 7,275 7,271 6,714 7,163 7,172
Other liabilities 8,190 9,327 9,383 12,911 12,847
Total assets 27,697 29,377 31,279 36,451 37,039
Proportion of total assets
Noncurrent assets 44.2% 47.6% 49.9% 55.8% 58.6%
Current assets 55.8% 52.4% 50.1% 44.2% 41.4%
Stockholders’ equity 43.4% 42.8% 48.0% 44.3% 45.7%
Liabilities 55.8% 56.5% 51.5% 55.1% 54.1%
Financial obligations 3,896 4,730 4,466 6,665 7,380
• Long-term 2,150 2,404 2,359 2,803 3,071
• Short-term 1,746 2,326 2,107 3,862 4,309
Interest income (expense) – net (157) (179) (196) (311) (349)
Noncurrent assets financed 
by stockholders’ equity 98.2% 89.9% 96.1% 79.3% 78.0%
Noncurrent assets and inventories financed by
stockholders’ equity and long-term liabilities 114.2% 105.0% 111.5% 93.0% 93.9%
Return on sales 11.0% 12.9%* 11.5%* 11.2%* 6.4%*
Return on stockholders’ equity 13.1% 12.9% 14.4% 11.7% 5.8%
Operating cash flow (gross) 3,313 3,394 3,192 4,164 2,923
Capital expenditures 2,331 2,703 2,632 2,647 2,617
Depreciation and amortization 1,479 1,521 1,744 2,122 2,464
Depreciation and amortization in
percent of capital expenditures 63.4% 56.3% 66.3% 80.2% 94.1%
Personnel expenses (including pension expenses) 7,895 8,106 7,549 7,735 7,849
Number of employees (year end) 144,600 145,100 120,400 122,100 116,900
Research and development expenses 1,983 2,045 2,252 2,393 2,559
Bayer AG
Income after taxes/Net income 746 1,095 1,076 1,702 657
Allocation to retained earnings 36 348 127 680 0
Total dividend payment 710 747 949 1,022 657
Dividend per share (€) 0.97 1.02 1.30 1.40 0.90
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Spring Financial News Conference 
Spring Investor Conference
Annual Stockholders’ Meeting 2002 
First Quarter Results 2002
Payment of Dividend
First Half Results 2002 
London Investor Conference
Fall Financial News Conference
Fall Investor Conference
Spring Financial News Conference
Spring Investor Conference
Annual Stockholders’ Meeting 2003
First Quarter Results 2003
Payment of Dividend
Wednesday, March 13, 2002
Friday, March 15, 2002
Friday, April 26, 2002
Thursday, May 2, 2002
Thursday, August 1, 2002 
Tuesday, November 12, 2002
Wednesday, November 13, 2002 
Thursday, March 13, 2003
Friday, March 14, 2003
Tuesday, April 29, 2003
Friday, May 2, 2003
Forward-Looking Statements
This Annual Report contains forward-looking statements. These statements use words like “believes”, “assumes”, “expects” or similar formu-
lations. Various known and unknown risks, uncertainties and other factors could lead to substantial differences between the actual future
results, financial situation, development or performance of our company and those either expressed or implied by these statements. These
factors include, among other things: 
• downturns in the business cycle of the industries in which we compete;
• new regulations, or changes to existing regulations, that increase our operating costs or otherwise reduce our profitability;
• increases in the price of our raw materials, especially if we are unable to pass these costs along to customers;
• loss or reduction of patent protection for our products;
• liabilities, especially those incurred as a result of environmental laws or product liability litigation;
• fluctuation in international currency exchange rates as well as changes in the general economic climate; and
• other factors identified in this Annual Report.
These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and
Exchange Commission (including our Form 20-F).
In view of these uncertainties, we caution readers not to place undue reliance on these forward-looking statements. We accept no obligation
to continue to report or update these forward-looking statements or adjust them to future events or developments.
